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Abstract  
Al-Hilal M. and Sanders T.A.B. (2012).Genetic variations in the FADS1, FADS2 genes influence 
the proportions of long-chain n-6 polyunsaturated fatty acids in erythrocyte and plasma lipids. 




Fatty acid composition of adipose tissue as biomarker of fat intake in a Caucasian female twin 
(2010) at the 9
th





The thesis reviews the previous use of biomarkers of fatty acid intake and concludes that there is 
a lack of supporting evidence from large randomized controlled trials (RCT) of sufficient 
duration for their use to be justified. The hypothesis that fatty acid biomarkers are robust indices 
of the intake certain fatty acids was tested by the analysis of blood samples from three large and 
long-term RCTs where dietary intake had been well controlled and compared with a control 
treatment. Erythrocyte lipid fatty acid composition was unable to detect changes in saturated 
fatty acid (SFA) or oleic acid intake. Plasma total lipids and phospholipids SFA were also poor 
indicators of SFA intake. The intake of n-3 long-chain polyunsaturated fatty acids (LC-PUFA) 
could be predicted from the proportions in plasma and erythrocytes. Principal components 
analysis appeared to be a valid data reduction technique to measure changes in fatty acid 
patterns. A co-twin study design conducted in 570 female participants enrolled in the St 
Thomas‟ Twins Study investigated the heritability of fatty acid biomarkers (adipose tissue and 
plasma). For most fatty acids, environmental factors (dietary intake) were dominant, but in the 
case of arachidonic acid, 65% of the variance was explained by additive genetic factors. 
Investigations subsequently explored the effects of variations in single nucleotide 
polymorphisms (SNP) in the fatty acid desaturase (FADS) genes on the fatty acid composition 
of the biomarkers.  Polymorphism in FADS1 rs174537 explained some of this variation. 
Carriage of the minor allele of rs174537 SNP also influenced the proportions of n-6 LC-PUFA 
in an RCT. Further research is suggested to identify what appeared to be a FADS1/FADS2 
haplotype predicting lower levels of LC-PUFA, which might be of public health significance.  
In conclusion, plasma fatty acid composition can be recommended to elucidate the potential 
relationships between polyunsaturated, trans-unsaturated and branched chain fatty acid intake 




The author conducted the fatty acid analyses of adipose tissue from the TwinsUK study and 
plasma from TwinsUK, MARINA and CRESSIDA studies and all statistical analyses.  
The author also planned and conducted a human intervention study aimed to investigate the 
acute and chronic effect of dietary palmitoleic acid using macadamia oil on markers of glucose 
and insulin sensitivity and cardiovascular risk factors. Unfortunately, the study failed to recruit 
the required number of subjects and thus was terminated. However, 6 subjects were recruited to 
the postprandial study and results from those are presented here. This study involved recruiting 
and screening subjects, handling and analysis of blood samples for plasma fatty acid 
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Dietary fat intake may be associated with cardiovascular disease but the relationship is 
marred by the limitations in the methods used to assess both the total fat intake and the 
type of fat consumed. Assessment of dietary intake of fat using traditional methods such 
as food frequency questionnaire is prone to a number of limitations, which may lead to 
unreliable assumptions about diet-disease relationships. Biomarkers could provide a 
potential robust alternative to assess dietary intake of certain types of fatty acids. 
Depending on the turnover of the lipid pool, biomarkers could be used to detect short, 
medium or long-term intake of fat. However, it is uncertain to what extent they are 
influenced by genetic factors. The work described tests some of the assumptions from 
prospective cohort studies by comparing changes in biomarkers in large well-controlled 
intervention studies with those predicted from accurate measurement of dietary intake. 
Further comparisons of biomarkers are made according to single nucleotide 
polymorphisms in the desaturase enzymes (FADS1, FADS2 and SCD1). The effect of 
additive genetics influencing adipose tissue and plasma biomarkers of fat intake were 
estimated using linear structural equation modelling based on analysis of biomarkers in 
pairs of twins. In order to preface this work, a brief introduction on nutritional 
biochemistry of fat, a summary of present knowledge with regard to different fatty acids 
and risk of cardiovascular disease, and a review of previous research on biomarkers of 




1.1 Chemistry and types of fat 
Lipids are fatty acids, esters and potential esters of fatty acids (Christie, 2010). Lipids 
can be separated into fatty acids, glycerolipids (mono-, di- and tri-acylglycerols), 
glycerophospholipids (e.g. phosphatidylcholine (lecithin), phosphatidylethanolamine, 
phosphatidylserine, and phosphatidylinositol), ceramides, sphingolipids, sterol lipids 
(e.g. cholesterol, cholesteryl esters), prenol lipids, glycolipids, waxes and polyketides. 
Lipids are often divided into simple and complex lipids: simple lipids include fatty 
acids, neutral fats (e.g. triacylglycerols) and waxes (e.g. esters of fatty acids); complex 
lipids include ceramides, phosphoglycerides, plasmalogens, sphingolipids, glycolipids, 
steroids and sterol ester (Christie, 2010; Fahy et al. 2005).  
From a nutritional standpoint, fatty acids and glycerolipids are concentrated sources of 
energy and the main energy store in animals. An Atwater factor of 9 kcal/g (37 kJ) is 
usually applied but the energy yield does vary with chain length but short (C2-C6) and 
medium chain (C6-12) length fatty acids yield 7 kcal/g. However, most fats contain 
C16-C18 fatty acids and food tables assume each gram of fat yields 9 kcal/g (37 kJ), 
compared to 4 and 3.75 kcal/g for protein and carbohydrate (CHO) respectively 
(WHO/FAO, 2010). Dietary fat is a mixture of triacylglycerols (TAG), where the three 
fatty acids are attached to a glycerol backbone in positions sn-1, sn-2 or sn-3 (Figure 
1.1). Most fatty acids are even number, straight chain molecules having a carboxyl 
group (COOH) at the proximal end and a terminal methyl group (CH3) at the other. 




saturation. A standardized shorthand nomenclature is used where the number of carbons 
in the molecule is given followed by a colon and the number of double bonds in the 
fatty acids with information about the positions of the double bonds from the carboxyl 
end (Table 1.1). For series of fatty acids derived from one of the parent unsaturated 
fatty acids, the suffix of n-x is more commonly used in nutritional sciences: where x is 
the number of carbons from the terminal (omega) methyl group. The older term omega-
3 and omega-6 is still widely used to refer to members of the n-3 and n-6 series of 
polyunsaturated fatty acids (PUFA). Depending on the length of carbon chain, fatty 
acids are divided into short chain (<7 carbons), medium chain (8-13 carbons), long 
chain (14-18 carbons) and very long chain fatty acids (>20 carbons) (Ratnayake & 
Galli, 2009); lauric acid (12:0) is sometimes included with long-chain fatty acids. 
Saturated fatty acids (SFA) contain single bond linkage between each carbon atom and 
most are straight rather branched chain as shown in Figure 1.2. At room temperature 
(22˚C), short-chain fatty acids are volatile; medium-chain fatty acids are liquid, whereas 
long-chain SFA are solid. The desaturase enzymes insert double bonds in the cis-
configuration where the hydrogen molecules are on the same side of the double bond 
and this creates a kink in the molecule of the fatty acids, which lowers the melting point 
considerably. Unsaturated fatty acids have one (monounsaturated; MUFA) or more 
(polyunsaturated; PUFA) double bonds in their structure.  Dietary fats are mixtures of 
fatty acids but are described as saturated, monounsaturated or polyunsaturated based on 
the dominant proportion of fatty acid present. Animal fats contains predominantly a 




and smaller amounts of myristic (14:0) and stearic (18:0) acids, the proportion of stearic 
acid being higher in the fat from ruminant animals. The amount of PUFA present in 
animal fat depends on the amount in the diet in monogastric food animals (poultry, 
swine, rabbits), but is always very low (<3%) in fat from ruminants (goats, sheep, 





Figure 1.1 Structure of a triacylglycerol (The lipid library - http://lipidlibrary.aocs.org/) 










Figure 1.2 Structure of saturated and unsaturated fatty acid. From 




Table 1.1 Main fatty acids in the diet. 
Systematic nomenclature 
  
Common name  Short hand notation 
Saturated fatty acids (SFA)  
Ethanoic acid Acetic acid 2:0 
Butanoic acid  Butyric acid  4:0  
Hexanoic acid  Caproic acid 6:0  
Octanoic acid  Caprylic acid  8:0  
Decanoic acid  Capric acid  10:0  
Dodecanoic acid  Lauric acid  12:0  
Tetradecanoic acid  Myristic acid  14:0  
Pentadecanoic acid  Pentadeciyic acid  15:0  
Hexadecanoic acid  Palmitic acid  16:0  
Heptadecanoic acid  Margaric acid  17:0  
Octadecanoic acid  Stearic acid  18:0  
Eicosanoic acid Arachidic acid 20:0 
Cis-monounsaturated fatty acids (cis-MUFA)  
Hexadecenoic acid  Palmitoleic acid  16:1Δ9c (18:1n-7) 
Octadecenoic acid  Oleic acid  18:1Δ9c (18:1n-9)  
Octadecenoic acid   Petroselinic acid 18:1Δ11t (18:1n-7) 
Eicosenoic acid  Gadoleic acid  20:1Δ9c (20:1n-11 
Docosaenoic acid Erucic acid 22:1Δ13c (22:1n-9) 
Docosaenoic acid Cetoleic acid 22:1 Δ11c (22:1n-11) 
Trans-monounsaturated fatty acids (trans-MUFA)  
Octadecenoic acid  Elaidic acid  18:1Δ9t (18:1n-9 trans)  
Octadecenoic acid  Trans-vaccenic acid  18:1Δ11t (18:1n-7 trans)  
Octadecenoic acid  Vaccenic acid  18:11Δ11t (18:1n-7) 
Polyunsaturated fatty acids (PUFA)  
n-6 Polyunsaturated fatty acids (omega-6 PUFA)  
Octadecadienoic acid  Linoleic acid  18:2Δ9c,12c (18:2n-6)  
Octadecatrienoic acid  γ-Linolenic acid  18:3Δ6c,9c,12c (18:3n-6)  
Eicosatrienoic acid  Dihomo- γ-linolenic acid 20:3 8c,11c,14c (20:3n-6) 
Eicosatetraenoic acid  Arachidonic acid  20:4Δ5c,8c,11c,14c (20:4n-6)  
Docosatetraenoic acid Adrenic acid 22: 4Δ7c,10c,13c,16c (22:4n-6) 
Docosapentaenoic acid Osbond acid 22: 4Δ 4c, 7c,10c,13c,16c (22:5n-6) 
n-3 Polyunsaturated fatty acids (omega-3 PUFA)  
Octadecatrienoic acid  α-Linolenic acid 18:3Δ9c,12c,15c (18:3n-3)  
Octadecatetraenoic acid Stearidonic acid 18:4Δ6c, 9c,12c,15c (18:4n-3) 
Eicosapentaenoic acid  Timnodonic acid 20:5Δ5c,8c,11c,14c,17c (20:5n-3)  
Docosapentaenoic acid  Clupanodonic acid 22:5Δ7c,10c,13c,16c,19c (22:5n-3)  
Docosahexaenoic acid  Cervonic acid 22:6Δ4c,7c,10c,13c,16c,19c(22:6n-3)  
Conjugated linoleic acid (CLA)  
Octadecadienoic acid  Rumenic acid  18:2Δ9c,11t  





The coconut (Cocos nucifera) and the kernel of the oil palm (Elaeis guineensis and 
Elaeis oleifera) contain high proportions of the medium chain fatty acids caprylic, 
capric and lauric acids, but very low levels of PUFA (<2%). Palm oil, which comes 
from the mesocarp of the palm fruit, contains about 42% palmitic acid, 37% oleic acid, 
10% linoleic acid and 5% stearic acid. It has a symmetrical triacylglycerol structures 
with the SFA at positions sn-1 and sn-3. Cocoa butter, which is the fat from the cocoa 
bean (Theobroma cacao), has a similar symmetrical structure but higher levels of stearic 
acid and less palmitic acid but is low in PUFA (<3%). Related tropical oils that share 
this symmetrical TAG structure are highly valued as cocoa butter equivalents for 
chocolate confectionary and include shea butter (Butyrospermum parkii), sal (Shorea 
robusta), kokum gurgi (Garcinia indica), illipe (Shorea spp) and mango kernel 
(Mangifera indica) oils. Most of the major seed oils; soyabean (Glycine max), rapeseed 
(Brassica napus), sunflower (Helianthus annuus), and corn (Zea mays) contain low 
levels of stearic acid unless hydrogenated. Plants seeds oils are generally high in MUFA 
and/or PUFA. Rapeseed and olive oil (Olea europaea) have a high content of MUFA 
but newer varieties of sunflower (high oleic sunflower oil) and soybean  (mid-oleic 
soybean oil) oils contain less linoleic acid and more oleic acid are also high in MUFA. 
Linoleic acid (18:2n-6; LA) is the dominant PUFA in seed oils and contains less than 
1% alpha-linolenic acid (18:3n-3; ALA) with the exception of soybean and rapeseed 
oils. A few exotic oils such as evening primrose (Oenothera biennis), borage (Borago 
officinalis) and hemp seed (Cannabis sativa) oils contain gamma-linolenic (18:3n-6; 




Ruminant animals (sheep, cows, goats) have a gut microbiota that biohydrogenate 
linoleic and α-linolenic acid present in diet mainly to stearic acid and C18 trans 
isomeric fatty acids (TFA) – levels are in the range of 3-7% of the total fatty acids 
(Sebedio & Christie, 1998). Higher levels of TFA are found in industrially processed 
fats particularly arising from the partial hydrogenation with a nickel or copper catalyst, 
where the proportion of TFA can be as high as 50%. Fully hydrogenated fats, however, 
contain no TFA. Smaller amounts of TFA can be formed during the steam deodorisation 
of fats particularly if temperatures are not correctly controlled. Levels of TFA as high as 
4-5% have been observed in rapeseed oil exposed to high temperature deodorisation 
(Ackman & Mag, 1998). However, under good manufacturing practice levels of TFA 
should be below 1%. TFA, though, are not formed in a significant amounts during 
cooking processes such as deep-fat frying (WHO/FAO, 2010). 
LA and ALA are considered essential nutrients because they cannot be synthesized de 
novo and are required for normal physiological functioning.  Animals cannot synthesize 
them is because they lack the desaturase enzymes, which are present in plants, that 
insert double bond beyond 6-carbons from the terminal methyl group. Both LA and 
ALA, however, can undergo further desaturation towards the carboxyl end and chain 
elongation to form two distinct series of metabolites. Both LA and ALA give rise to 
parallel series of metabolites, n-6 and n-3 respectively (see Figure 1.3). Arachidonic 
acid (20:4n-6; AA) and docosahexaenoic acid (22:6n-3; DHA) both have unique 




and n-3 series play an important role in membrane function, but it is the metabolites of 
AA that have received most attention because of their key role in mediating thrombosis 
and inflammation. Metabolites of AA and dihomo-gamma-linolenic acid (20:3n-6; 
DGLA) are involved, as second messengers, in cell signalling. Phospholipids containing 
AA in particular are important in this respect. AA when released from phospholipids 
can undergo oxidation and molecular rearrangement to form signalling molecules such 
as prostaglandins but partial glycerides containing arachidonic acid and anandamide are 
also physiologically important ligands for the endocannabinoid receptor (Pertwee et al. 
2010).  When released from phospholipids, AA is oxidized by cyclo-oxygenase to form 
an endoperoxide which is subsequently rearranged according to tissue to give rise to 
various daughter compounds such as classical 2- series prostaglandins e.g. PGE2, PGF1-
α, and thromboxane TXA2 in platelets and prostacyclin PGI2 in endothelial cells. It can 
also act as a substrate for 5-lipooxygenase which gives rise to the 4-series leukotrienes 
(notably LTB4) which is a chemotactic molecule involve in bronchoconstriction. DGLA 
gives rise to the 1-series prostanoids but does not give rise to a thromboxane, 
prostacyclin or leukotrienes. Eicosapentaenoic acid (20:5n-3; EPA) can give rise to a 
parallel series of cyclo-oxygenase and lipoxygenase metabolites: the 3-series 
prostanoids (PGE3, TXA3, PGI3) and 5-series leukotrienes (LTB5). However, these 
metabolites with the exception of PGI3 are generally inactive or less active than those 
derived from AA.  Under normal circumstances, the main endpoint of ALA metabolism 
is DHA. DHA plays an important role in visual function (WHO/FAO; 2010).  DHA is 




1988). More recently, Serhan et al. (2004) have described other metabolites of 20-22 
carbon PUFA called resolvins and neuroprotectins and some of these molecules can be 
derived from DHA but their exact physiological role remains at present uncertain. 
Collectively these metabolites are called eicosanoids and docosanoids and are signalling 
molecules that have important local biological activities at low concentrations (Calder, 
2006).  
Cyclo-oxygenase metabolites of AA are essential for normal physiological functioning 
in a variety of tissues and a failure to produce these metabolites explains reproductive 
failure, impaired platelet aggregation and impaired immune function in essential fatty 
acid deficiency (Sanders, 1988). Overproduction of cyclo-oxygenase metabolites can 
occur resulting in inflammation and this is usually a consequence of increased 
expression of the inducible cyclo-oxygenase-2 (COX-2) enzyme rather than the 
constitutive cyclo-oxygenase-1 (COX-1) enzyme. Cyclo-oxygenase is the target for 
most non-steroidal anti-inflammatory drugs (NSAID) such as aspirin, ibuprofen and 
paracetamol. Low dose aspirin is a powerfull inhibitor of platelet thromboxane A2 
production from AA and is widely used at a dose of 75mg/d to prevent second heart 
attack and stroke. However, a major side effect of aspirin is gastric irritation, which 
would indicate a protective effect of prostaglandins on the stomach, and an increased 
risk of intestinal haemorrhage. COX-2 inhibitors were developed, which do not cause 
gastritis, as anti-inflammatory agents for pain relief in rheumatism and other 




than a reduced risk of cardiovascular disease (CVD) (Drazen, 2005). The Nobel 
Laureate Sir John Vane, who was awarded the prize for his work on aspirin, suggested 
that replacing AA by EPA in membrane phospholipids would alter the balance of active 
eicosanoids and, therefore, have anti-thombotic and anti-inflammatory effects 
(Dyerberg et al. 1978). He proposed that this might explain the relatively low incidence 
of inflammatory disorders in some populations that consume very large amounts of fish 
or marine mammals as documented by Bang et al. (1980). However, later research 
showed that the levels of intake of EPA and DHA required to produce these anti-
thombotic and anti-inflammatory effects are usually well in excess of 3g/d and in the 
case of Greenland Inuit it was in the range of 5-14g/d (Bang et al. 1980).  In most 
populations, the levels of intake of EPA and DHA are usually well below 1g/d 
(WHO/FAO, 2010). There are many studies in animals that clearly demonstrate 
decreased risk of thrombosis and inflammation when fed diets high in fish oil, rich in a 
mixture of EPA and DHA and low in LA (Sanders, 1988; Calder 2006). It is also 
possible to produce similar effects in animals by restricting LA intake and increasing 
the intake of ALA (Sanders, 1988). However, human studies have found that dietary 
supplementation with ALA only leads to a small increase in EPA and no changes in 
DHA in blood (Sanderson et al. 2002). Stable isotope studies also suggest that the rate 
of synthesis of DHA from ALA is low (Burdge et al. 2004; Goyens et al. 2006). In 
contrast, even small amounts of dietary DHA result in pronounced increases in blood 
levels of DHA. This has led some to suggest that the human ability to make ALA from 




However, for most populations dietary fat intake is derived from plant oils and the fat 
from land animals and vegetarians who consume little preformed DHA appear to be in 
good health (Key et al. 2009) 
 
 






Figure 1.4 Global vegetable oil production in millions of metric tons. Source: USDA 
Economic, Statistics and Market Information ( http://usda.mannlib.cornell.edu ) [Accessed 
04/03/2013]. 
 
1.2 Global food sources of oils and oil crops  
Palm oil is currently the major vegetable oil produced globally followed by soybean oil 
and then rapeseed and sunflower seed oils (Figure1.4). Most vegetable oil is used for 
food but some is used in cosmetics and in biodiesel. Palm oil is produced mainly in 
Indonesia and Malaysia and to a lesser extent in West Africa (WHO/FAO, 2010). While 
crude red palm oil which is rich in carotene is consumed in West Africa, most of the 
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Indonesian and Malaysian palm oil is physically refined removing the carotenoids and 
fractionated into palm stearin, palm olein, palm mid-fraction and super palm olein 
which have decreasing levels of SFA. Palm stearin (65% SFA) is a high value product 
used in blend to provide the solid fat component of margarine and palm olein mid-
fraction (mainly 1-3 dipalmitoyl, 2-oleyl glycerol). It is also a high value product used 
as a cocoa butter substitute (Marangoni et al. 1995). The cheaper and more abundant 
palm olein contains about 45% SFA, whereas super-palm olein (mainly 1 palmitoyl, 2-3 
dioleyl glycerols) contains about 35% SFA. Both palm olein and super palm olein are 
liquid at room temperature. Palm olein has a melting point around 14°C in contrast to 
coconut oil, which tends to be solid at room temperature. Soybean oil is mainly 
produced in the United States and South America. Most of the olive oil production is in 
the Mediterranean basin, but olive cultivation is increasingly established in other 
countries with a Mediterranean climate. Most other seed oils, such as sunflower and 
corn oils, also require strong sunlight to be grown and do not flourish in temperate 
climates. In contrast, rapeseed and linseed grow well in temperate climates such as 
Canada and Northern Europe (WHO/FAO, 2010) 
A substantial amount of vegetable oil is used by the food industry to make processed 
foods such as margarine, cakes, biscuits and snack foods such as crisps. The type of fat 
used is usually dependent upon the market price of the fat being used (blend flexibility 
describe the ability to change the oils used depending on price) and the physical 




products and chocolate confectionary as oils with a low melting point make inferior 
products. Many food manufacturers also specify the use of vegetable oil rather than 
cheaper animal fats in their products so that they are acceptable to consumers in markets 
where derivatives of beef and pork are not acceptable for religious reasons. There is also 
increasing demand for products that are acceptable to vegetarians. This generally has 
led to increased use of fats with higher LA content and there is evidence to show that 
the intake of LA has increased in many Western European countries, North America. In 
contrast, the use of animal fats used for these purposes has fallen as shall be discussed 
in later sections.  Historically, intakes of LA have been high in the Middle East owing 
to the traditional use of oils such as sunflower and safflower oil (Cobley, 1976). 
Animal fats make a substantial contribution to fat intake in economically developed 
countries. This fat intake is mainly derived from carcass meat and from milk and its 
products. The composition of these fats is far less variable and so risk of errors in 
estimation of intake from these sources is low. However, the levels of fat in meat can 
vary with production methods and it is necessary to take account of fat discarded during 
butchering, food preparation and plate waste. Processed meat products generally have a 
higher fat content than carcass meat and foods such as sausages may contain about a 
third of their weight as fat (McCance & Widdowson, 1998). Ruminants (cattle, goats, 
sheep, and camels) produce most milk for human consumption and butter fat with a 
high SFA content (63%) with only small amounts of PUFA (Table 1.2). Meat fat 




acid and only small amounts of PUFA.  The fat from monogastric animals (pigs and 
chickens) contains higher levels of PUFA (about 10% of the fatty acids) because the 
dietary PUFA are not biohydrogenated by rumen bacteria and lamb and beef typically 
contains less than 3% PUFA. Fish only provide small amounts of fat in most diets but 
the oil from fish contains relatively high amounts of n-3 LC-PUFAs (EPA and DHA).  
These n-3 LC-PUFA are synthesised by marine algae (Metz et al. 2001) and accumulate 
up the food chain with the highest amounts being found in predator fish e.g. tuna, 




Table 1.2 Fatty acid composition (wt %) of some edible oils and fats (ESFA, 2010) 
  
Butter fat  Coconut oil  Palm kernel oil  Palm oil  Cocoa butter  Olive oil  Rapeseed 
oil 
Sunflower oil  Corn oil  Soybean oil  
SFA  63.4 86.5 81.5 49.3 59.7 13.8 7.4 10.3 12.9 15.3 
<12:0  11 14.1 7.2 0 0 0 0 0 0 0 
12:0 3.2 44.6 47 0.1 0 0 0 0 0 0 
14:0 9.1 16.8 16.4 1 0.1 0 0 0 0 0 
16:0 26.8 8.2 8.1 43.5 25.4 11.3 4.3 5.9 10.6 10.7 
18:0 12.3 2.8 2.8 4.3 33.2 2 2.1 4.5 1.8 4 
MUFA  25.9 5.8 11.4 37 32.9 73 63.3 19.5 27.6 22.7 
18:1n-9 21 5.8 11.4 36.6 32.6 71.3 61.7 19.5 27.3 22.6 
Trans-18:1  3.7          
PUFA  3.7 1.8 1.6 9.3 3 10.5 28.1 65.7 54.7 57.3 
18:2 n-6 3.3 1.8 1.6 9.1 2.8 9.8 18.6 65.7 53.2 50.1 





1.3 Dietary sources of essential fatty acids (EFAs) 
Both LA and ALA are essential nutrients and a lack of these PUFA causes essential 
fatty acid (EFA) deficiency, a condition first described in rats (Burr & Burr, 1929) but 
later described in human infants and adults undergoing parenteral nutrition. Classical 
EFA deficiency, which occurs when the intake of LA falls below 1% energy, is unlikely 
to occur among individuals self-selecting their diets because even the most meagre diets 
provide more than this. The manifestations of EFA deficiency include a scaly skin with 
dryness, increased water loss throughout the skin, poor growth and impaired energy 
utilisation. Deficiency is regarded as iatrogenic and was first reported in infants fed 
skimmed milk and later adults receiving fat-free intravenous nutrition. It was estimated 
that about 1% of the energy as LA is sufficient to prevent classical EFA deficiency. The 
essentiality of ALA hinges on its conversion to DHA, which is an important component 
of the retinal membranes and the brain. Where DHA is replaced by osbond acid (22:5n-
6) impairment of visual function and learning have been reported. There is some debate 
concerning the human capacity to convert ALA to DHA but the requirements for visual 
function can be met by ALA alone (WHO/FAO, 2010). Estimates for the minimum 
requirements of ALA suggest a minimum intake of 0.2% energy (Department of Health, 
1991). Human milk contains varying amounts of PUFA depending on the maternal diet 
but on average contains about 8%-10% PUFA. In the past milk formula were based 
around cow‟s milk and had a low PUFA content (<2%), but then it became fashionable 




This resulted in higher levels of LA. Modern infant breastmilk substitutes are formulate 
to mimic breastmilk using: enzymically modified palm oil (Betapol™), where the 
palmitic acid is in the sn-2 position, to improve fat digestibility; vegetable oils to supply 
LA and ALA (typically in a ratio of 5:1); single cell oils/egg lecithin to provide AA and 
DHA (WHO/FAO 2010). 
Exposure to high temperatures, metals such as copper and iron and oxygen results in 
oxidation of PUFA and this increases with the number of double bonds in the molecule. 
For this reason, food processors often select oils with low levels of ALA where heat 
treatment might lead to oxidative rancidity especially for deep frying applications. Oils 
used are partially hydrogenated to reduce their ALA content and thus improve their 
stability to oxidation. It has been argued that the consumption of n-3 fatty acids was 
considerably high in early human diets. However, industrialization and fast foods 
development diminish the content of n-3 fatty acids and amplify those of n-6 in the 
human diet. It has been argued that early human beings, who were hunter gatherers, 
would have had a low n-6:n-3 ratio in their diet. Nowadays, the ratio is much higher 
because of the inclusion of high sources of n-6 rich vegetable oils in the diet and this 
may have adverse health consequences (Simopoulos, 2011). Some researchers blame 
this change for the increase in many diseases such as CVD, cancer and inflammatory 
diseases (Das, 2008). However, there are other more plausible factors to explain these 
changes such as tobacco and alcohol use, physical inactivity and obesity. Furthermore, 




pattern for increased life-expectancy and in the UK and many Western European 
countries. For example, deaths from CHD under the age 75 have fallen by over 50% in 
the last 10 years (Smolina et al. 2012). The dietary reference intakes for PUFA are 
substantially high than the amounts to prevent EFA deficiency and these recommended 
intakes are based on the association of the quality of fat intake with risk of CVD which 
shall be discussed in the following section. 
 
1.4 Cardiovascular disease  
CVD is a term that refers to arterial diseases affecting the heart and circulatory system: 
the major forms of CVD are coronary heart disease (CHD) or ischemic heart disease 
(IHD), which affects the heart, cerebrovascular disease/stroke, which affects the brain 
and peripheral vascular disease, which affects the limbs and results in claudication. A 
common feature in the pathology of these disorders is atherosclerosis, which is a 
nodular thickening and hardening of the arterial wall resulting in cholesterol rich lesions 
called atheromatous plaques. These lesions narrow the lumen of medium and large 
arteries and if they rupture trigger thrombosis which results in a clinical event i.e. heart 
attack, stroke or claudication (Warrell et al. 2010). 
1.4.1 Incidence and prevalence of CVD 
CVD is the leading-cause of death worldwide. However, there is great variation in the 




MONICA study (Tunstall-Pedoe et al. 2000). Stroke rates tend to be more strongly 
associated with elevated blood pressure than atherosclerosis, whereas CHD is more 
strongly associated with atherosclerosis. Generally, rates of stroke are higher than that 
of CHD in the Far East. The lowest rates of CHD are in Japan and some of the Southern 
Mediterranean countries and the highest are now in Eastern European countries. 
Mortality from CVD has been falling steadily in Western Europe over the past 30 years.  
In the UK, CVD accounts for 36% of premature deaths (aged <75 years) in men and 
27% in women according to the British Heart Foundation (www.bhf.org.uk). Recent 
data suggest that CVD death rates have fallen by over 50% in the last 10 years (Smolina 
et al. 2012). The reasons for the fall are uncertain but are thought to be due to better 
treatment, smoking cessation and a secular fall in blood pressure and serum cholesterol 
despite an increase in the prevalence of diabetes and obesity (Bajekal et al.2012). 
Dietary fat has been linked to risk of CVD mainly, but not exclusively, through its 
effects on blood lipids.  
1.4.2 Risk Factors for cardiovascular diseases 
CVD risk factors can be split into modifiable and un-modifiable risk factors (age, 
gender and genes). Modifiable factors include elevated serum cholesterol concentrations 
and a low high density lipoprotein cholesterol (HDL-C) which are best indicated by a 
high total cholesterol:HDL-C ratio (TC:HDL-C) (Lewington et al. 2007),  cigarette 
smoking, high blood pressure (BP), type-2 diabetes mellitus and physical inactivity. 




when their effects on blood lipids, risk of diabetes and BP are taken into account. 
However, obesity is important in causing these abnormalities and there is robust 
evidence showing an almost linear increase in risk of stroke and IHD mortality as BMI 






Figure 1.5 Relative risks with 95% confidence interval of ischaemic heart disease and stroke 
mortality versus BMI in the range 15–50 kg/m2 (excluding the first 5 years of follow-up)  in 
subjects aged 35–89 years, adjusted for age at risk, sex, smoking, and study Area of square is 
inversely proportional to the variance of the log risk. The numbers below represent the number 




Risk of CVD increases markedly with age and is higher in men than in women. A 
family history of a parent or a sibling with CHD under the age of 55 years is strongly 
associated with increased risk. In a clinical setting various algorithms such as the 
Framingham Risk Score or the QRISK score (www.qrisk.org) are used to assess risk 
based on age, gender, BMI, systolic blood pressure and various measures of serum 
lipids (NCEP-3, 2001; Hippisley-Cox et al. 2007). 
1.4.3 Plasma lipids 
Generally, the risk of CHD is high in countries where the average serum cholesterol is 
high, compared to those where the average cholesterol concentration is low. Raised 
serum cholesterol concentrations are usually due to increases in the low density 
lipoprotein (LDL). LDL is derived from the metabolism of very low density lipoprotein 
particles (VLDL) that are secreted from the liver. VLDL is converted to LDL first by 
TAG removal from VLDL through the action of lipoprotein lipase to produce smaller 
particles, referred to as intermediate-density lipoproteins (IDL). IDL can be either 
cleared from the circulation by the liver particularly if they contain apolipoprotein E or 
converted to LDL by further removal of their TAG by hepatic lipase. LDL contains 
apolipoprotein B100 and is enriched with cholesterol. Serum LDL cholesterol (LDL-C) 
concentrations are usually estimated by determining the total cholesterol concentrations, 
high density lipoprotein cholesterol (HDL-C) and triacylglycerol (TAG) concentration 
using the Friedwald formula (total cholesterol – [HDL-C+TAG/2.2]). Desirable levels 




by the activity of LDL receptors which are expressed mainly in the liver (Goldstein & 
Brown, 2009). Various hormonal and genetic factors influence the activity of the 
receptors. First discovered by Nobel Laureates Goldstein and Brown, this receptor was 
found to be lacking in patients with familial hypercholesterolemia (FH). Heterozygous 
FH, where only half of the numbers of LDL receptors are function, is characterised by 
very high LDL-C typically well above 6 mmol/L and a 25 fold increase in risk of CHD 
before the age of 60 years. The prevalence of FH is above 1:500 in the general 
population. Increases in LDL-C occur with increasing age and it is believed that LDL 
receptors activity declines with age and is affected by thyroid hormone activity and 
oestradiol. The increase in LDL-C seen in women post menopause is believed to be due 
to a decline in LDL receptors activity due to the loss of oestradiol. LDL particles play a 
crucial role in the atherogenic process, but native LDL particles required to undergo 
oxidative modification before they are taken up by scavenger receptors on macrophages 
within the sub-endothelial space (Steinberg, 1989). The accumulation of lipid laden 
macrophages results in fatty streaks in the artery and these can progress to form the 
more complex lesions of atherosclerosis (Ross et al. 1999). There is now firm evidence 
to show that lowering LDL-C by drugs slows the atherogenic process and reduces 
coronary events (Baigent et al. 2010). High levels of HDL-C, on the other hand, may 
exert a protective effect on the development of CVD by promoting the removal of lipid 
from fatty steaks. However, clinical trials have yet to demonstrate that raising HDL-C 
reduces risk of CVD and a Mendelian randomization study has failed to show an effect 




1.4.4 Plasma triacylglycerols (TAG) 
It has been shown that higher fasting serum TAG (>1.7 mmol/l) are associated with an 
increased risk of CHD. One mechanism involves unfavourable modifications to LDL 
and HDL particles. This happens through the transfer of large amounts of TAG to HDL 
and LDL particles, which is catalyzed by the cholesteryl ester transfer protein (CETP) 
reaction. After that, TAG in the HDL and LDL particles is hydrolyzed by the action of 
hepatic lipase resulting in the formation of small dense LDL and HDL particles. This 
leads to a rapid uptake of HDL particles by the liver and poor recognition of small LDL 
particles by LDL receptors. The consequences are a low level of HDL-C and high level 
of small dense LDL, which may be depleted in cholesterol content, but is indicated by 
increased apoprotein B (apoB) concentrations (Sarwar et al. 2010). 
 
1.5 Effects of diet on plasma lipids 
Obesity contributes to elevated LDL-C. Furthermore, central obesity is strongly 
associated with atherogenic dyslipidemia (hypertriglyceridemai and low HDL-C) and 
high proportions of atherogenic small dense LDL. Keys et al. (1957) and Hegsted et al. 
(1965) first observed that SFA C12-C16 raised TC when exchanged for other fats in 
experimental diets containing 40% energy from fat. Keys and Hegsted developed 
various equations to predict effects on TC. The most commonly used version is given 





Keys equation:  
Δ cholesterol (mg/dL) = 2.3 ΔS –ΔP; which can be divided by 38.5 convert to mmol/L 
 ΔS is the difference in SFA % energy minus stearic acid and ΔP is the difference in 
energy % from PUFA. 
Numerous studies have subsequently evaluated the effects of different fatty acids on 
plasma lipid and lipoprotein concentrations and these have been subject to meta-
analyses by Mensink et al. (2003). 
SFA differ in their cholesterol-raising effects on the basis of the length of their carbon 
chain. Short (< 7) and medium chain (7-11) fatty acids have no effect on blood 
cholesterol because they are water-soluble and absorbed directly into the blood stream. 
Of the long chain fatty acids, stearic acid (18:0) has a negligible effect, possibly because 
it is desaturated to oleic acid (18:1n-9). Lauric (12:0), myristic (14:0) and palmitic acids 
(16:0), which are found in high proportions in dairy fats and tropical oils, increase LDL-
C and HDL-C. In comparison to other SFA or unsaturated fatty acids, lauric acid was 
found to have the largest HDL-C raising effect and myristic acid raised LDL-C to the 
greatest effect (Mensink et al. 2003). The mechanism by which these fatty acids 
influence LDL-C is uncertain, but is probably due to an effect on LDL synthesis rather 
than catabolism via LDL receptors. The net effect of replacing these C12-C16 saturates 




they are replaced with MUFA or PUFA (Mensink et al. 2003). TFA increase both LDL-
C and the LDL-C:HDL-C or TC:HDL-C  ratio compared to CHO and thus has the worst 
net effect on the lipid profile. PUFA slightly lower the TC:HDL-C ratio more than 
MUFA. One possible mechanism for the effect of TFA is increase in the activity of 
cholesteryl ester transfer protein (CETP) (Abbey & Nestel, 1994). 
PUFA, when consumed in large amounts act as ligands for the PPAR-alpha receptor 
which inhibits TAG synthesis, decreases VLDL production and promotes fat oxidation 
by the liver (Jump, 2011). LA appears to upregulate the expression of LDL receptor 
protein leading to rapid LDL removal from the circulation according to studies in 
hamsters and primates (Hayes & Khosla, 1992). In human studies, replacing SFA with 
PUFA increases the fractional catabolic rate of LDL (Goodnight et al. 1982) which 
would be consistent with increased removal of LDL by LDL receptors and increased 
bile secretion. Consumption of n-3 PUFA from fish oil markedly lowers TAG but does 
not lower LDL-C and may increase it in some individuals (Sanders, 2009a). At intakes 
of about 3g/d, it lowers VLDL TAG and synthesis, but lower intakes have a small 
effect. However, studies using purified DHA have found that it increases both LDL-C 













Figure 1.6  Predicted changes in low density lipoprotein cholesterol (LDL-C) (Panel A) and 
high density lipoprotein cholesterol (HDL-C) (Panel B) concentrations that result from 
exchanging 5 % energy as carbohydrate or monounsaturated (MUFA) or polyunsaturated 
(PUFA) fatty acids with different saturated fatty acids (SFA) or a mixture of dietary SFA, 












































































Figure 1.7 Effects (mean values with 95% CI) on the ratio of total 
cholesterol:HDL cholesterol (TC:HDL-C) resulting from the exchange 
of  1% energy as carbohydrate with equivalent amounts of food energy 
provided by different saturated, trans, monounsaturated (MUFA) and 





1.6 Dietary fat and risk of CVD 
Keys proposed that the intake of SFA was strongly related to risk of CHD based on the 
Seven Countries Study, which was an ecological study (Keys et al. 1986). However, 
this simplistic assertion has been strongly challenged (Astrup et al. 2011) because it 
does not agree with recent systematic reviews of prospective cohort studies that show 
no relationship between the intake of SFA and CHD mortality (Skeaff & Miller, 2009; 
Siri-Terano et al. 2010). In contrast, a more consistent positive relationship between 
TFA intake and CHD mortality has been observed (WHO/FAO, 2010). It was estimated 
that replacement of TFA with SFA or MUFA would lower risk (Mozaffarian & Clarke, 
2009). Jakobsen et al. (2009) in a separate analysis examined the relationship between 
MUFA, PUFA and CHO intake on the risk of CHD from 11 American and European 
cohort studies. They found that a 5% energy replacement of SFA by PUFA leads to a 
significant reduction in risk from CHD mortality (hazard ratio: 0.87; 95% CI: 0.77, 
0.97), while replacing SFA by CHO leads to a significant direct relationship (hazard 
ratio: 1.07; 95% CI: 1.01, 1.14). MUFA appeared to non-significantly increase risk 
compared with SFA but this finding may have been confounded by the inclusion of 
TFA with the MUFA. Hooper et al. (2012) in an updated Cochrane review of dietary 
interventions concluded that modification of fat intake, but not replacement of fat by 
carbohydrate, resulted in a significant 14% reduction in CHD incidence and a non-
significant 7% reduction in CVD mortality. However, Hooper concluded that 




review, Hooper et al. (2012) concluded that dietary advice to decrease fat intake was 
associated with moderate weight loss, in this respect it would be predicted that a lower 
intake of fat might be associated with a lower risk as a reduction in body weight is 
associated with favourable changes in blood pressure and blood lipids. 
 
1.7 Dietary reference intakes for fat and fatty acids 
Several bodies such as WHO/FAO, EFSA and the Institute of Medicine (IOM) in the 
USA have recently reviewed recommendations for fat intake, which are summarised in 
Table 1.3. Current UK guidelines are based on the COMA report (Department of 
Health, 1994) and are incorporated into NICE Guidelines (CG 67; www.nice.org.uk ). 
In the UK for example, the contribution from fat should not exceed 35% of energy, no 
more than 10% of energy should come from SFA and less than 2% from TFA. The UK 
has a dietary reference value (DRV) of 6% energy from PUFA, but makes no specific 
recommendations for MUFA. In most guidelines, estimates of acceptable intakes for 
MUFA are based on the calculations by difference (Department of Health, 1994). The 
WHO/FAO 2009 consultation (WHO/FAO, 2010) suggested average macronutrient 
distribution ranges for n-6 and n-3 PUFA combined as 6-11.5% energy. The slightly 
higher value for the upper limit was due to considerations regarding n-3 fatty acids 
(WHO/FAO 2010). All three recent reports now have total fat intakes in the range of 




but EFSA has specified as low as possible. More recent (Table 1.3) recommendations 
for TFA are no more than 1% energy or as low as possible. Neither EFSA nor IOM 
specified a DRV for PUFA. The ranges of acceptable intakes for PUFA in the IOM 
report were similar to the WHO/FAO whereas the acceptable intake was lower in the 
EFSA report.  In the UK, the National Diet and Nutrition Survey data (NDNS) show 
that total fat intake and PUFA is close to the UK recommendations but the intake of 
SFA is above the target (Henderson et al. 2003). The same pattern is seen in most 
European countries and in North America and Australia. Generally, over the past thirty 
years intakes of total fat expressed as a percentage of the energy have fallen. This may 
seem surprising in the light of the major increases in vegetable oil production. There is, 
however, a possibility that actual intakes of fat may be substantially under-reported and 
that there may be a mismatch between estimates of fat moving into consumption from 
actual reported intake. The various techniques for measuring dietary fat and their 




Table 1.3. Summary of dietary recommendations for the intakes of total fat and fatty acids intakes for adults as set by different organizations. 
  Fat SFA MUFA PUFA Trans n-6 n-3 n-3 LCP 
UK DoH 1994 <35% DRV <11% NA DRV 6% <2% EAR 1% EAR 0.2% DRV 0.45 
FAO/WHO 2009 20-35%* <10% NA 6-11.5* <1% 2.5 -9.0%  0.5-2.0%  0.25g-2g 
EFSA 2010 20-35% ALAP NA No DRV ALAP AI 4.0% AI 0.5% 0.25g 
Dietary guidelines for Americans 2010  20-35%* <10% NA No DRV ALAP AI 5-10% * AI 0.6-1.2%*  NA 
DRV: dietary reference value; EAR: estimated average requirement; AI: acceptable intake; ALAP: as low as possible; NA:not advised. 




1.8 Assessment of dietary intake of fat 
There is a great interest in understanding the relationship between fat intake and the 
development of chronic diseases including CVD and cancer, which leads to a pressing 
need for an accurate and precise measurement method that is able to reflect actual fat 
and fatty acids intake of an individual. Thus, it is very important to assess dietary fat 
intake using methods of measurement that are able to estimate the actual intake of type 
and amount of fat (Hodson et al. 2008).  Methods used to obtain information on food 
and dietary intakes are either based on the intakes of groups of people or individuals. 
1.8.1 Population studies 
Information on food supply at the national level can be obtained using food balance 
sheets or food disappearance data, which provide a picture of per capita accessibility of 
food items. Thus, the figures offer an indication of food availability rather than intake or 
consumption. According to population studies, patterns of dietary intake can be 
categorized chiefly by the food sources of macronutrients, as countries differ in the 
accessible sort of CHO staples (wheat, potatoes or rice), proteins (animal, vegetable or 
fish) or fats (animal fat, tropical oils, coconut oil, palm kernel oils and others). Such 
data does consider non-food uses of fat (soap, biodiesel) or exports. For example, a food 
balance sheet approach would indicate that Malaysia and Indonesia have high per capita 
availability of fat but most is exported and fat intakes are in the range of 25-30% energy 




1.8.2 Community data 
Community data based on surveys of groups of people rather than individuals and can 
be utilized for community surveys of nutrients intake and for identifying different food 
consumption patterns. It provides community, socioeconomic and geographic 
information and permits comparison between different times and regions. Food 
accounts, inventories, household record and list recall are the four major methods of 
measurements used in community surveys. This method becomes unreliable when large 
amounts of food are eaten outside the home and it gives no indication of distribution of 
food intake within households (Thomson & Subar, 2001; Eastwood, 2009).   
1.8.2.1 Food accounts 
This method is based on the household where the person liable for purchasing and 
preparing the food maintains a record of the amounts of food items entering the house. 
These comprise purchases, garden food, gifts, payment in kind and others. This kind of 
survey relies on the assumption that the average level of food stocks within the houses 
food store is stable, which is highly unlikely. In Great Britain, the Household Food 
Consumption and Expenditure Survey (MAFF, 1991) started in 1940 to evaluate the 
nutritional quality of the diet of urban, working-class households, to track the 
significance of the wartime food rationing policy, which finished in 1954, but continued 
until 2000. Thus, these reports provide a broad account of the British food habits since 
then i.e. over 60 years. The survey became unreliable when the proportion of food 





Using the inventory method, respondents are asked to keep records of individual food 
items entering the house. At the beginning and end of the survey, a larder inventory is 
accomplished. This method allows for direct measurement of the quantity of food and 
nutrients available within a single household (Thomson & Subar, 2001; Eastwood, 
2009). 
1.8.2.3 Household record 
In the household records, household measures are used to weigh or estimate the foods 
available for consumption (raw or processed) allowing for preparation waste. Then food 
eaten is calculated and subtracted from the total. This technique is ideal for population 
consuming home based diet and for simple and unsophisticated societies. In some 
communities measurements of food consumption of individuals is sophisticated and 
requires careful studies that begins from meal preparation and continue to watching the 
individuals eat (Thomson & Subar, 2001; Eastwood, 2009). 
1.8.2.4 List recall    
In this method, the individuals are requested to recall the amount and cost of food 
acquired for household use over a given period usually from 24h up to a week. This 
technique helps to estimate food cost and net household consumption of foods and 
nutrients, and is ideal when most of the consumed food is purchased rather than home 




1.8.3 Individual data 
1.8.3.1 Description, weighed and estimated records 
In this method each item consumed has to be weighed before consumption by either 
participants themselves or an investigator in addition to recording a detailed description 
of the consumed food in a specially designed booklet. Participants can be taught by 
trained personnel to describe and provide detailed information of the weighed food prior 
to consumption and record any leftover. Weighed intake can be measured for up to 
three, four, five or seven days. A 7-day weighed intake is widely used and has the 
advantage of providing a more precise estimation of portion size. High respondent 
burden, misreporting, and the cost of the method are among the main limitations 
associated with this method. Because of the high subject burden and the time spend for 
coding food; this method has often been not used in epidemiological studies (Wrieden et 
al. 2003; Thomson & Subar, 2001; Eastwood, 2009).  
1.8.3.2 Diet histories 
Diet histories collect information on frequency and quantity of food consumed on 
previous occasions and accuracy of these methods rely mainly on memory. The optimal 
period for collection data on dietary intake is 3-4 days. However longer periods are 
necessary for alcohol, several vitamins, minerals and cholesterol. Only 24h recalls will 





A detailed interview to determine quantity and frequency of food 
A cross-check frequency list 
A 24h recall 
A 3-day record (voluntary)  
The main disadvantages of diet histories include dependence on memory, interviewer 
bias and participant bias as a result of being interviewed. Furthermore, these methods 
are of limited value in some population groups such as children under the age of 12 
years. On the other hand, retrospective methods are quick, cheap, and require no 
motivation and literacy (Eastwood, 2009).    
1.8.3.3 24h recall 
24h recall, like other diet histories, relies on memory to recall intake in the recent past 
days. Subjects are requested to recall and describe all food and drinks consumed in the 
24h before the interview by asking a systematic series of questions. The focus of the 
questions is on amount and frequency of food intake meal-by-meal and looking for day-
to-day and seasonal differences. The accuracy of this method is highly dependent on the 
ability of the subjects not to under or misreport their intake and to estimate the portion 
size precisely. This can be helped by using a well-trained interviewer who can assist in 
the process of recalling and estimation of portion size. This method causes low burden 
on the subject and can be administered by the use of telephone and thus is suitable for 
large-scale surveys. The main limitation is that this method is not representative of 




the weekday and weekend intake. In addition, this method, apart from being memory 
dependent, is likely to be associated with bias in relation to estimation of portion size 
and in recording the “good/bad” food. For more accurate data a multiple 24hr recalls 
might be applied, which may add extra burden on the subject (Nelson & Bingham, 
1997). Moreover, peoples with low intake are liable to report higher than actual intake, 
and those with higher intake are likely to report lower (Thomson & Subar, 2001; 
Eastwood, 2009).   
1.8.3.4 Questionnaires  
Questionnaires are one of the most widely used tools for assessment of dietary intake. 
Subjects are asked about the frequency of consumption of food or drink. They are easy, 
cheap and can be self or interviewer administered. When self-administered, interviewer 
bias is eliminated. However, questions have to be very straightforward and explicit or 
they may be left unanswered. Questions are closed or open, simple or comprehensive, 
and may comprise from 9 to 190 food items (Thomson & Subar, 2001; Eastwood, 
2009).  
1.8.3.5 Food frequency questionnaire  
Food frequency questionnaires (FFQs) attempt to collect information about food 
consumption from a large number of individuals (100 or more) beside information 
regarding portion size and incidence of consumption within a specific period and 




selection of options regarding frequency of consumption of each food in the list. The 
length of the food list varies depending on the nutrient under investigation and its 
sources.  Because the FFQ has a low respondent burden and can be self-completed, it is 
suitable for use in a large epidemiological studies and surveys. However, problems such 
as portion size estimation, over-reporting of healthy foods (e.g. fruits and vegetables 
and dairy products) and under-reporting of unhealthy food raises questions regarding 
their ability to provide an accurate assessment of fat intake. Particularly when the FFQ 
is unable to discriminate, which fats and oils are used in compound foods and a number 
of assumptions are made regarding portion sizes, which in the case of fat, which is 
energy dense, could lead to large errors. For instance, Bingham et al. (2003) 
investigated the relationship between SFA intake and breast cancer in 13070 women 
between 1993 and 1997 showed that the risk of breast cancer was associated with SFA 
intake when assessed by the 7-day food diary (P=0.005) but was unable to demonstrate 
the relationship when FFQ (P=0.23) was used. 
1.8.4 Limitations and sources of errors 
Table 1.4 summarises the limitations of the various methods to assess fat intake. Most 
epidemiological studies have used FFQs to estimate dietary intake of fat and fatty acids 
and relatively few have used weighed food records that are the most reliable. More 
recent surveys in the UK have used repeat 24h recalls or 4-d record. However, a major 





Table 1.4 Summary of limitations of dietary assessment methods with regard to type of fat 
Method  
Subject burden Mis-reporting Miscoding Accuracy Uncertainty 
Duplicate diets Very High Low N.A. High Moderate 
Weighed intake High Moderate Moderate Moderate Moderate 
FFQ Low Moderate High Low Low 
24h recall Low High Moderate Low Low 
7-day food diary High Moderate Low Moderate Moderate 
Mis-reporting – both over and under-reporting 
Miscoding – difficulties in assessing correct food code or portion size 
Accuracy  - problems with recall, description of foods consumed 
Uncertainty – participants may change what they eat to make recording simpler 
 
In comparison to other macronutrients in the diet, amount and type of dietary fat is one 
of the most difficult to measure using traditional assessment methods due to a number 
of reasons. Added fat used in food preparation including frying, cooking and dressing, 
is very difficult to recognize and quantify. Furthermore, bias is associated with accuracy 
of reporting foods high in fat, the problem that is well known among overweight and 
obese persons, who tend to underreport their intake (Arab, 2003). Fat can be subject of 
recall bias. Traditional assessment methods, such as FFQ and 24h recall, which are the 
main assessment methods used in epidemiological studies to estimate individuals and 
populations habitual intake, are subject to  limitations and measurement errors that are 




systematic bias, interviewer bias, social desirability bias and miscoding in the food 
composition table (Nelson & Bingham, 1997).  
 
1.9 Current intakes and sources of fat in the UK diet 
In terms of sources of fat intake, NDNS has provided useful data. The earlier surveys 
are probably more robust as they recorded weighed food intakes, whereas the more 
recent surveys resorted to using multiple pass food recalls. Using the more robust 
NDNS data (Henderson et al. 2003), the main sources of fat in the UK diet were meat 
and meat products (23%), cereal and cereal products (19%, this included added fats in 
processing), milk and milk products (14%), fat spreads (12%) and potatoes and savoury 
snacks (10%) as shown in Figure 1.8. The contribution of SFA to the energy intake was 
similar at 13.4% and 13.2% for men and women respectively. The mean percentage of 
food energy from TFA for both men and women was 1.2% lower than the old target but 
still above 1%. Regarding the cis MUFA, the average intakes were 12.1% and 11.5% 
for men and women respectively. For the n-3 PUFA, the mean intake was greater in 
men than women and was lower for women aged 25 to 34 years than those between 50 
to 64 years of age. There were no reliable estimates of short-chain SFA and LC n-3 
PUFA. The average daily intake for n-6 PUFA was significantly higher in men than 
women (P<0.01) but based on percentage energy they were similar (Henderson et al. 




products, although the contribution from milk products has fallen markedly since earlier 
surveys.  Reliable data on changes in the fatty acid intake of the UK and other European 
diets are hard to assess, and the food industry is continually modifying the composition 
of fats and oils to meet consumer demands as well as keep ingredient cost as low as 
possible. The UK food composition data base is limited and much of the data are based 
on the analyses having been conducted over 20 years ago (Holland et al. 1991; MAFF 
1998) and the published food tables lack information on the detailed fatty acid content 
of commonly consumed foods being restricted to total fat, SFA, MUFA, trans isomers 
and PUFA.  There is a pan-European project called EUROFIR (www.eurofir.org) which 
is trying to address issues of food composition in the European Union. The situation 
with regard to accurate food composition data is even more vague in many emerging 
economies particularly those of the Middle East where there is only limited food 
composition data available. 
 
 






Main sources of fat in the UK diet 
Meat & meat products
Cereal & cereal products







1.10 The use of biomarkers for assessment of fat intake 
1.10.1 Major types of biomarkers used in estimating fat intake 
1.10.1.1 Adipose tissue 
Adipose tissue is the main fat storage site. It has been considered as a suitable 
representative of long-term dietary intake of fat because it has a slow turnover time in 
weight stable subjects, which is about 1.5 years (Strawford et al. 2004). In healthy 
adults, adipose tissue consists approximately of 99% TAG, 0.3% cholesterol, and less 
than 0.1% phospholipid (PL) (Hodson et al. 2008). The major fatty acids in adipose 
tissue are oleic acid (18:1n-9; 37.0-49.7 mol%), palmitic acid (16:0; 18.1-23.5 mol%), 
LA (18:2n-6; 8.6-24.9 mol%), palmitoleic acid (16:1n-7; 4.5-10.1 mol%), stearic acid 
(18:0; 2.6-4.7 mol%) and a very low proportion of very LC-PUFA (<1 mol%). There 
are some difference in composition between different adipose tissue sites with high 
proportions of MUFA in subcutaneous fat and lower proportion of SFA compared with 
abdominal fat, especially perirenal fat, but they lack any differences in the distribution 
of LA (Hodson et al. 2008).  
Six studies, investigated the composition of human adipose tissue as reliable biomarker 
of dietary fat intake, were found. All studies analyzed fatty acid composition of human 
tissues by gas chromatography (GC) and dietary assessment by FFQ. Among these, one 
study measured habitual fish intake by analyzing marine LC n-3 PUFA composition of 




al. 2004); two studies measured ALA and the risk of nonfatal acute myocardial 
infarction (Baylin et al. 2003; Campos et al. 2008). Two further studies were conducted 
to investigate the reliability of adipose tissue as biomarker for a range of fatty acids 
(Baylin et al. 2002; Craig et al. 2009).  
 All six studies investigating human adipose tissue indicated that its composition 
reflects that of dietary fat intake as assessed by FFQ. It has been shown in case-control 
studies on Australian cohorts that adipose tissue TFA composition is significantly 
associated with the intake of TFA from the diet (18:1n-9, r=0.66, 18:1n-10, r=0.66) 
(Clifton et al. 2004). Another interesting point is that when TFA were removed from the 
margarine in mid-1996, levels of TFA (18:1n-9 and 18:1n-11) were higher in cases 
biopsied before mid-1996 (P< 0.03, P< 0.001 respectively). This study concluded that 
TFA in the diet correlated with adipose tissue TFA (18:1n-9 and 18:1n-10) indicating 
that adipose tissue is a good biomarker of dietary TFA intake (Clifton et al. 2004). An 
initial study in Costa Rica found lower levels of ALA in the adipose tissue of patients 
who had suffered a myocardial infarction (MI) compared with their controls (Baylin et 
al. 2003). In a follow-up of this study, Campos et al. (2008) investigated the intake of 
ALA and the risk of MI on 1819 cases and equivalent number of controls and showed 
that estimates of dietary ALA intake were correlated with the proportion of ALA in 
adipose tissue. When using adipose tissue as biomarker of habitual fish intake, the 
results showed that the consumption of fish (r= 0.55) and marine n-3 PUFAs (r= 0.58) 




not significantly associated with EPA and DPA (Marckmann, 1995). The remaining two 
studies compared the reliability of the use of adipose tissue as a biomarker of different 
fatty acids. The first one concluded that adipose tissue is suitable for the assessment of 
n-3 (r=0.24), n-6 (r=0.58) PUFA and TFA (r=0.58) intake from the diet, (Baylin et al. 
2002). The other study reported the reliability of adipose tissue to significantly reflect 
DHA (P=0.037) and EPA (P=0.018) (Craig et al. 2009). 
In conclusion, the evidence suggests that adipose tissue can be utilized to estimate 
intake of PUFA and TFA. The reliability for assessing intake of MUFA and specific 
SFA remain uncertain.   
1.10.1.2 Plasma total lipids 
Plasma total fatty acid composition typically reflects a mixture of all plasma lipid 
fractions that contain fatty acid in their structure. These include PL, TAG, cholesteryl 
ester (CE) and non-esterified fatty acids (NEFA). The fatty acid composition of plasma 
total fatty acids is in the following order 18:2n-6 (30.4 mol%), 16:0 (23 mol%) and 
18:1n-9 (19.5 mol%). These lipid fractions have different fatty acid composition and 
thus any change in the concentration of any of these lipid fraction results, in turn, in a 
distinctive difference in plasma total fatty acids composition. Typically, the 
concentration of PL is about 1 mmol/L, NEFA 0.6 mmol/L, CE 4 mmol/L and TAG 1 
mmol/L. So the molar contributions of fatty acid from PL, NEFA, CE and TAG can be 
estimated as 2, 0.6, 4 and 3 respectively. Hodson et al. (2008) ranked fatty acids in 




20:4n-6, 20:5n-3, 22:6n-3, 18:1n-9, 18:2n-6, 16:1n-7, 18:0 and 16:0. Palmitic and 
stearic acids were surprisingly the least variable given the relatively large range of 
variation in SFA intake between individuals.  Plasma CE are particularly enriched in 
LA probably because it derives its fatty acids from lecithin via the enzyme lecithin 
cholesterol acyl transferase (LCAT) and lecithin is rich in LA. NEFA in the fasting state 
tend to represent the fatty acid composition of adipose tissue whereas in the 
postprandial state they represent the composition of the dietary fat ingested. TAG in the 
fasting state represents TAG synthesised in the liver, which is dependent on recent 
dietary intake as well as the flux of NEFA from adipose tissue. Following a fatty meal, 
the TAG composition will tend to be more similar to that of the fat consumed. Some 
researchers have measured total phospholipids or lecithin as biomarkers of intake but 
total plasma fatty acids appear at least a robust index of fatty acid intake and are much 
easier to measure directly than PL (Lepage & Roy,1986) and is widely used (Kuratko & 
Salem, 2009). 
1.10.1.3 Plasma phospholipids 
Plasma PL composed of a glycerol molecule having two fatty acids at positions sn-1, 
which is predominated by SFA or MUFA, and sn-2, which is predominated by MUFA 
or PUFA, and a phosphoric acid residue at the third position. The PL species include 
sphingomyelin (SPH), lecithin/phosphatidylcholine (PC), phosphatidylserine (PS), 
phosphatidylinositol (PI) and phosphatidylethanolamine (PE). Lecithin and SPH are the 




sensitive to the level and type of PUFA. The major fatty acids of plasma total PC are in 
the order of 16:0, 18:2n-6, 18:0, 18:1n-9, 20:4n-6 and 22:6n-3 (Sanders et al. 1978; 
Hodson et al. 2008). 
1.10.1.4 Erythrocyte phospholipids 
Erythrocyte phospholipids are characterized by a large amount of 16:0 (21.2-34.9%), 
which is twice as abundant as any other fatty acid. The proportions of 18:0, 18:1n-9 and 
20:4n-6 were around 14%. 18:2n-6 has a lower quantity (11.2%). With reference to 
plasma PL fatty acid composition, the profusion of very LC n-3 PUFA is equivalent to 
that of plasma PL. However, the abundances of 18:2n-6 and 20:4n-6 are half and double 
that of plasma PL respectively. This lower amount of 18:2n-6 in erythrocyte PL is a 
typical feature of cell membrane and indicates a tight metabolic regulation of the 
composition of this fatty acid (Hodson et al. 2008). Erythrocyte lipids have been widely 
used to assess the balance between n-6 and n-3 fatty acids in the diet but are relatively 
insensitive to changes in SFA intake. Erythrocyte phospholipids are considered a 
longer-term indicator of past intake. Although erythrocytes have a life span of about 
120 days, it is possible to bring about changes in their composition within a few days 
and while changes in the proportion of LC n-3 PUFA persist for longer following 
withdrawal of supplementation, values for EPA still changed over a 5-week period 




1.10.1.5 Other tissues i.e. buccal cells 
The use of buccal cells as biomarker of fatty acids intake has been used as a reliable 
marker of LC-PUFA status as the PL are the major component of cell membranes. 
Buccal cells are preferred over other biomarkers when measuring fatty acids 
composition in infants. This is because this tissue is available and helps avoiding 
repetitive blood sampling. In addition, small amount of oral mucosal cells are sufficient 
for the analysis and detectable by the GC. Furthermore, this fraction has a rapid 
turnover rate, which is 5 days, and thus reflects current intake and is sensitive to 
changes in dietary intake. Moreover, this tissue is not affected to a great extent by 
contamination with dietary lipid, which is predominantly composed of TAG. The main 
SFA in cheek cells are palmitic and stearic acids. Oleic acid has the highest proportion 
among the unsaturated fatty acids. For the LC-PUFA, the order of the fatty acids is, 
from highest to lowest, 18:2n-6, 20:4n-6, 22:6n-3, 20:3n-6, 20:5n-3, 20:2n-6, 18:3n-3 
and 18:3n-6. In conclusion, cheek-cell lipid analysis is of possible value in nutrition 
research studies and of useful use in epidemiological studies on fatty acid analysis 
particularly from children (Laitinen et al. 2006; Koletzko et al. 1999; McMurchie, 
1984). However, the amount of material for analysis is very small and there is the 
danger of contamination of swabs with food particles.  
1.10.2 Previous studies using biomarkers of fat intake 
Four studies were identified from a Medline search. One was on ten European countries 




and the United Kingdom) contributed in the EPIC study. This was a cross-sectional 
study to determine the plasma fatty acids composition of 3,000 subjects or more from 
16 different European countries. The authors aimed to analyze the relationship between 
the plasma PL fatty acid concentration and dietary intake of major food groups using 
FFQ and a single 24hr recall. They examined the potential of two different dietary 
assessment methods to predict plasma fatty acids concentration at a population level. In 
addition, they tried to evaluate the influence of the endogenous (age, sex and BMI) as 
well as the exogenous (region and lab variables) factors on plasma fatty acid 
concentration as a secondary objective. A total of 22 fatty acids were separated from 
fatty acids methyl ester (FAME) of chain length between 14 and 22 carbon atoms and of 
different fatty acid classes including SFA, MUFA, PUFA, and TFA using GC 
technique. This study showed that specific plasma PL fatty acids are considered good 
biomarkers of some, but not all, types of food consumed in each region of the EPIC 
study, which suggest differences in food intake between regions under study. For 
example, some patterns of fatty acids appeared to be linked to specific dietary groups. 
For instance there was a significant correlation with mean high intake of fish and LC n-
3 PUFAs (r=0.78, P<0.01), olive oil and oleic acid, cis 18:1n-9, (r=0.73, P<0.01) and 
margarine and elaidic acid, TFA 18:1n-9, (r=0.76, P<0.01). The observed association 
was strongly determined by region, which implies that there is variation in dietary 
intake across regions. For example, olive oil intake was correlated with oleic acid (cis 
18:1n-9) concentration only in areas where consumption of olive oil was high, but the 




that plasma PL concentration can be used as a reliable biomarker of some fatty acids, 
especially those that are not endogenously synthesized such as branched chain fatty 
acids and TFA (Saadatian-Elahi et al. 2009).  
Chajes et al. (2008) investigated the relationship between fatty acid composition of 
serum PL and the risk of breast cancer among women in the French component of the 
EPIC study. A total of 19,934 women, who has been followed up for seven years, were 
matched by controls for age, menopausal and fasting status at the time of blood 
sampling, and date and center where collection took place. This study showed that a 
high level of serum trans MUFA (palmitoleic and elaidic acids) was associated with 
increased risk of breast cancer. Dietary consumption of foods rich in trans MUFA 
assessed by FFQ significantly correlated with serum PL levels of these fatty acids 
(trans-palmitoleic, P=0.003 and elaidic acids, P=0.0001) (Chajes et al. 2008). 
A further case-control study aimed to evaluate the relationship between levels of 
different TFA of plasma PL in older adults and the development of fatal Ischemic Heart 
Disease (IHD) and sudden cardiac death (Lemaitre et al. 2006). They found that 
elevated levels of TFA 18:2 (OR 2.34, 95% CI 1.27-4.31) and decreased levels of TFA 
18:1 (OR 0.18, 95% 0.06-0.54) are associated with an increased risk of fatal IHD and 
sudden cardiac death, (Lemaitre et al. 2006). The last study examined the association 
between plasma PL and CE fatty acid composition and those of habitual diet measured 
by FFQ in 3570 free-living middle-aged adults. The results of this study showed that 




respectively), MUFA was weakly correlated (r= 0.05 and r= 0.01 respectively) and 
PUFA was well correlated with both plasma PL (r= 0.25) and CE (r= 0.31). Of all 
PUFA, plasma DHA was strongly correlated with dietary intake (r= 0.42). Moreover, 
they found that dietary SFA was positively associated with concentration of plasma 
MUFA and 18:1n-9 (both r= 0.26). On the contrary, MUFA and 18:1n-9 from the diet 
were not associated with plasma concentrations of MUFA and 18:1n-9 (range r= -0.02-
0.06). Whereas, plasma concentrations of EPA and DHA were associated with dietary 
intake of LA (r= 0.15) and, interestingly, the strongest correlations were observed 
between plasma and dietary intake of both EPA (r= 0.44) and DHA (r= 0.42). SFAs and 
LA were chosen to perform a further analysis to examine the effects of disease status, 
body fatness, smoking and alcohol drinking. The statistical analysis revealed that male 
participants with chronic disease (i.e. having either CVD, diabetes or hypertension), 
who were overweight, smokers, or who drank alcohol heavily, had an elevated level of 
mean plasma SFA and/or decreased levels of mean plasma LA than those who were free 
from these factors (Ma et al. 1995).  
Two studies have compared both subcutaneous adipose tissue biopsies from the upper 
buttock and plasma as biomarkers of fat intake. The first one examined the hypothesis 
that high ALA in plasma and adipose tissue is associated with reduced prevalence of the 
metabolic syndrome (MS). They found that elevated levels of ALA were associated 
with a lower risk (P< 0.02) (Truong et al. 2009). The purpose of the last study was to 




compared to adipose tissue and plasma in 101 females and 99 males in Costa Rica 
between 1999 and 2001. All participants completed 135-items FFQ and supplied 
adipose tissue in addition to fasting blood samples. Fatty acid analysis of the samples of 
blood and adipose tissue were analyzed by gas chromatography. The authors found that 
strongest correlation with dietary intake was for adipose tissue with the highest 
correlation for ALA (P= 0.024), LA (P= 0.039), and 18:2 trans as compared to plasma. 
The authors concluded that fasting whole blood is a suitable biomarker for long-term 
LA and ALA intake. Fasting whole blood require minimum sample processing, 
accessible as well as its ability to predict dietary intake as good as fasting plasma 
(Baylin et al. 2005).  
The majority of the studies included in this review were consistent in supporting the 
hypothesis that adipose tissue and plasma fatty acid composition are valid biomarkers of 
PUFA, TFA and other exogenous fat (such as branched chain fatty acids) and should be 
used in line with FFQ. However, some studies showed that plasma can be used as 
biomarker for some (e.g. n-3 PUFA of marine origin), but not all (e.g. MUFA), fatty 
acids (Ma et al. 1995). Furthermore, obtaining adipose tissue biopsies is less acceptable 
for participants than giving blood and for large scale epidemiological studies. This 
suggests that plasma is the most suitable material for biomarker use. This is evaluated 





1.10.3 Factors influencing fatty acid measurements in biomarkers 
Measurement of fatty acids in biomarkers is influenced by a number of factors that may 
affect the actual levels of fatty acid in the analysed specimen. The first factor is 
handling and storage of the sample. For instance, oxidation of PUFA by exposure to air 
or contact with iron present in erythrocyte can happen because of inappropriate handling 
and storage. Long storage can result in sample degeneration or the consequences of 
refrigeration loss. In addition, changes in the PUFA profile can happen as a result of 
sensitivity to temperature and oxygen, which can be minimized by careful storage at -
80°C under nitrogen gas or with added anti-oxidants such as butylated hydroxytoluene. 
Another important factor is tissue-sampling site. A comparison of fatty acid profile of 
deep seated sites (perirenal) and subcutaneous sites (abdominal and buttocks) show that 
perirenal adipose tissue has high proportions of SFA, while buttock has the lowest 
proportion of SFA and a highest proportion of MUFA. Abdominal adipose tissue 
consists mainly of SFA. PUFA profile showed no significant differences across the sites 
(Arab, 2003). Moreover, nutritional status of the subject can affect fatty acid profile of 
the individual. For example, adequate amounts of minerals including iron, zinc, copper 
and magnesium is required for the desaturase enzymes, which are metalloenzymes, to 
function properly. Furthermore, because the measurement reflects the percentage of 
individual fatty acids not the absolute amount of the consumed fatty acid, the increase in 
the intake of some fatty acids can drive down the relative percentage of the other even 




accurately long-term intake. Changes in the diet of a normal weight person require three 
to four years for adipose tissue to equilibrate to the new diet. Adipose tissue have a 
tendency to reflect long-term dietary intake (~1-2y), which makes it impossible to 
obtain accurate dietary information from the respondent that reflect the same period of 
measurement. Consumed fatty acids in the diet are not stored directly, but some are 
oxidised while others undergo metabolic reactions before storage (Arab, 2003; Hodson 
et al. 2008).  
1.10.4 Biomarkers of fat intake: A review of the cohort studies and trials 
1.10.4.1 Background  
In order to identify systematically cohort studies that have compared these biomarkers 
with estimates of dietary intake and randomized controlled trials that have validated 
biomarkers, a structured search strategy was adopted.  
1.10.4.2 Review questions 
The research questions posed were:   
How well do biomarkers of fatty acid intake correlate with traditional estimates from 
dietary intake? 
What evidence is there from randomized controlled trials of modification of fat intake to 




1.10.4.3 Defining inclusion/exclusion criteria 
Cohort studies were included in the review according to the following criteria:  
There were at least 64 participants in the study. 
Analysis of fatty acid composition of the biomarker by gas chromatography. 
Dietary intake of fat is reported. 
A statistical measure of association (Pearson‟s or Spearman‟s correlation coefficient) 
between proportions of fatty acids in biomarker and diet is reported.  
Only English language publications were considered. 
Criteria for randomized controlled trials are:   
Participants were randomly allocated to control or treatment. 
The sample size for each group was greater than 64 and the duration of intervention was 
at least 12 weeks. 
Analysis of fatty acid composition of the biomarker by gas chromatography. 




1.10.4.4 Search strategy 
Searches of electronic databases Embase, Scopus, Ovid Medline, Pubmed, Web of 
knowledge and Web of science using the following search terms/key words in 
combination with Boolean operators: 
Biomarkers Fat Fat intake 
Adipose tissue Fatty acids FFQ 
Plasma Lipids  Food diary 








  Cholesteryl ester 
    
1.10.4.5 Results  
Seventeen articles that matched with the inclusion criteria were identified. Some studies 
compared more than one biomarker. Five studies compared adipose tissue as biomarker 
with fat intake (Godley et al. 1996; Garland et al. 1998; Yli-Jama et al. 2001; Baylin et 
al. 2005; Cantwell et al. 2005). Erythrocytes were used in seven studies (Godley et al. 




Zhang et al. 2010; Jeppesen et al. 2012). The use of plasma phospholipids was 
examined in four studies (Ma et al. 1995; Anderson et al. 1996; Hodge et al. 2007; 
Thiebaut et al. 2009). Total plasma was reported in four studies (Baylin et al. 2005; 
Sullivan et al. 2006; Sun et al. 2007; Astorg et al. 2008).  One study used plasma 
cholesteryl esters (Brunner et al. 2001).  
The findings are summarised in Table 1.5. Most studies found no significant correlation 
between SFA and MUFA intake and those of the biomarkers. However, few exceptions 
reported weak correlations for SFA intake and an Italian study (Fuhrman et al. 2006) 
reported a surprisingly strong correlation between oleic acid intake and the proportion in 
erythrocytes. Most studies found positive correlations with PUFA, TFA, LA, EPA and 
DHA intakes. The findings were most consistent for EPA and DHA. Variable results 
were found for ALA, which implies that there may have been limitations in the dietary 
assessment procedures that may have overlooked dietary sources of ALA. Total plasma 
lipids appeared to yield comparable results to plasma PL and CE. 
The OPTILIP study (Sanders et al. 2006a) which compared different ratios of long and 
short chain n-3 PUFA showed dietary EPA and DHA, but not ALA, to be reflected in 
changes in the proportions of EPA and DHA in erythrocyte lipids. With the exception of 
the MARINA and RISCK studies, which shall be reported on later in this thesis, no 




Table 1.5 Correlation between dietary intake and biomarkers of fatty acid intake in previously reported studies. 
Study Tissue  No M/F Correlation SFA MUFA PUFA TFA 16:0 18:0 OA LA ALA EPA DHA 
Yli-Jama et al. 2001 Adipose 218 MF Pearson       0.31** -0.009 0.123 -0.111 0.49** 0.437* 0.609** 0.588* 
Baylin et al. 2005 Adipose 196 MF Pearson 0.04 0.06 0.51** 0.31** 0.1 0.05 0.15 0.52 0.51 -0.08 0.26 
Cantwell et al. 2005 Adipose 84MF Pearson 
   
0.17 
   
0.58* 
   Garland et al. 1998 Adipose 140F Spearman 0.16** 0.04 0.40** 0.40** 0.14 NA 0.12 0.37** 0.34** NA NA 
Godley et al. 1996 Adipose 109 M Spearman 
         
0.38** 0.32** 
Fuhrman et al. 2006 Erythrocytes 94PRE-F Pearson 0.14 0.40** 0.17 
   
0.45** 0.23* 0.14 
  Fuhrman et al. 2006 Erythrocytes 104PM-F Pearson 0.07 0.48** 0.39** 
   
0.47** 0.39** 0.07 
  Sullivan et al. 2006 Erythrocytes 53MF Spearman 
         
0.40** 0.39** 
Wennberg et al. 2009 Erythrocytes 88M Spearman         -0.02     -0.08 -0.3 0.42** 0.48** 
Wennberg et al. 2009 Erythrocytes 92F Spearman 
    
0.04 
  
0.09 0.12 0.46** 0.51** 
Zhang et al. 2010 Erythrocytes M44F8§ Spearman -0.15 0.07 -0.08 
     
0.19* 0.37** 0.16** 
Godley et al. 1996 Erythrocytes 124M Spearman 
         
0.44** 0.41** 
Jeppesen et al. 2012 Erythrocytes 2224MF Pearson 
         
0.4** 0.18** 





Table 1.5  continued 
Study Tissue No M/F Correlation SFA MUFA PUFA TFA 16:0 18:0 OA LA ALA EPA DHA 
Baylin et al. 2005 Plasma 196 MF Pearson 0.11 0.14* 0.39** 0.11 0.14* 0.01 0.32** 0.41** 0.39** 0.28** 0.31** 
Sun et al. 2007 Plasma 306F Spearman 0.16** 0.04 0.23** 0.3** 0.12** 0.06 0.12** 0.25** 0.23** 0.21** 0.48** 
Sullivan et al. 2006 Plasma 53MF Spearman 
         
0.54** 0.48** 
Astorg et al. 2008 Plasma  276M Pearson 
       
0.22** 0.06 0.24** 0.25** 
Astorg et al. 2008 Plasma  257F Pearson 
       
0.19** 0.05 0.27** 0.27** 
Hodge et al. 2007 Plasma PL 4439MF Pearson 0.10** 0.26** 0.26** -0.22 0.09 
 
0.22** 0.20** 0.07 0.18** 0.40** 
Ma et al. 1995 Plasma PL 1712M,1858F Pearson 0.20** 0.07 0.44**   0.13**  0.13** 0.26** 0.26** 0.36** 0.55* 
Anderson et al. 1996 Plasma PL 462M 117F Pearson 
    
-0.23** 
 
-0.21 -0.04 -0.04 0.51** 0.49** 
Thiebaut et al. 2009 Plasma PL 1114F Spearman 
       
0.11** 0.01 0.28** 0.36** 
Brunner et al. 2001 Plasma CE 115M Spearman 0.16 
 
0.43** 




 Brunner et al. 2001 Plasma CE 71F Spearman 0.26* 
 
0.50** 




 SFA=saturated fatty acids, MUFA=monounsaturated fatty, PUFA=polyunsaturated fatty acids, TFA=trans isomeric fatty acids, OA=oleic acid, LA=linoleic 
acid, ALA=alpha-linolenic acid, EPA=eicospentaenoic acid, DHA= docosahexaenoic acid, PL=phospholipid, CE=cholesteryl esters, PRE-F=premenopausal 
women, PM-F=postmenopausal women. 




1.11 Digestion, absorption and metabolism of dietary fats 
Most dietary fats are present as TAG, which is composed of a mixture of long chain and 
a small fraction of short- and medium chain fatty acids. The latter are hydrophilic and 
volatile and thus are directly absorbed by the intestinal capillaries and travel via the 
portal vein. On the contrary, emulsification is the central step for hydrolysis of long 
chain fatty acids, which are hydrophobic, to monoacylglycerol and free fatty acids 
(FFA) prior to absorption. This process is accomplished by three main stages: 
emulsification in the stomach, micelle formation facilitated by bile salt in the 
duodenum, lipolysis by pancreatic lipase in the duodenum and jejenum; uptake by the 
enterocytes in the ileum by passive transport (Bauer et al. 2005). The absorbed fatty 
acids and monoacylglycerols are re-synthesized into TAG in the enterocytes, secreted 
into lymph as chylomicrons and transferred via lymphatic vessels into the blood stream. 
To facilitate their transportation, they need to form lipoprotein complexes containing 
apolipoprotein B48. 
Chylomicrons, which are large TAG rich lipoprotein particles, carry the esterified fatty 
acids from enterocytes to peripheral tissues such as muscle and adipose tissue, where 
TAG are hydrolysed by the action of lipoprotein lipase attached to the capillary 
endothelium. The resulting NEFA and glycerol, which travels through endothelial cells 
that make up blood capillaries, can either be used as an energy supply or stored as TAG. 





In contrast to exogenous fat, which is transported by chylomicrons to tissues, 
endogenous fat arising from TAG synthesis in the liver is secreted as  very low density 
lipoprotein (VLDL) which contains apolipoprotein B100 as opposed to 
apolipolipoprotein B48 in chylomicrons. VLDL reacts with lipoprotein lipase on 
endothelial cells where fatty acids are cleaved from the TAG. As TAG is removed from 
VLDL it decreases in size to form IDL, which may also contain apolipoprotein E, IDL 
particles without apolipoprotein E become substrates for hepatic lipase and are 
converted to LDL which contain apolipoprotein B100 as its sole protein. LDL is 
removed from circulation by the process of receptor-mediated endocytosis where 
apolipoprotein B100 binds to the LDL receptor and is taken up into cells. Most LDL 
receptors are expressed in the liver, which is thus the main site for removal of LDL. 
HDL is secreted from the liver and to some extent from the small intestine in a discoidal 
form low in lipid but as it acquires lipids in circulation it become spherical (Basso et al. 
2003; Brunham et al. 2006). The main proteins in HDL are apolipoprotein A1 and A2. 
HDL particles acquire cholesterol and phospholipid from the liver and peripheral 
tissues. Mature HDL goes back to the liver although it can transfer cholesterol and 
phospholipid to TAG rich lipoprotein particles such as VLDL and IDL in exchange for 
TAG by the action of cholesterol ester transfer protein (Rader & Daugherty, 2008; 
Ratnayake & Galli, 2009). 
The majority of fatty acids (~ 90%) circulating in the plasma are in the esterified form 




levels are high NEFA released from chylomicron TAG by lipoprotein lipase (activated 
by insulin) are stored in adipose tissue or taken up by muscle for energy metabolism. In 
the fasting state, NEFA are released from adipose tissue by the action of hormone 
sensitive lipase (activated by adrenaline) and transported in blood bound to albumin 
where they can be taken up by tissues for oxidation to supply energy or can be 
resynthesized into TAG in the liver (Bergman et al. 1971; Coppack et al. 1992; 
Hellerstein, 1999).   
The type of fat consumed influences the composition of these various lipid fractions. 
However, it is necessary to consider how each fraction changes in relation to dietary 
intake. TAG reflects intake over the past few hours and are subject to large variations 
(Durrington et al. 1977; Moore et al. 1977; Vessby et al. 1980). CE is marker of a 
longer-term intake to some extent (~3-5 days) (Zock et al. 1997, Zuijdgeest-van 
Leeuwen et al. 1999). Phospholipids are representative of intake over similar time 
periods to CE and are most frequently used lipid fraction in spite of low concentrations 
(Seppanen-Laakso et al. 2001; Zuijdgeest-van Leeuwen et al. 1999). Cell membrane 
PLs have been commonly used in nutritional studies as a marker of fat intake. It has 
been implied that fatty acids of cell membranes, which have a lifespan of 120 days, are 
a better indicator of fat intake than plasma fatty acids (Arab, 2003) particularly for DHA 
(Sun et al. 2007). Alternatively, adipose tissue is the marker of choice to mirror long-
term fatty acids intake over years because of its slow turn over (Dayton et al. 1966; 




Katan et al. 1997; Strawford et al. 2004). SFA and MUFA can be synthesized 
endogenously, while PUFA are almost solely exogenous and accordingly are superior 
biomarker of fat intake (Arab, 2003). There are other factors that influence efficiency of 
absorption and metabolism. These include, but are not limited to, TAG structure and 
type of fatty acid of interest. For instance, EPA and DHA from fish oils are incorporated 
at diverse rates into CE, erythrocytes and adipose tissue (Katan et al. 1997). The 
proportions of fatty acids in a lipid fraction as opposed to their absolute concentrations 
appear to be a more robust index of the quality of fat intake than traditional dietary 
assessment methods such as FFQ. Furthermore, they are increasingly being used to 
measure association between fatty acid intake and CVD risk in intervention and 
epidemiological studies (Harris et al. 2007; Khaw et al. 2012; Mozaffarian et al. 2013).     
1.11.1 Factors influencing EFA metabolism 
Metabolism of fatty acids including EFAs occurs in the mitochondria. Delta-5 (D5D) 
and delta-6 (D6D) desaturases and elongases are the key enzymes responsible for 
metabolism of LA and ALA to their respective metabolites (Figure 1.3; P35). A 
competition for these enzymes takes place between these two EFA with ALA being the 
preferred substrate over LA. Another fatty acid that is metabolised by the same 
desaturases is oleic acid and under normal physiological states, oleic acid metabolites 
are produced in negligible amounts only. As a consequence, high tissue and plasma 




indicator of EFA deficiency that is used to distinguish the incidence of EFA deficiency 
in patients, experimental animals and in vitro studies (Siguel et al. 1987).  
There are several factors known to influence desaturases and elongases activities. D5D 
and D6D are inhibited by SFA, cholesterol, TFA, alcohol, adrenaline and 
glucocorticoids. Aging, diabetes, oncogenic viruses and radiations, total fasting, protein 
deficiency and glucose rich diets reduces D6D activity. On the other hand, insulin, fat 
free diet and caloric restriction enhance D6D activity. Normal D6D activity requires 
pyridoxine, zinc and magnesium as co-factors. Disease states such as diabetes, 
hypertension, metabolic syndrome and hyperlipidaemia are all associated with 






1.12.1 Heritability: definition and determination  
Heritability is a simple measure of the significance of genetic factors in explaining the 
variation between human beings, permitting comparison of the same trait across 
populations and of different traits within a given population. Such comparisons can 
guide insights into the biology of the phenotype. In medicine and human genetics, 
estimates of heritability can be measured in both healthy and disease states to gauge the 





is defined as the proportion of total variance in a population for a 
particular measurement, taken at a particular time that is attributable to differences in 
the magnitude of additive genetic values. Heritability is a ratio of variances: the 
denominator contains the total observed variation due to both genes and environment 
and the numerator contains variation that is due to additive genetic values in the 
population (Visscher et al. 2008).  
Heritability relates mainly to the population under study, because both the variation in 
additive genetic factors and the environmental variance are population-specific. The key 
determinants of genetic variance are segregation in a population of the alleles that 
influence the trait, the allele frequencies, and the effect sizes of the variants and the 
mode of gene actions, which can differ across populations. Similarly, environmental 




not necessarily predict the heritability of the same trait in another, although in practice it 




Box 1 | Heritability and the partitioning of total variance 
 
Observed phenotypes (P) of a trait of interest can be partitioned into a statistical model 
representing the contribution of the unobserved genotype (G) and unobserved environmental 
factors (E):  
  
Phenotype (P) = Genotype (G) + Environment (E)  
 
The variance of the observable phenotypes (σ2P) can be expressed as a sum of unobserved 








E     
 
Heritability is defined as a ratio of variances, by expressing the proportion of the phenotypic 
variance that can be attributed to variance of genotypic values.  
 
The genetic variance σ2G can be partitioned into the variance of additive genetic effects, of 
dominance genetic effects (interactions between alleles at the same locus) and of epistatic 
genetic effects (interactions between alleles at different loci). The additive genetic variance σ2a 
represents phenotypic variance which is transmissible from parents to offspring. This is the 
basis for most of the observable correlation among relatives and is used to compute heritability 




The environmental variance σ2E can be broken down into contributing factors including the 




















From this the heritability in the narrow sense, h
2
 can be obtained, i.e. the ratio of the additive 
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1.12.2 Determining heritability of metabolites 
Statistical methodology to partition variation and to estimate heritability is well 
established (Neale et al. 2002). A high heritability implies that most of the variation that 
is observed in the population is caused by variation in genotypes. It indicates that, in the 
population, the phenotype of an individual is a good predictor of the genotype. A low 
heritability means that of all observed variation; a minute proportion is caused by 
variation in genotypes (Teucher, 2007; Lee, 2010). 
As many metabolites are represented in overlapping pathways, correlation of 
metabolites is likely. To understand the correlation, principal components analysis 
(PCA) is a data reduction technique which can be used to decrease the large number of 
correlated variables into clusters of fewer uncorrelated factors using raw metabolite 
values. Linear structural equation modelling (SEM) is used to approximate the genetic 
and environmental components of variance in the scores for the principle components. 
Univariate twin analyses are performed, in which the phenotypic variance is decayed 
into additive genetic (A: additive effects of genes on multiple loci), common 
environmental (C: environmental effects shared by twins reared in the same family) and 
unique environmental effects (E: environmental effects unique to the individual). The 
ACE models assume that monozygotic (MZ) pairs share the same A genetic variance 
(completely correlated) and dizygotic (DZ) pairs share one-half of the A variance (have 




twin pairs (the shared environment contributes equally to the correlations for MZ and 
DZ twins) (Teucher, 2007; Lee, 2010). 
The significance of variance components A or C in the model is tested by dropping 
these parameters and comparing the fit of the models. The model fit is based on χ2 tests, 
where a small χ2 and a high P-value indicate a good fit. Parsimony is assessed by the 
Akaike information criterion, which corresponds to χ2 with 2df. The model with the 
least Akaike information criterion is favoured. A likelihood ratio test is used to test 
whether a significantly poorer fit was obtained when removing parameters. Estimates of 
variance components are derived from the best fitting model and presented with 95% 
confidence intervals (CIs) (McCaffery et al. 2007). 
1.12.3 Twin studies can distinguish genetic and environmental influences 
The classical twin study is the definitive design for exploring the relative significance of 
genetic and environmental factors to traits and diseases in human populations. Twin 
studies utilize the unique degree of genetic and environmental sharing between the two 
types of twin pair; MZ twins (share a general set of genes) and DZ twins (share only 
50% of their genes overall). Additionally, both types of twins share the same uterus, 
birth date, age and aspects of their early and later environment. These characteristics 
allow the population-level variation of traits and diseases to be broken up into genetic, 
shared environmental and random environmental components. Separating shared genes 
from the shared family environment as origins of family similarity is difficult to attain 




twin data aids in estimating the size of the contribution of these individual components 
of variation, to offer an estimate of heritability. Studies of twins have been used 
commonly to explore the heritability of common complex diseases. The outcomes have 
consistently revealed an important contribution from genetic variation to disease 
susceptibility. MZ twins are genetically alike. DZ twins are genetically 
indistinguishable from typical siblings, but the exact matching for age and date of birth 
is exclusive among family studies. For most complex diseases, age is vitally essential in 
disease expression. The shared family environment of twins offers a greater degree of 
matching for a range of environmental variables, both measured and unmeasured, which 
might contribute to the expression of diseases. Therefore, it is much easier to attribute 
phenotypic dissimilarities between twins to genetic rather than to environmental factors. 
A further advantage of studying twins is that the probability of non-paternity, an 
essential cause of misclassification in sibling studies, is diminished to approximately nil 
(Macgregor et al. 2000). 
1.12.4 Application to biomarkers: genetic and environmental influences on 
plasma/adipose fatty acid proportions 
It has been assumed in most studies that the biomarkers of fat intake are not influenced 
by genetic factors but this assumption may not be justified. As far as could be 
ascertained there is absence of reports on heritability of fatty acids measured as a 




branched chain fatty acids (Stewart et al. 1986) and heritability of metabolites (Shah et 
al. 2009).  
Stewart et al. (1986) in 13 twin pairs examined the genetic influences on proportions of 
iso-branched fatty acids with even carbon number (iso-even) in sebaceous wax esters. 
They found very small intra-pair differences and a large inter-pair difference in the 
proportions of iso-branched fatty acids with even carbon number. This study was 
limited by a small number of subjects. Furthermore, the iso-branched fatty acids are 
derived from catabolism of valine, which is an essential amino acid. Thus, diet has 
made no contribution to the proportions of iso-branched fatty acids in sebaceous wax 
esters and their measurement is of no value with regard to biomarkers of fat intake. 
Whereas the study conducted by Shah et al. (2009) on heritability of metabolites was 
not performed on twin subjects and thus was omitted.  
 
1.13 Candidate genes 
A single nucleotide polymorphism (SNP) is a variation in base pair of DNA typically 
substitution of cytosine (C) to thymine (T) or adenine (A) to guanine (G) or a deletion 
within a gene. SNPs occur with high frequency (>1% population) and are not regarded 
as mutation and may or may not be functional i.e. carriage of the SNP does not affect 
the gene product. Two third of the SNPs are C-T or G-A (Ziegler & Konig, 2006). Fatty 




of the metabolic pathways. The main enzymes involved in PUFA metabolism are D5D 
and D6D, as discussed earlier (see Figure 1.3 P.35). D5D and D6D are encoded by 
FADS1 and FADS2 genes respectively. SNPs at or near these genes are associated with 
increased or decreased levels of some of the LC-PUFA in the body. In MUFA 
metabolism, stearoyl-CoA desaturase is another enzyme that is influenced by SNPs in 
the encoding genes SCD-1 and SCD-5 (Paton & Ntambi, 2009). SNPs may either have 
functional effects or act as co-inherited markers of unknown functional sites in the gene. 
Estimation of a high heritability of an observed phenotype indicates important genetic 
factors in its determination. The next logical step is to explore which genes might be 
responsible. Some gene variants have shown particularly strong signals in genome-wide 
studies of association with plasma fatty acid proportions. Several SNPs in the FADS1-
FADS2 gene cluster have been shown to be associated with plasma or erythrocyte 
phosphoglyceride LC-PUFA concentrations in genome-wide association (GWA) studies 
(Lemaitre et al. 2011; Tanaka et al. 2009). Associations of SNPs and haplotypes in this 
region have been shown to be associated with fatty acids in plasma (Martinelli et al. 
2008; Schaeffer et al. 2006), erythrocyte membranes (Martinelli et al. 2008; Tanaka et 
al. 2009; Zietemann et al. 2010) and adipose tissue (Baylin et al. 2007). Such studies 
provided evidence that carriage of variants in the FADS gene cluster associates with 
plasma proportions of a number of LC-PUFA. SCD-1 gene variants were found to be 




There is a lack of association studies on SCD-1 SNPs and proportions of fatty acids as 
biomarkers. 
1.13.1 Fatty acid desaturases (FADS) 
Levels of LC-PUFA are determined in the body by both dietary intake and metabolism 
of the precursor EFAs, LA and ALA, as a result of a successive desaturation and chain 
elongation (see Figure 1.3; P.35).  D5D and D6D desaturases, which are membrane 
bound microsomal enzymes and consist of 444 amino acids, are the main enzymes 
involved in the conversion of n-3 and n-6 fatty acids to their LC-PUFA in the human 
body. The first step in the synthesis of n-6 fatty acids requires that D6D desaturates LA 
to GLA by the addition of an extra cis double bond at the position six of the chain. Then 
elongation of the existing fatty acid leads to the production of DGLA. Further 
desaturation by the action of D5D results in the formation of very LC-PUFA, AA, that 
is metabolized to produce eicosanoids or elongated and desaturated by the assistance of 
D6D enzyme resulting in the formation of 22:4n-6, 24:4n-6, 24:5n-6, and 22:5n-6. The 
production of LC-PUFA from n-3 fatty acids involves the desaturation of ALA by D6D 
to form stearidonic acid (18:4n-3), which is then elongated to form eicosatetraenoic acid 
(20:4n-3). After that a desaturation step by D5D takes place to give rise to EPA, which 
is either metabolized to produce eicosanoids or further elongated and desaturated to give 
rise to 22:5n-3, 24:5n-3, 24:6n-3 and 22:6n-3. The latter is a product of β-oxidation 




Both D5D and D6D are crucial enzymes for the synthesis of LC-PUFA as well as cell 
membrane fluidity. The expression of desaturases enzymes occurs in all human tissues 
with higher rates in liver tissues followed by brain, heart and lung (Schaeffer et al. 
2006). There are two genes coding for D5D and D6D in humans beings. These are fatty 
acid desaturase 1 (FADS1), which encodes D5D, and fatty acid desaturase 2 (FADS2), 
which encodes D6D. In 1999, first cloning of the human desaturases took place, while 
FADS1 and FADS2 genes were mapped in 2000 in the region 11q12-13.1 of 
chromosome 11 with head-to-head orientation (see Figure 1.9). This region was 
previously associated with complex diseases such as type 2 diabetes, osteoarthritis, 
asthma and allergy (Schaeffer et al. 2006). FADS1 and FADS2 genes share the same 
exon/intron organization, which are 12 exons and 11 introns. Around 500 SNPs 
identified in the FADS1 and FADS2 region and were recorded in the NCBI database 
(Lattka et al. 2009). Schaeffer et al. (2006) performed the first association study 
involving FADS polymorphism and fatty acids levels in serum PL and identified 11 
SNPs with a highly significant association with n-3 and n-6 fatty acids except for 
docosapentaenoic acid (DPA, 22:5n-6) and DHA. The authors found that carriers of the 
minor alleles of (rs174544, rs174553, rs174556, rs174561, rs3834458, rs968567, 
rs99780, rs174570, rs2072114, rs174583, rs174589) express elevated levels of LA, 
eicosadienoic acid (20:2n-6), DGLA, and ALA and a low levels of GLA, AA, adrenic 
acid, EPA, and DPA (Schaeffer et al. 2006). A study investigating the association 
between levels of PUFA in serum PL with FADS1, FADS2, and FADS3 SNP genotypes 




AA levels in serum PL (P<0.0001) and LA, ALA and eicosadienoic acid in erythrocyte 
cell membranes (P<0.0001). Homozygotes and heterozygotes for the minor allele were 
associated with increased levels of LA, ALA, eicosadienoic acid and decreased levels of 
AA. The association of stearidonic acid (18:4n-3), EPA and DHA was not significant 










Figure 1.9 Location of FADS1 and FADS2 genes on chromosome 11.The SNPs 




1.13.2 Stearoyl-CoA desaturase (SCD) 
Stearoyl-CoA desaturase (SCD), a delta-9 desaturase, is the rate-limiting enzyme in the 
biosynthesis of MUFA from SFA aerobically in the endoplasmic reticulum (see Figure 
1.3; P.35). Palmitoyl-CoA and stearoyl-CoA are the main substrates for the 
biosynthesis. There are two genes for the SCD that are expressed mainly in humans. 
SCD-1, which is expressed almost everywhere in the body and SCD-5, which is 
expressed mainly in the brain and pancreas. SCD-1 is located on chromosome 10 
(10q24.31) as shown in Figure 1.10, while SCD-5 is located on chromosome 4 
(4q21.22). SCD-1 shares 85% homology with murine SCD genes. Studies on animals 
showed that mice deficient in SCD-1 produce low body adiposity, improved sensitivity 
to insulin and were resistant to diet-induced obesity. Therefore, the block of SCD-1 
gene expression might be of beneficial effect in the treatment of metabolic diseases such 
as obesity and diabetes (Paton & Ntambi, 2009). Another study found that homozygotes 
of the rare alleles of rs10883463, rs7849, rs2167444, and rs508384 SNPs are associated 
with a lower BMI and waist circumference as well as enhanced insulin sensitivity 
(Warensjö et al. 2009). In contrast, research regarding the association between SCD-1 
SNP genotypes with fatty acid profile is lacking. However, a small number of 
investigations have been done on sheep (Garcia-Fernandez, 2009) and cattle (Milanesi 
et al. 2008; Kgwatalala et al. 2007). SCD-5 was not investigated in the present thesis 
because it is mainly expressed in brain and pancreas, unlike SCD-1, which is widely 









Figure 1.10 Location of SCD-1 gene on chromosome 10. The locations of the SNP investigated 






1.14 Aims and Objectives 
The main aim of the present thesis was to test the reliability of the use of biomarkers in 
reflecting fat intake where diet had been modified in large randomized controlled trials. 
The second aim was to assess the effect of genetic factors on these biomarkers and 
specifically any effects on genes encoding fatty acid desaturase enzymes, FADS1, 
FADS2 and SCD-1. 
It was hypothesised that biomarkers would act as reliable markers of purely exogenous 
fatty acids i.e. PUFA and TFA and a poor marker of endogenously synthesised fatty 
acids i.e. SFA and MUFA 
It was, also, hypothesised that genetic variation in FADS1, FADS2 and SCD-1 would 
modulate proportions of these fatty acids as biomarkers of intake.  
The answers to the following questions were explored in this thesis: 
To what extent does adipose tissue, plasma and erythrocyte phospholipid fatty acid 
composition change in response to varying the intake of specific fatty acids? 
How much of the variance in fatty acid composition of adipose tissue and plasma total 
lipids can be explained by additive genetic effects?  
Do variations in known SNPs for FADS1, FADS2 and SCD-1 influence the proportion 

















This chapter provides a description of the methods used, the principal underlying them 
and a justification for the choice of analytical methods applied and the statistical 
approaches employed. 
2.1 Lipid analysis 
2.1.1 Determination of adipose tissue fatty acid composition 
Several methods were initially evaluated these included a) extraction of the total lipids 
with chloroform:methanol, removal of the solvent and trans-esterification with sodium 
methoxide; b) extraction of the adipose tissue in hexane and removal of the water with 
anhydrous sodium sulphate and trans-esterification with sodium methoxide; c) acid 
catalysed interesterification as described below. 
Reference:  
Direct transesterification of all classes of lipids in a one-step reaction (adapted from 
Lepage, G. and C. C. Roy (1986)  
Principle: The lipids are transesterified with methanol using HCL as catalyst. Toluene 
is added to the reaction mixture to facilitate the extraction of non-polar lipids. The 
reagent is a mixture of methanol in toluene (80:20 by volume), which solubilises the 
lipids, and contains HCL which catalyses the methylation of fatty acids to form methyl 
esters. After refluxing the mixture, potassium carbonate solution is added to facilitate 




is collected for gas chromatography on a polar capillary column that separates the 
volatile fatty acid methyl ester (FME) based on molecular weight and unsaturation.  
 
 Materials for fatty acids extraction from adipose tissue 
Item  Supplier  
Toluene Analytical reagent grade (AR) BDH, Poole, Dorset 
Hexane Puriss BDH, Poole, Dorset 
0.5 N HCL in methanol  Superlco obtain through Sigma-Aldrich 
6% potassium carbonate in distilled water BDH, Poole, Dorset 
Fatty acid methyl standards 189-1, 189-2,189.3 Sigma-Aldrich, BDH, Poole, Dorset 
MaxEPA Seven Seas Ltd, Hull, UK 
Column BPX70 SGE (60m x 250m x 0.25m) SGE Analytic Science, Milton Keynes 
Gas chromatography Agilent 7890A GC; Agilent Technologies 
Methylating reagent HCL methanol:toluene (4:1 by volume) prepared by adding 20ml 
toluene to 80ml 0.5 N HCL in methanol solution (Sigma). 
 
Standards preparation 
External standards used were fatty acid methyl standards of Sigma 189-1, 189-2 
and189-3 dissolved in hexane 1mg/ml and methyl esters of MaxEPA as an external 






Adipose tissue (~5mg) was transferred into a clean culture tube fitted with Teflon lined 
screw-cap (16x25mm). 2 ml of methylating reagent was added and tube sealed and 
incubated in water bath for 2hrs at 60°C. Sample was left to cool down and 5ml of 6% 
potassium carbonate was added. Sample was vortex mixed and centrifuged at 2500rpm 
for 10min. The upper layer was then collected into an amber GLC vial and 0.5ml 
toluene was added. Samples were then analysed by GLC and each sequence contained a 
sample blank, a set of standards and a quality control sample in addition to the samples. 
Fatty acid methyl esters (FAME) were separated on an Agilent 7890 Gas 
Chromatograph (Agilent Technologies) with electronic pressure control fitted with a 
flame ionisation detector (FID) with a 60m BPX70 column (SGE). Hydrogen was used 
as the carrier gas at a constant flow rate of 1.37ml/min. Peaks for the FAME were 
identified by comparison of the retention times with standards of known composition 
obtained from Sigma Aldrich (Individual fatty acids were identified by reference to 
standards obtained from Sigma (FAME standard 189-1,189-2, 189-3) and a secondary 








GC was Agilent 7890A GC; Agilent Technologies operated under the following conditions: 
 
Injector   
Type  Front injector 
Injection volume 3L 
Inlet detector   
Injection mode Split 50:1 
Inlet temperature 250ºC 
Gas   
Carrier gas Hydrogen at 1.37ml/minute 
Make up gas Nitrogen 
Column  
Column BPX70 SGE (60m x 250m x 0.25m). 
Oven   
Temperature/programme Initial temperature 180ºC, held for 50 minutes. 
Run time 50 min 
Detector   
Type  Flame ionization detector 
Detector temperature 280ºC 








Figure ‎2.1 Fatty acid chromatogram of adipose tissue lipids. Initial peak at a retention time of 
~3 min is solvent peak followed by individual fatty acids methyl esters. The run was isothermal 











2.1.2 Determination of plasma fatty acid composition 
Reference:  
Method adapted from Lepage, G. and C. C. Roy (1986).  
Principle: Total lipids are transesterified with HCL as a catalyst in methanol:toluene 
solution and the FAME analysed by gas chromatography in the presence of a 15:0 as an 
internal standard. The reagent is prepared by added acetyl chloride to methanol. 
 
Materials for fatty acids extraction from plasma 
Item  Supplier  
Toluene AR BDH, Poole, Dorset 
Hexane Puriss BDH, Poole, Dorset 
Methanol AR BDH, Poole, Dorset 
Acetyl chloride AR BDH, Poole, Dorset 
6% potassium carbonate in distilled water BDH, Poole, Dorset 
Internal standard:  pentadecanoic acid Sigma-Aldrich, BDH, Poole, Dorset 
External standards: Sigma 189-1, 189-2,189.3 Sigma, BDH, Poole, Dorset 
MaxEPA Seven Seas Ltd, Hull, UK 
BPX70 column (25 m X 220 μm X 0.25 μm) SGE Analytic Science, Milton Keynes 
Gas chromatography Agilent 7890A GC; Agilent Technologies 





Preparation of the internal standard took place by adding 5ml of 1mg/ml internal 
standard in methanol to 75ml methanol. Toluene was then added to make-up to 100ml. 
The mixture was then chilled on ice in a conical flask and acetyl chloride (10ml) added 
drop-wise while swirling the flask in a fume cupboard. The reagent was allowed to cool 
before use and was stable for up to two weeks at room temperature. 
Authentic reference standards were used. FAME standards of Sigma 189-1, 189-2 and 
189-3 dissolved in hexane 1mg/ml and FAME of MaxEPA as a reference standard for 
DHA and EPA dissolved in hexane 1mg/ml. 
Sample preparation 
Sample preparation took place by pipetting 0.1ml plasma into a tube fitted with Teflon 
lined screw cap (16x25mm) using a positive displacement pipette. 2.2ml of internal 
standard mixture were added into the tube, which is then sealed and heated in water bath 
for 2hrs at 60°C. After cooling down, 5ml of 6% potassium (or sodium) carbonate were 
added and sample centrifuged at 2500rpm for 10min. The upper phase was then 
transferred into an amber vial for GLC analysis.  
FAMEs were separated on an Agilent 7890 Gas Chromatograph (Agilent Technologies) 
fitted with a FID with a 25m BPX70 column (SGE). Peaks for the FAMEs were 
identified by retention time with standards of known composition obtained from Sigma 




Sigma, FAME standard 189-1,189-2, 189-3) and a secondary reference standard of 
MaxEPA (Seven Seas Ltd, Hull, UK) for LC n-3 PUFA. 
Calculations 
Fatty acid composition = area of fatty acid of interest  (total area –area of internal 
standard) 
 
GC was Agilent 7890A GC; Agilent Technologies operated under the following conditions: 
Injector   
Type  Front injector 
Injection volume 5L 
Inlet detector   
Injection mode Split 50:1 
Inlet temperature 240ºC 
Gas   
Carrier gas Hydrogen at 1 ml/minute 
Make up gas Nitrogen 
Column  
Column BPX70 SGE (25 m x 220 m x 0.25 m). 
Oven   
Temperature/programme Initial temperature 160ºC, held for 4 min,  
then ramped 10ºC/min for 10 min to 200ºC,  
then 40ºC/min for 10 min to 240ºC. 
Run time  29 min 
Detector   
Type  Front Ionisation Detector (FID) 
Detector temperature 250ºC 






Figure ‎2.2 Fatty acid chromatogram of plasma lipids. The peak at retention time ~1.5min 
respresent the solvent peak followed by FAME. Analysis conducted on 25m BPX70 column 
using a temperature programme. 
  































































































































































































































































2.1.3 Determination of erythrocyte phospholipids 
Reference:  
Rose & Ocklander (1965) as modified by Sanders et al. 1997.  
 
Determination of erythrocyte phospholipids was done by Mr Robert Gray (Diabetes and 
Nutritional Sciences Division, King‟s College London). 
 
Principle: Fatty acids present as acyl moieties in membrane bound lipids are converted 
(transesterified) to FAME and analyzed by capillary column FID gas chromatography. 
Erythrocytes were first washed with isotonic saline to remove plasma and then the lipids 
extracted with a mixture of isopropanol:chloroform (11:7 by volume). The extracted 
lipid sample was stored at -20°C until analysis when FAMEs were prepared by 





Materials for fatty acids extraction from erythrocyte phospholipids 
Item  Supplier  
Toluene AR BDH, Poole, Dorset 
Hexane Puriss BDH, Poole, Dorset 
Methanol AR BDH, Poole, Dorset 
Acetyl chloride AR BDH, Poole, Dorset 
6% potassium carbonate in distilled water BDH, Poole, Dorset 
Internal standard:  pentadecanoic acid Sigma-Aldrich, BDH, Poole, Dorset 
External standards: Sigma 189-1, 189-2,189.3 Sigma, BDH, Poole, Dorset 
MaxEPA Seven Seas Ltd, Hull, UK 
BPX70 column (25 m X 220 μm X 0.25 μm) SGE Analytic Science, Milton Keynes 
Gas chromatography Agilent 7890A GC; Agilent Technologies 
Cold saline (0.89% NaCl; 8.9g NaCl/L containing 40mg EDTA/L) 
 
Sample preparation 
Blood was collected into EDTA coated tubes (BD vacutainer 367873). Plasma was 
removed and the erythrocytes were washed three times with ice-cold isotonic saline (8.9 
NaCl/L water containing 40mg EDTA/L). 1ml of packed cells was then haemolysed by 
the addition of 1ml distilled water and ice-cold isopropanol (11 volumes). After 
standing for 30min on ice, 7ml chloroform was added followed by vortex mixing. The 
sample was allowed to stand for a further 30min before centrifuging. The lipid extract 




stored at -20°C until fatty acid methyl esters were prepared for analysis. Prior to 
analysis solvents were removed in a centrifugal evaporator and the lipid extract trans-
methylated with sodium methoxide in methanol. FAME were analysed by capillary 
GLC on a 25m BP70X capillary column (SGE, Milton Keynes). 
 
GC was Agilent 7890A GC; Agilent Technologies operated under the following conditions: 
Injector   
Type  Front injector 
Injection volume 5 L 
Inlet detector   
Injection mode Split 50:1 
Inlet temperature 240ºC 
Gas   
Carrier gas Hydrogen at 1ml/minute 
Make up gas Nitrogen 
Column  
Column BPX70 SGE (25 m x 220 m x 0.25 m). 
Oven   
Temperature/programme Initial temperature 160ºC, held for 4 min,  
then ramped 10ºC/min for 10 min to 200ºC,  
then 40ºC/min for 10 min to 240ºC. 
Run time 29 min 
Detector   
Type  FID 
Detector temperature 250ºC 





Figure ‎2.3 Fatty acid chromatogram of erythrocyte phosphoglycerides. The peak at retention 
time ~1min respresent the solvent peak followed by FAME.  Analysis conducted on 25m 



















2.2 DNA extraction and SNP genotyping 
DNA extraction from MARINA samples was performed by Dr Aseel AlSaleh. DNA 
extraction from TwinsUK samples was performed by staff at KCL Department of Twin 
Research (DTR). Buffy coats removed from blood samples were stored in EDTA at -
20°C. Genomic DNA was extracted from 200μl using an Illustra blood genomic prep 
mini spin kit (GE Healthcare, Amersham, UK) according to manufacturer‟s instructions. 
Genotyping was performed on the 310 participants for whom DNA was available by 
KBiosciences (Hoddesdon, UK), using the KASPar system. Genotype accuracy, as 
assessed by inclusion of duplicates in the array was 98% and negative controls (water 
blanks) were included on each plate. The mean genotyping success rate was 97.7% 
(95.8-99.7%). 
2.2.1 DNA extraction: Materials 
DNA was extracted from the buffy coats using the Illustra blood genomic prep spin kit, 




2.2.1.1 Materials for DNA extraction 
Item  Supplier 
Proteinase K GE Healthcare, UK 
Lysis buffer GE Healthcare, UK 
Wash buffer GE Healthcare, UK 
Elusion buffer GE Healthcare, UK 
Illustra blood mini column GE Healthcare, UK 
Collection tubes GE Healthcare, UK 
96-well microplates Qiagen, Crawley, Surrey, UK 





Microcentrifuge that accommodates 1.5 ml 
microcentrifuge tubes 
DJB Labcare Ltd, Buckinghamshire, 
UK 
Water bath or heat-block for 70
o
C incubation  
Vortex mixer 
Grant Operation 





2.2.2 DNA extraction procedure 
DNA extraction from buffy coats of 310 MARINA subjects was carried out using an 
Illustra blood genomic prep mini spin kit (GE healthcare, UK). Buffy coats in EDTA 
had been frozen since preparation of blood samples. Genomic DNA was purified from 
200μl buffy coat. This process was carried out according to manufacturer‟s instructions. 
This includes the below steps: 
1- Blood cell lysis: 20μl of Proteinase K was added into the bottom of a 1.5ml 
microcentrifuge tube. This digests protein, removing contamination and 
inactivating nucleases that might otherwise degrade the DNA during purification. 
This was followed by adding 200μl of the buffy coat and then 400μl lysis buffer 
into the same tube. The tube was mixed well for 15sec and incubated at room 
temperature for 10min. 
2- Genomic DNA binding: a mini column was assembled in a collection tube. The 
sample was loaded on to the centre of the column and was centrifuged. The flow 
through in the collection tube was discarded. The column was placed back inside 
the collection tube.  
3- Wash: to ensure complete cell lysis and to denature any residual protein; 500μl 
of lysis buffer was added to the column and centrifuged. And again, flow through 




4- Wash and dry: into the column, 500μl of wash buffer was added. This was 
centrifuged for 3min. The collection tube and flow through were discarded.   
5- Elution: the purification column was transferred into a fresh DNAse-free 
microcentrifuge tube. Followed by adding 200μl of 70°C preheated elusion 
buffer on the centre of the column. This was centrifuged for 1min. Purified 
genomic DNA was stored at -20°C. 
2.2.3 Quantitation of DNA samples 
The quality of the DNA samples was checked by NanoDrop (DNA quality analyses). 
NanoDrop accurately measures dsDNA samples up to 3700ng/µl without dilution. It 
automatically detects the high concentration and utilizes the 0.2mm path length to 
calculate the absorbance. For NanoDrop spectrophotometry, 1.0µl of sample was used 
to quantify DNA concentration. A blank of nuclease-free water, was used to optimise 
the instrument. Sample pedestals were first cleaned with nuclease-free water and 




2.3 Blood Analytic methods 
2.3.1 Fasting lipids for RISCK, CRESSIDA and MARINA studies 
Analyses of total cholesterol (TC), HDL-C and triacylglycerol (TAG) were carried out 
at KingsPath, King‟s College Hospital. Precision estimates were based on each sample 
assayed 2 times per run, 2 runs per day, for at least 10 days and computed according to 
CLSI document EP05-A2, Evaluation of Precision Performance of Quantitative 
Measurement Methods: Approved Guideline. Reagents were supplied by Bayer 
Diagnostics Europe Ltd. (Newbery, Berks, UK). TC was determined using an enzymatic 
method using cholesterol esterase, cholesterol oxidase and peroxidase in a 
chemiluminescent reaction to produce a red quinoneimine dye. The increase in 
absorbance was measured as an endpoint reaction at 505/694 nm. Inter-assay 
coefficients of variation (CV) were 1.1, 1.5 and 1.0 at 3.9, 5.2 and 5.7 mmol/L 
respectively. HDL-C was analysed using a two-step automated procedure (Bayer Advia 
Direct method, Bayer Diagnostics Europe Ltd, Newbery, United Kingdom). CVs were 
2.2, 2.1 and 2.5 at 0.91, 1.39 and 1.95mmol/L respectively. TAGs were measured using 
an enzymatic assay (The Bayer Advia method, Bayer Diagnostics Europe Ltd, 
Newbery, United Kingdom). CVs were 2.5 and 1.5 at 1.32 and 2.36 mmol/L 
respectively. LDL cholesterol was calculated using the Friedwald formula if fasting 
plasma TAG concentrations are < 4.49 mmol/L. Formula used:  




2.4 Carotid intimal mediated thickness (CIMT)    
CIMT was measured by trained ultrasonographer in the participants at the final visit. 
CIMT is a non-invasive method for measuring carotid atherosclerosis. These 
measurements were not part of the contract but were funded by the National Institute of 
Health Comprehensive Biomedical Centre at Guy‟s and St Thomas‟ Hospital under the 
Atherosclerosis theme. Images of the left and right common carotid arteries were 
obtained by high resolution ultrasound at the endpoint visit. CIMT is measured from 
digitized images obtained in diastole of the near and far walls of both common carotid 
arteries 1-2cm proximal to the flow divider. This method is recognized as providing a 
robust measure of IMT with reproducibility higher than that in other segments.  
The two dimensional scanning measures both left and right carotid systems, including the 
common carotid artery (CCA), carotid bifurcation and internal and external carotid artery (ICA 
and ECA). The carotid system was scanned longitudinally and cross-sectionally. Plaque was 
defined as a thickness over 1.5 mm, and classified soft and hard plaque, according to echo 
characteristics. Soft plaque is hypo-echogenic, where calcification is less than 50%. The hard 
plaque is calcified plaque with hyper-echoicones over 50%.  
The measurement of CIMT was performed in the CCA, 1-2cm proximal from the 
bifurcation. The IMT was determined as the distance from the leading edge of the first 
echogenic line to the second echogenic line, which present the lumen-intima interface 
and the medial-adventitia interface respectively. The IMT was measured on both 




readings. Doppler colour and spectral analysis was performed to assess the 
haemodynamic state. For documentation, the static image of all plaque was taken. In 
order to minimise variability during the cardiac cycle, the longitudinal image of CCA 
was frozen at the top of R wave of the ECG and stored for measuring diameter and IMT 
of the CCA. The edge detecting software Carotid Analyzer (Medical imaging 
Application LLC, USA) was used to measure the diameter of CCA and CIMT. 
 
2.5 Statistical methods 
All statistical analysis was performed using SPSS versions 17.0 and 20.0 for Windows 
(SPSS Inc, Chicago, IL, USA) unless otherwise specified.  
2.5.1 Linear regression modelling 
Linear regression is a statistical method aimed to test and to describe the linear 
relationship between two or more variables. The regression coefficient describes the 
angle of the regression line and reflects the amount of variance of the dependent 
variable that is explained by the variation of the independent variable (Boomsma et al. 
2002). Linear regression modelling was used to compute EPA and DHA intake of the 
twin subjects using plasma proportions of these fatty acids and intakes data from the 




2.5.2 Adjustment for covariates 
In a multivariate analysis, a variable or variables with known effect that is used to 
examine the impact of the variables of interest independent of those known effects. In 
the present thesis the inclusion of age, gender, BMI and ethnicity was taken into 
account when performing the main analysis to test the effect of the independent 
variable. Multivariate analysis can be defined as the inclusion of two or more dependent 
variables simultaneously (Boomsma et al. 2002).   
2.5.3 Analysis of variance (ANOVA) 
ANOVA is a statistical technique applied to test the null hypothesis that the mean 
values of two or more groups are equivalent. The variance around the means in groups 
is compared with the variance of the group means. In genetic applications, the variance 
between families is compared with the variance within families (Boomsma et al. 2002).   
2.5.4 Generalized estimating equations (GEE)  
For related individuals, conventional statistical analyses lead to inflated significance. 
Dependency of the observations within twin pairs was accounted for by the use of the 
Generalized Estimating Equations (GEE) procedure (Trégouët et al. 1997) in which 
both MZ and DZ twins can be used in tests of association. The approach accounts for 
dependency of the observations within pairs and yields unbiased standard errors and P-
values. Association analyses in TwinsUK subjects were performed by members of the 




2.5.5 Principal component analysis (PCA)  
PCA was used to reduce the large number of correlated variables into clusters of fewer 
uncorrelated factors using raw metabolite values without removal of outliers. The factor 
with the maximum „eigenvalue‟ accounts for the largest amount of the variability within 
the data set. Standardized residuals determined for each metabolite from linear 
regression models adjusted for age, sex and BMI are used as inputs for PCA. PCA using 
residuals is recommended when the units for each variable vary considerably in size. 
Factors with an eigenvalue were identified based on the frequently used Kaiser 
criterion. Varimax rotation is then applied to produce understandable factors. 
Metabolites with a factor load are reported as composing a given factor, as is commonly 
used as a random threshold. Scoring coefficients are then used to calculate factor scores 
for each individual (consisting of a weighted sum of the values of the standardized 
metabolites within that factor, weighted on the factor loading calculated for each 
individual metabolite). These factor scores are then used to calculate heritabilities for 
each factor with suitable software (Shah et al. 2009). 
2.5.6 Structural equation modelling using Mx software 
Linear structural equation modelling also known as covariate modelling, is a technique 
that estimates regression coefficients (parameters) between latent (unobserved) and 
observed variables. These estimates diminish the dissimilarity between the covariance 
structure of the observed data and that predicted by the model. It was used to estimate 




given phenotype into additive genetic effects (A), environmental effects shared in 
common (C) and non-shared environmental effects (E) using the Mx software package 
(Neale et al. 2002). The goodness-of-fit analysis was completed by calculating the 
difference between the model fitted and the fully saturated model. Adjustment allowing 
for differences in age and BMI were done using the linear regression analysis module 
within SPSS and save the residuals as a new variable. The distribution of the residual 
was then checked for normality and where appropriate was log-normalised before 








1. Data need to be restructured (i.e. the 2 twins treated as one individual) 
Note: restructuring the data using the SPSS software: 
 
Data »» restructure »» a data wizard will come up 
 
 Chose: restructure selected cases into variables (middle option) and click next 
 Identified variable: Twin ID, index variable: order 
 Cases to variables: sorting data 
o Yes: if data not sorted 
o No: if data sorted, i.e. 1st born followed by 2nd born as in the TWIN data file, so we 
selected this option 
 Click next 
 Cases to variables: options 
o Select “group by index” and click next and then finish  
2. Check normality of the data 
1. Use scatter plot to check normality of the data 
2. Correlation between FA and age for example 
3. Histogram 
4. Skewness 
3. Transform the data if required 
1. Log transformation  
2. Reciprocal is another transformation (-1/FA) 
Note: always log/transform the data then regress 
4. Regress possible covariates  
1. Age 
2. Gender  
3. BMI 
4. Total cholesterol, for example TC was regressed for the plasma fatty acids 
Note: regression of the covariates using the SPSS software: 
 
Analyze »» regression »» linear regression OR  
Analyze »» general linear model »» univariate 






Preparing the data file for analysis using Mx software 
1. Replace missing data with (. ) or large number (999) 
2. Twin ID »» family id  
3. Check (min/max, SD) 
 If SD<1, multiply the variable by 10, because Mx can‟t deal with values <1 
i. 0.9 is ok, but if smaller than 0.5 
 If min is close to zero, add 1 to the variable to avoid –ve values 
 Then restructure the data file as detailed in step 1 
 Save file as a fixed format (comma separated file (.CSF) or fixed ASCII (.dat) 
 
 Script 
o saturated model 
 reveals correlation of MZ and DZ without making any prediction of genetics 
or environmental influences  
 REC file = name of the file as saved (e.g. trial.dat or oleic.dat) 
 Labels = order of the variables in the file (famid age FA1 FA2 zyg) 
 data input = number of variables (e.g.5) 
 missing = the label that was given to the missing values (999) 
 O= MZ correlation        P= DZ correlation 
 unace= univariate ACE  
o looking to non-sig difference between predicted and reality 
o using excel, calculate the P-value 
 using the CHIDIST function, insert Chi sq and df to compute P- value 
o we can‟t have a model dropping E. E is always significant  
o if the CI overlapping or contains zero, then it is not significant 
 
 Some interpretation of the results 
o E is very important and always significant 
o when values of A and C are too close then 
 It is familial effect (A+C) and there is not enough power to detect genetic, but 
together familial influence is bigger than random variation 
 Significant MZ correlation implies genetic influence 
 If  MZ corr & DZ corr is not significan, then we can‟t expect genetic effect  
 E tests if we can drop C & A together 
 Genetics can only be detected if and only if MZ corr above 0.5 & DZ corr is 





2.5.7 Haplotype analysis using THESIAS software 
Statistical reconstruction of haplotypes in unrelated individuals, for whom phase is 
unknown, is possible when SNPs are in strong linkage disequilibrium (LD). Inter-locus 
linkage disequilibrium based on observed numbers of diplotypes was established using 
CubeX software (Gaunt et al. 2007), available online at: 
(http://www.oege.org/software/cubex/ )  and represented in a correlation matrix as 
Lewontin's D′ and squared correlation r2 measures between each pair of SNP loci. 
Strong LD between the SNPs is indicated by r
2
 >0.8.  
Reconstruction of haplotypes of the three SNPs at the FADS1 FADS2 locus (rs174537- 
rs174561- rs3834458) was based on MARINA participants for whom all genotypes 
were available, to avoid errors resulting from missing data. Analysis of haplotypes was 
performed using the graphical JAVA interface of the THESIAS software package 
(Trégouët & Garelle, 2007), (available online at: http://ecgene.net/genecanvas/ ). This 
program is based on the maximum likelihood model linked to the stochastic expectation 
and maximization (SEM) algorithm (Trégouët et al. 2004) and is used to statistically 
reconstruct haplotypes in unrelated individuals and perform haplotype-based association 






LD and haplotype analysis was performed by Dr Sandra O‟Dell. 
Box 2.2| THESIAS haplotype analysis procedure  
 Load the .txt data file. Click on Menu/Open file. 
  
Results 1: Haplotype frequencies (null option) 
 Select the polymorphisms to be studied.  
The genotypes of the three SNPs are in 3 columns L to R corresponding to the txt. file. Genotypes are 
designated 11, 12 and 22. This first step is necessary to determine the haplotypic structure derived from 
the studied polymorphisms independently of any other phenotype/covariates.  
 
 Press the Run button with the Null option.  
 
In the Output Window information is displayed on:  
- Number of individuals with and without missing data  
- Allele frequencies of the polymorphisms with the corresponding test for Hardy-Weinberg equilibrium  
- Haplotype frequency estimates under the assumption of no Linkage Disequilibrium (LD).  
- Haplotype frequencies estimates under the assumption of LD  
 
Results 2: Log likelihood no haplotype 
 Select the Quantitative option  
The main screen changes to show an additional panel in the right part of the screen which provides a list 
of the inferred haplotypes sorted by decreasing frequencies (Fq).  
 
 Note only the top reference haplotype is checked in the RH panel. 
 Once the additional right panel is activated, select the location of the quantitative Phenotype 





The plasma FA phenotypes (baseline) are in numbered columns L to R corresponding to the txt. file. 
The covariates ethnicity, gender, age and BMI are in numbered columns L to R corresponding to the txt. 
file. 
 
 Press Run. 
 
In the Output Window are displayed:  
-The observed phenotypic mean with its standard error.  
-The intercept of the linear model. In absence of covariate and haplotype effects, it corresponds to half of 
the observed phenotypic mean.  
-The estimated regression parameter associated with the covariate is then given.  
-The log-likelihood of the data (without haplotype effect but here with 4 covariates) is given with its 
corresponding degree of freedom (df). 
 
Results 3: Haplotype effects  
 Check Estimation of haplotype effects 
 Check the haplotype (s) in the haplotype list in the RH panel with frequency >5%.  
 Press Run. 
The Output Window now gives the estimated regression parameters characterizing the association 
between haplotype and the phenotype, compared to the most frequent haplotype. In the case of a 
quantitative phenotype, a linear formulation is used to link the haplotype to the phenotype under the 
assumption of additive effects. The order in which the haplotypes are displayed is based on the order 
polymorphisms are read in the datafile. Each haplotype is given a number that corresponds to its rank in 
the list of haplotype sorted by decreasing frequency. Haplotype 1 (the most frequent haplotype) always 
corresponds to the intercept of the regression model. Haplotype 2 is the second most frequent haplotype 





One minus the square of the ratio of the residual standard error over the global standard error provides an 
estimate of the percentage of phenotypic variance explained by the covariates and the haplotype 
effects. 
  
The regression parameter associated with the covariate is then listed and followed by the log-likelihood 
of the data with df.   
The log-likelihood of the data (without haplotype effect but with covariates) with corresponding df 
was produced in Results 2. 
 
The Likelihood Ratio Test (LRT) for haplotype-phenotype association is twice the difference between the 
log    - likelihood under the null (Results 2) and the alternative (Results 3)  
i.e. (-R3 alternative – (-R2 null) = R2 null – R3 alternative. 
 
The Likelihood Ratio Test (LRT) for haplotype-phenotype association adjusted for covariates is then 
 χ
2 
= 2 x ((-R3 alternative – (-R2 null)) with (df alternative – df null) df 
 
Find P from chi sq tables. 
 
Testing successive phenotype variables 
Return to the beginning of the Results 2 procedure. 
Select the next phenotype in the LH panel. 
Deselect all the haplotypes in the RH panel, except the first reference haplotype.  
Deselect “Estimation of haplotype effects”.  










 Chapter 3: CRESSIDA study – effect of integrated dietary 






Recommendations for the prevention of CVD have been based on epidemiological 
evidence suggesting a relationship between certain dietary components and risk of CVD 
and the effects of these components on surrogate markers of risk. Most attention has 
been focused on dietary fat and salt but more recently has broadened to include 
increased intakes of fruit and vegetables, fish and whole grains and reduced intake of 
added sugars and high glycaemic index carbohydrate (CHO) foods. Most dietary 
intervention trials have focused on modifying single components of diet and few have 
modified more than one component. The DASH study was the first large scale study to 
evaluate the effects of multiple dietary interventions on blood pressure. This study 
showed that the effects on blood pressure of dietary advice to increase fruit and 
vegetable intake was enhanced when accompanied by advice to increase the intake of 
low fat dairy products and whole grains (Appel et al. 2006).  
Serum total cholesterol (TC) is positively associated with CVD risk (Lewington et al. 2007), 
which increases with age and BMI. Dietary intervention studies show that the intake of C12-
C16 SFA increase TC and LDL-C concentrations compared with unsaturated fatty acids or 
CHO (Mensink et al. 2003). However, prospective studies have been unable to demonstrate an 
effect of SFA intake on serum cholesterol concentrations. Keys & Parlin (1966) constructed an 
equation to predict the effect of increasing intake of C12-C16 SFA on serum cholesterol 
concentrations in mmol/L shown below. 
                       
                              





The limitation of the Keys equations is that they were based on dietary intakes of 40% 
energy of fat. The equations developed by Mensink et al. (2003) were elaborated to 
compare changes in TC, LDL-C, HDL-C, TAG and the ratio of TC:HDL-C compared 
with CHO, MUFA, trans fatty acids (TFA) and PUFA. However, these do not include 
the effects of long-chain n-3 PUFA on serum lipids. The consumption of high amounts 
of these fatty acids was reviewed by Balk et al. (2006) and show that a reduction in 
plasma TAG. However, the amounts provided by consuming intakes equivalent to two 
portions of fish a week are more modest (Sanders et al. 2006a; Sanders et al. 2011) and 
generally do not affect TC or LDL-C concentrations. Plasma and erythrocyte fatty acid 
composition is very sensitive to small increases in the intake of LC n-3 PUFA. The aim 
of this chapter was to see if was possible to develop a global biomarker of compliance 
to dietary fat modification that would indicate compliance with the dietary fat targets for 
a cardio-protective diet. 
The measurement of carotid intimal media thickness (CIMT) by high resolution 
ultrasound is a non-invasive method to gauge the extent of atherosclerosis of the carotid 
artery in health. The MESA study reported an association between the omega-3 index 
and CIMT (He et al. 2009). Data were available on CIMT on the participants of the 
CRESSIDA study and it was decided, therefore, to conduct exploratory analyses to see 
if there was any relationship between CIMT in the study population and fatty acid 





3.2 Purpose of the study 
Current dietary fat advice for the prevention of cardiovascular disease (CVD) in the 
United Kingdom is based on the recommendations of the 1994 COMA report. It 
recommends a reduction in SFA intake and their partial replacement with MUFA, no 
increase in n-6 PUFA but an increase in n-3 PUFA from increased consumption of oily 
fish. In order to assess the use of plasma and erythrocyte lipids to ascertain compliance 
to such advice, analyses of erythrocyte and plasma lipids were compared in subjects 
participating in a randomized controlled trial of diet (CRESSIDA). 
The CRESSIDA trial was a multifaceted dietary intervention trial whose targets 
involved modification of fat intake, reduction of salt intake, increased consumption of 
fruits and vegetables, increased intake of wholegrain cereals  (50% of the intake) and a 
restricted intake of added sugars. The study aimed to recruit 196 subjects who were 
randomized to either a control diet, which represented the typical British diet, or an 
intervention diet that approximated to the dietary recommendations of COMA (1994).  
Thus the objectives of this chapter were: 
1. To analyse erythrocyte phospholipids and total plasma fatty acid composition by 
gas chromatography. 





3. To conduct exploratory analysis to examine whether the fatty acid biomarkers 
were related to the extent of carotid intimal medial thickening at baseline. 
 
Hypothesis 
Alterations in the fatty acid composition of plasma and erythrocyte lipids will indicate 




3.3 Study design and dietary intervention 
3.3.1 Study design 
The CRESSIDA study was a parallel randomized controlled trial design on risk factors 
of CVD and vascular function in non-smoking men and women aged 40-70 y, who as a 
consequence of their age are at higher risk of CVD than younger people. The study 
aimed to compare on CVD risk factors the influence of implementation of an integrated 
dietary approach versus a habitual UK diet (control diet). The intervention diet was 
restricted to a low salt (<6 g/d) and SFA intake (<10% energy), increased intake of 
whole grain and cereals (>50%), fruit and vegetables (5 portions/week) and 
consumption of oily fish (2 portions/week one of which should be oily).  
The primary outcome was a change in major cardiovascular risk factors, which were 
defined as 4 mmHg change in day-time blood pressure and a 5% change in TC:HDL 
ratio. Secondary outcomes were changes in endothelial function, arterial stiffness, 
insulin sensitivity and C-reactive protein concentrations.  However, the focus of this 
Chapter is on indices of compliance to the dietary fat advice. Figure 3.1 shows the 







Figure ‎3.1 Overall design of the CRESSIDA study 
 
 
3.3.2 Dietary intervention 
Dietary fat formulation approach was a modified dietary fat exchange model. 
Participants were provided with vegetable oils and spreading fats and dietary advice 
regarding type of milk products and choice and preparation of meat. Table 3.1 
summarises dietary intakes targets.  
VISIT: Heart Health 1
(St Thomas’ 
Hospital)
Food Pick up & Diet 
Information
6 weeks 6 weeksApprox 2-4 weeks
DIETARY INTERVENTION





Whole day’s urine & 
blood pressure







Whole day’s urine & 
blood pressure
Whole day’s urine & 
blood pressure
Whole day’s urine & 
blood pressure










Table ‎3.1 Composition of control and intervention diets 
  Control diet Intervention diet 
SFA ~ 14 % en ~ 10 % en 
MUFA ~12 % en ~16 % en 
PUFA ~6 % en PUFA ~6 % en 
TFA <1 % en TFA < 1% en 
Salt  No restrictions <6 g/d 
Oily fish <1 serving/month 2 portion/week 
Fruit & veg/day 3 portions 5 portions 
Wholegrain cereals - >50% en 
% en=% food energy 
 
3.4 Study participants 
Study participants were healthy non-smoking men and women aged 40-70 y with a 
systolic BP <160 mmHg and diastolic BP <105 mmHg and were not receiving 
medication for treatment of high blood pressure or taking lipid-lowering medications. 
Participants were recruited by newspaper advertisement. Randomization to treatment 




online electronic clinical trial database (MedSciNet AB, Stockholm, Sweden). Where 
two participants cohabited, both were allocated to the same treatment group. 
Participants were required to complete 4-day diet records at baseline and at follow-up. 
The records were checked by a dietician (Dianne Reidlinger) and coded into the dietary 
analysis program NETWISP (version 3.0). Basal metabolic rate was estimated using the 
Schofield equations as described in the Dietary Reference Values report (1991) and 
participants with energy intake less than 1.2 x BMR were regarded as under-reporters 
and were excluded as a result. 
 
3.5 Analysis of fatty acid proportions and fasting blood lipids 
Erythrocyte lipid extracts were prepared and analysed by Robert Gray (Diabetes and 
Nutritional Sciences Division, King‟s College London) using methods as previously 
described in Chapter 2 and plasma fatty acids were prepared and analysed by author. 
The fasting lipid profile was determined by Tracy Dew at KingsPath at King‟s College 
London under the supervision of Dr Roy Sherwood. TC, HDL-C and TAG 
concentrations were measured using fully enzymatic procedures on the Siemens 
ADVIA 2400 automated chemistry analyser. LDL-C was estimated by the Friedwald 
equation as described in Chapter 2. Carotid intima-medial thickness (CIMT) assessed 




participants at the end of the study by a trained ultrasonographer Dr Benyu Jiang at St 
Thomas‟ Hospital. 
 
3.6 Statistical analysis 
Statistical analysis was conducted using IBM SPSS/PC (version 20). Standard 
distributional checks were made on all data and where data did not conform to normal 
distribution a loge transformation was attempted. Comparison between treatments were 
analysed by analysis of covariance (ANCOVA) adjusting for covariates used in the 
minimisation procedure (age, gender, ethnicity and body mass index). Spearman‟s 
correlation was performed between individual fatty acids of erythrocyte phospholipids 
and total plasma fatty acids. Data reduction conducted using principal component 
analysis (PCA). Obtained components were then subjected to varimax rotation to 






3.7.1 Characteristics of the study population 
A total of 162 participants completed the study (3-months) and their characteristics are 
shown in Table 3.2. BMI at baseline was 1.5 kg/m
2
 lower in the control group but 
otherwise the participants well matched. 
Table ‎3.2 Baseline characteristics of the study participants stratified by group. 
  
Control  
 (n= 82) 
Intervention  
 (n= 80) 
Male 32 (39%) 32 (40%) 
Female 50 (61%) 48 (60%) 





 26.9±3.9 25.4±3.7* 
Systolic BP  (mm Hg) 119.7±14.8 120.2±17.1 
Diastolic BP  (mm Hg) 79.4±10.0 78.1±9.1 
Heart rate (beats/min) 67.6±9.3 65.3±8.8 
Glucose  (mmol/L) 5.2±0.4 5.3±0.5 
Insulin  (mU/L) 8.4±6.3 6.6±4.2 
HsCRP (mg/dL) 1.7±2.0 1.8±3.0 
Triacylglycerol  (mmol/L) 1.3±0.6 1.2±0.6 
Cholesterol  (mmol/L) 5.1±1.0 5.1±1.2 
LDL-cholesterol  (mmol/L) 3.1±0.8 3.0±0.9 
HDL-cholesterol  (mmol/L) 1.5±0.4 1.5±0.4 
TC:HDL-C ratio 3.6±1.0 3.5±0.9 





3.7.2 Dietary intake of the study participants 
The effects of the dietary intervention on the dietary intakes are presented in Table 3.3. 
Protein as a proportion of the dietary energy was slightly greater in intervention group. 
There were no differences in carbohydrates intake, but the intakes of fat and SFA were lower in 
the intervention group, and those of MUFA and PUFA were greater. The estimated intake of LA 
was greater following the intervention on the integrated dietary approach compared with the 
control diet, as were the intakes of EPA and DHA. Excluding data from participants with energy 














Energy (MJ/day)    
Baseline 8.99 (2.26) 8.95 (2.48)   
Endpoint 8.73 (2.31) 9.35 (2.34) -0.62 (-1.35, 0.10) 0.09 
Protein (% energy)    
Baseline 16.0 (2.9) 15.8 (3.2)   
Endpoint 17.7 (2.9) 15.7 (2.9) 1.8(-0.2, 3.8) <0.001 
CHO (% energy)    
Baseline 47.0 (7.4) 48.8 (7.5)   
Endpoint 47.1 (7.0) 46.7 (6.4) 0.3 (-4.5, 5.0) 0.158 
Fat (% energy)    
Baseline 36.1 (5.9) 34.7 (6.2)   
Endpoint 33.8 (5.4) 37.1 (5.3) -3.6 (-5.2, -1.9) <0.001 
SFA (% energy)     
Baseline 12.3 (3.5) 11.6 (3.2)   
Endpoint 7.7  (1.7) 14.8 (2.8) -7.2 (-8.0, -6.5) <0.001 
MUFA (% energy)    
Baseline 11.9 (2.5) 11.8 (2.7)   
Endpoint 15.7  (3.5) 12.3 (2.1) 3.4 (2.5, 4.5) <0.001 
PUFA (% en     
Baseline 6.6 (2.2) 6.1 (1.7)   
Endpoint 7.0 (1.8) 5.3 (1.7) 1.9 (1.4, 2.4) <0.001 
Linoleic acid (% energy)    
Baseline 6.2 (2.1) 5.7 (1.6)   
Endpoint 6.3 (1.5) 4.9 (1.6) 1.4 (0.9, 1.9) <0.001 
n-3 PUFA (g/d)    
Baseline 0.23 (0.47) 0.36 (0.82)   
Endpoint 1.39 (1.66) 0.08(0.15) 1.32 (0.95, 1.32) <0.001 
EPA (g/d)     
Baseline 0.07 (0.16) 0.11 (0.25)   
Endpoint 0.42 (0.57) 0.02 (0.09) 0.39 (0.27, 0.52) <0.001 
DHA (g/d)     
Baseline 0.13 (0.28) 0.21 (0.48)   




 n= 82, 
3
 mean difference with 95% CI. 
Mean values (SD).  




3.7.3 Changes in serum lipid concentrations 
Table 3.4 shows the serum lipid concentrations. The intervention diet resulted in an 
8.1% fall in serum cholesterol and 10% fall in LDL-C compared with the control 
treatment. However, HDL-C differed by 6.2% from the control value. Overall, the 
TC:HDL-C ratio was 4.2% lower on intervention diet compared with the control diet 
and serum TAG concentration was 8.8% lower. The change in TC between diets was 
very close to that predicted by the Keys equation (Δ cholesterol (mg/dL) = 2.3 ΔS –ΔP) 
which can be divided by 38.5 convert to mmol/L (ΔS is the difference in SFA % energy 
minus stearic acid and ΔP is the difference in energy % from PUFA). Substituting ΔS as 
6.0 and ΔP as 1.9 predicts a 0.41 mmol/L difference in TC. The difference in 
cholesterol intake would be predicted to result in a 0.06 mmol/L difference between 
diets. The observed difference in serum cholesterol between diets was 0.46 mmol/L vs. 
the estimated 0.47 mmol/L. The results of the dietary analysis and the changes in serum 
cholesterol concentration indicate that the participants were compliant with the dietary 
advice given. The change in serum TAG concentrations is close to what would be 
predicted from the results of the MARINA and OPTILIP studies for this level of intake 














  n= 80 n= 82   
Cholesterol
5 
Baseline 5.33 (1.11) 5.35 (0.86)   
(mmol/L) Endpoint 5.06 (0.93) 5.49 (0.89) -8.1% (-11.4, -4.8) <0.0001 
      
LDL-C  Baseline 3.18 (0.89) 3.18 (0.77)   
(mmol/L) Endpoint 3.00 (0.75) 3.29 (0.78) -10.0% (-14.3, -5.7) <0.0001 
      
HDL-C
5 
Baseline 1.61 (0.40) 1.56 (0.42)   
(mmol/L) Endpoint 1.58 (0.38) 1.62 (0.44) -6.2 % (-10.3, -2.0) 0.005 
      
TC:HDL-C
5 
Baseline 3.46 (0.91) 3.63 (0.98)   
 Endpoint 3.31 (0.87) 3.59 (0.96) -4.2% (-8.0, 0.2)  0.044 
      
TAG
5 
Baseline 1.24 (0.59) 1.33 (0.58)   
(mmol/L) Endpoint 1.06 (0.45) 1.23 (0.55) -8.8 % (-15.9, -1.1) 0.027      






Percentage change (95% CI) on treatment adjusted for age, BMI, ethnicity, gender and baseline 
value. 
4
Probability of treatment effect from analysis of covariance regressed against age, BMI, 






3.7.4 Erythrocyte phospholipids and total plasma fatty acid composition pre- and 
post-intervention 
Table 3.6 and Table 3.7 show the changes in proportions of fatty acids in erythrocyte 
phospholipids and total plasma lipids in control and intervention groups respectively. 
There were no significant differences between groups in fatty acid proportions at 
baseline. The most abundant fatty acids in erythrocytes membrane were 16:0, 20:4n-6, 
18:1n-9 and 18:0. While the plasma was associated with higher levels of 18:2n-6, 
18:1n-9, 16:0, 20:4n-6 and 18:0. A significant amount of DHA (22:6n-3) was found in 
erythrocyte membrane (5.69%) in comparison with plasma (2.35%). EPA (20:5n-3) was 
similar in the two biomarkers. Alpha-linolenic (ALA, 18:3n-3) and palmitoleic acids 
(16:1n-7) were both lower in erythrocytes. Proportions of 18:1trans isomers were low 
but were slightly greater in erythrocytes.  
Significant differences between treatments were observed following intervention in the 
proportions in erythrocyte lipids of 20:5n-3 (P<0.001), 22:6n-3 (P<0.001), 18:1n-9 
(P=0.008) and MUFA  (P=0.004) whereas proportions of 22:5n-6 (P=0.002), 20:3n-6 
(P=0.008), 20:4n-6 (P=0.018), 18:2n-6 (P=0.02), and 22:4n-6 (P=0.037) were 
correspondingly lower compared with the control group. No other significant 
differences were noted.   
Significant differences between treatments were observed following intervention in 
plasma proportions of 20:5n-3 (P<0.001), 22:6n-3 (P<0.001), 18:1n-9 (P=0.002), 




increased, whereas the proportions of SFA (P<0.001), 14:0 (P<0.001), 16:0 (P<0.017), 
18:0 (P<0.001), 18:3n-6 (P<0.001), 20:3n-6 (P<0.001), 16:1n-7 (P=0.001), 18:3n-3 
(P=0.001), 20:4n-6 (P=0.004) and 16:0 (P=0.017) fell compared with the control group. 
No other significant differences were noted.  
Lower levels of GLA, DGLA and AA in the intervention group might indicate 
inhibition of D6D by LC-PUFA. The proportion of osbond acid appeared high in 
plasma but not in erythrocyte lipids. It is possible that this may reflect co-elution of 
24:2n-6 with 22:5n-6. The slightly high proportion of ALA in the plasma of the control 
group might be due to higher intake of dairy fat and red meat (beef, lamb) in the control, 
which contains appreciable amount of ALA (1-2% by wt). Increased proportions of 
EPA, DPA and DHA indicate compliance to dietary advice to consume oily fish. 
Receiver operator curves (ROC) were plotted to estimate the sensitivity of total plasma 
SFA as a predictor of a diet high in SFA. Figure 3.2 shows receiver operator curves for 
proportion of total SFA in plasma and erythrocyte lipids to identify subjects on high 
SFA diet vs. intervention diet. Area under the curve was 0.72 (95 % CI 0.62, 0.80) for 





Figure ‎3.2 Receiver operator curves for proportion of total SFA in plasma and erythrocyte 




Table ‎3.5 Area under the curve for the proportions of total SFA in plasma and erythrocyte 
lipids. 
Area Under the Curve 









Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
SFA in plasma wt%  0.719 0.040 0.000 0.640 0.798 
SFA in RBC wt% 0.470 0.046 0.518 0.381 0.560 
The test result variable(s): Total SFA in RBC wt% has at least one tie between the positive 
actual state group and the negative actual state group. Statistics may be biased. 
a
Under the nonparametric assumption 
b






Table ‎3.6 The proportions of saturated (SFA), trans (TFA), monounsaturated (MUFA) and polyunsaturated (PUFA) fatty acids in erythrocyte lipids at baseline  
and after 3-months on control or intervention diet. 
Fatty Acid Baseline (n= 162)  Control (n= 82) Intervention
 
(n= 80) Mean difference P 
SFA 35.40 ± 3.62 35.01 (34.22,35.79) 34.47 (33.69,35.25) -0.53 (-1.66,0.59) 0.350 
16:0 19.86±  2.87 19.76 (19.18,20.35) 19.52 (18.94,20.10) -0.24 (-1.08,0.59) 0.819 
18:0 15.54±  1.78 15.27 (14.82,15.73) 14.92 (14.47,15.37) -0.35 (-1.00,0.30) 0.486 
MUFA 17.31±  1.43 17.60 (17.31,17.89) 18.22 (17.92,18.52) 0.62 (0.20,1.04) 0.004 
16:1n-7 0.43±  0.24 0.41 (0.36,0.45) 0.42 (0.38,0.46) 0.02 (-0.04,0.08) 0.614 
18:1n-9 15.78±  1.30 15.86 (15.46,16.26) 16.64 (16.24,17.04) 0.78 (0.21,1.35) 0.008 
18:1n-7 1.12 ± 0.41 1.31 (1.02,1.60) 1.25 (0.96,1.55) -0.06 (-0.47,0.36) 0.726 
TFA: 18:1 trans 0.25±  0.35 0.19 (0.16,0.22) 0.16 (0.12,0.19) -0.03 (-0.08,0.01) 0.343 
PUFA 43.14±  3.85 43.32 (42.48,44.16) 43.42 (42.57,44.26) 0.10 (-1.10,1.29) 0.873 
18:2n-6 11.64 ± 1.63 11.67 (11.39,11.94) 11.20 (10.92,11.47) -0.47 (-0.87,-0.08) 0.020 
20:3n-6 1.93±  0.42 1.93 (1.86,1.99) 1.80 (1.74,1.87) -0.13 (-0.22,-0.03) 0.008 
20:4n-6 15.87±  2.08 16.01 (15.56,16.46) 15.22 (14.77,15.67) -0.78 (-1.43,-0.14) 0.018 
22:4n-6 2.79±  0.78 2.81 (2.66,2.96) 2.58 (2.43,2.73) -0.23 (-0.44,-0.01) 0.037 
22:5n-6 0.42±  0.16 0.45 (0.42,0.48) 0.38 (0.35,0.41) -0.07 (-0.12,-0.03) 0.001 
18:3n-3 0.26±  0.27 0.34 (0.26,0.42) 0.29 (0.21,0.36) -0.05 (-0.16,0.06) 0.332 
20:5n-3 1.41±  0.74 1.21 (1.09,1.33) 1.83 (1.71,1.95) 0.62 (0.45,0.79) <0.001 
22:5n-3 3.06±  0.65 3.19 (2.97,3.41) 3.07 (2.85,3.29) -0.12 (-0.43,0.19) 0.438 
22:6n-3 5.69±  1.71 5.26 (4.94,5.58) 6.50 (6.18,6.82) 1.25 (0.78,1.71) <0.001 
n-6:n-3  3.40±  0.96 3.46 (3.28,3.64) 2.79 (2.61,2.98) -0.66 (-0.92,-0.40) <0.001  
Baseline data presented as mean ± SD; no differences between groups as baseline. 




Table ‎3.7 Saturated (SFA), trans (TFA), monounsaturated (MUFA) and polyunsaturated (PUFA) fatty acids (wt%) in total plasma lipids at baseline and at follow-up. 
Fatty Acid Baseline (n= 162) Control (n= 82) Intervention (n= 80) Mean difference  P 
SFA 27.94 ± 1.94 27.93 (27.68,28.18) 27.01 (26.76,27.26) -0.92 (-1.28,-0.56) <0.001 
14:0 0.84 ± 0.30 0.83 (0.78,0.88) 0.66 (0.61,0.71) -0.17 (-0.24,-0.11) <0.001 
16:0 20.32 ± 1.75 20.23 (19.99,20.47) 19.81 (19.56,20.05) -0.42 (-0.77,-0.08) 0.017 
18:0 6.50 ± 0.57 6.59 (6.50,6.68) 6.29 (6.20,6.39) -0.30 (-0.43,-0.17) <0.001 
20:0 0.28 ± 0.11 0.28 (0.26,0.29) 0.26 (0.24,0.27) -0.02 (-0.04,0.00) 0.036 
MUFA 24.90 ± 3.39 24.58 (24.15,25.01) 25.28 (24.84,25.71) 0.69 (0.08,1.31) 0.028 
16:1n-7 2.34 ± 0.97 2.28 (2.17,2.38) 2.02 (1.91,2.12) -0.26 (-0.41,-0.11) 0.001 
18:1n-9 20.85 ± 2.75 20.64 (20.26,21.01) 21.52 (21.13,21.90) 0.88 (0.34,1.42) 0.002 
18:1n-7 1.71 ± 0.35 1.67 (1.63,1.72) 1.74 (1.70,1.78) 0.06 (0.00,0.12) 0.035 
TFA 18:1 0.13 ± 0.16 0.13(0.07,0.18) 0.12(0.07,0.18)  0.10 (-0.05,0.25) 0.209 
PUFA 42.47 ± 4.12 42.68 (42.14,43.23) 43.63 (43.08,44.19) 0.95 (0.17,1.74) 0.018 
18:2n-6 27.31 ± 3.84 27.56 (27.10,28.01) 27.62 (27.16,28.09) 0.07 (-0.59,0.73) 0.845 
18:3n-6 0.50 ± 0.19 0.51 (0.48,0.53) 0.43 (0.40,0.45) -0.08 (-0.12,-0.04) <0.001 
20:3n-6 1.57 ± 0.37 1.64 (1.58,1.70) 1.43 (1.37,1.49) -0.21 (-0.30,-0.13) <0.001 
20:4n-6 6.58 ± 1.44 6.74 (6.56,6.93) 6.35 (6.17,6.54) -0.39 (-0.65,-0.13) 0.004 
22:4n-6 0.44 ± 0.19 0.46 (0.45,0.48) 0.46 (0.44,0.47) -0.01 (-0.03,0.01) 0.517 
22:5n-6 0.83 ± 0.33 0.85 (0.81,0.89) 0.92 (0.89,0.96) 0.07 (0.02,0.13) 0.006 
18:3n-3 0.68 ± 0.20 0.67 (0.63,0.70) 0.59 (0.56,0.62) -0.07 (-0.12,-0.03) 0.001 
20:5n-3 1.34 ± 0.88 1.22 (1.04,1.40) 2.02 (1.84,2.19) 0.79 (0.54,1.05) <0.001 
22:5n-3 0.86 ± 0.65 0.84 (0.76,0.93) 1.00 (0.91,1.08) 0.16 (0.03,0.27) 0.012 
22:6n-3 2.35 ± 1.13 2.18 (2.04,2.31) 2.83 (2.70,2.97) 0.66 (0.47,0.85) <0.001 
n-6:n-3 ratio 7.77 ± 2.20 8.23 (7.84,8.61) 6.34 (5.96,6.73) -1.88 (-2.43,-1.33) <0.001 




3.7.5  Correlations between erythrocyte lipids and plasma total fatty acid 
composition post intervention. 
Spearman‟s correlations between erythrocyte lipid and total plasma fatty acid 
composition are shown in Table 3.8. Strong correlations were found for 20:5n-3 
(ρ=0.725), n-6:n-3 ratio (ρ= 0.654; P< 0.001); 20:3n-6 (ρ= 0.616), 18:2n-6 (ρ= 0.537), 
16:1n-7 (ρ= 0.522), 22:6n-3 (ρ= 0.506), 20:4n-6 (ρ= 0.380), 18:1n-7 (ρ= 0.347), 22:5n-
3 (ρ= 0.338) and TFA (ρ= 0.305). Weaker correlation were found for MUFA (ρ= 
0.236), 16:0 (ρ= 0.197, P= 0.012), 18:1n-9 (ρ= 0.193, P= 0.014), SFA (ρ= 0.190, P= 
0.016), and 18:0 (ρ= 0.179, P= 0.023). These findings indicate that erythrocyte lipids 
are good indices of the balance between n-6 and n-3 LC-PUFA and a low intake of 
PUFA as judged by lower proportions of LA and high proportions of palmitoleic acid 
which were negatively correlated (ρ= -0.207, P= 0.009) but are not a good indicator of 
the PUFA/SFA ratio. This is not entirely surprising as there is specificity in 
phosphatidyl choline for palmitic acid in the sn-1 position and for stearic acid in 
ethanolamine and serine phosphoglycerides which are the major phosphoglycerides in 
erythrocyte lipids. In plasma, cholesteryl esters have high specificity for LA and choline 
phosphoglycerides, which make up the bulk of plasma phospholipids, have a high 
content of palmitic acid in the sn-1 position and a high specificity for LA in the sn-2 
position. Plasma TAG concentrations are more likely to reflect dietary fat composition 





Table ‎3.8 Correlations between proportions of fatty acid in plasma and erythrocyte lipids after 3 


















SFA 0.190 0.016 
16:0 0.197 0.012 
18:0 0.179 0.023 
MUFA 0.236 
 16:1n-7 0.522 <0.001
18:1n-9 0.193 0.014 
18:1n-7 0.347 <0.001 
TFA 
  18:1 trans 0.305 <0.001
n-6 
  18:2n-6 0.537 <0.001
20:3n-6 0.616 <0.001 
20:4n-6 0.380 <0.001 
22:4n-6 -0.228 0.004 
22:5n-6 -0.191 0.019 
n-3 
  18:3n-3 0.121 0.141
20:5n-3 0.72 <0.001 
22:5n-3 0.338 <0.001 
22:6n-3 0.506 <0.001 
n-6:n-3 ratio 0.654 <0.001 
P:S ratio 0.095 0.267 




3.7.6 Principal component analysis 
Data reduction was attempted using principal component analysis on the plasma and 
erythrocyte fatty acids post intervention. Table 3.9 and Table 3.10 show the 
components for the analysis and Figure 3.3 and Figure 3.4 show the scree plots 
generated from plasma and erythrocyte phosphoglycerides respectively. Table 3.11 and 
Table 3.12 show the differences between control and intervention groups for the 
components. Component 1, which explained 24% of the variance, appeared to reflect 
changes in the P/S ratio and is being determined by higher proportions of SFA and 
MUFA, a lower proportion of LA and higher proportion of LC-PUFA. This is likely to 
indicate a low absolute intake of PUFA which favours desaturation and chain 
elongation of the parent fatty acids into longer chain derivatives as well as enhanced 
desaturation of palmitic to palmitoleic and stearic to oleic acids. Component 2, which 
explained 14.1% of the variance showed a strong correlation with arachidic, adrenic, 
osbond acid and DHA and may indicate a higher intake of LC-PUFA. Component 3 
explained 11.8% of the variance and was associated with higher proportions of EPA and 
22:5n-3 but lower proportions of the products of desaturation of LA, GLA and DGLA. 
Component 4 was found to explain 9.1% of the variance and correlates well with 
myristic, oleic, ALA and 22:5n-3 and negatively correlated with AA and DHA. When 
looking at component 5, it appeared to explain 8.1% of the variability and was well 
correlated with stearic, GLA, DGLA, AA and 22:5n-3. It was also found to correlate 




of the variability and correlates strongly with vaccinic, AA, 22:5n-3 and negatively with 




Figure ‎3.3 Scree plot of the components generated from the application of principal component 





Table ‎3.9 Association between 18 plasma fatty acid proportions and the 6 components 
identified in the CRESSIDA study following 3-months intervention. 
















Variance explained (%) 24.1 14.1 11.8 9.1 8.1 5.7 





  14:0 0.606 -0.284 -0.145 0.517 0.153 -0.047 
16:0 0.790 0.070 0.004 0.053 -0.068 0.042 
18:0 -0.211 0.021 -0.043 -0.086 0.718 -0.071 
20:0 0.1017 0.8824 -0.1050 0.0261 -0.125 0.027 
MUFA 
      16:1n-7 0.745 0.015 -0.130 0.082 -0.304 0.155 
18:1n-9 0.292 -0.160 -0.389 0.255 -0.570 -0.139 
18:1n-7 0.322 -0.284 0.166 0.102 -0.407 0.563 
TFA 
      18:1 trans 0.084 -0.023 0.146 0.015 -0.021 -0.677 
PUFA 
      n-6 
      18:2n-6 -0.884 0.080 -0.095 0.133 0.165 0.165 
18:3n-6 0.519 -0.351 -0.332 -0.053 0.538 0.061 
20:3n-6 0.503 -0.056 -0.595 0.003 0.254 0.124 
20:4n-6 0.098 -0.104 -0.036 -0.735 0.392 0.201 
22:4n-6 -0.073 0.916 -0.068 -0.144 0.134 -0.075 
22:5n-6 -0.133 0.864 0.267 -0.119 0.040 -0.098 
n-3 
      18:3n-3 0.012 -0.097 -0.009 0.675 -0.113 0.093 
20:5n-3 0.047 0.047 0.881 -0.111 -0.005 -0.189 
22:5n-3 0.067 -0.264 0.593 0.439 0.282 0.394 
22:6n-3 -0.188 0.230 0.193 -0.575 -0.312 -0.450 




Components generated from PCA analysis from erythrocyte phospholipids are 
summarised in Table 3.10. Figure 3.4 shows scree plot generated from the application 
of PCA on the erythrocytes phospholipids. Component 1, which explained 19.6% of the 
variability, correlates strongly with n-6 PUFA with the exception of LA. It correlates 
negatively with palmitic, EPA and DHA. Component 2 explained 18% of the variability 
and was found to correlate strongly with palmitic, vaccinic, and osbond acids and 
negatively with oleic acid. Component 3 explained 13% of the variability and strongly 
correlated with AA, adrenic acids and n-3 PUFA with the exception of ALA. It was 
negatively correlated with palmitic, stearic, palmitoleic and ALA. Component 4 
explained 10.2% of the variability and correlates with stearic and n-3 PUFA with the 
exception of ALA and EPA. It correlates negatively with the essential fatty acids LA 
and ALA. Finally component 5, which explained 7.3% of the variability, correlated 
strongly with stearic, TFA, LA and AA. It also correlated negatively with palmitoleic, 







Figure ‎3.4 Scree plot of the components generated from the application of principal component 




Table ‎3.10 Association between 15 fatty acid proportions in erythrocytes and the 5 components 
identified in the CRESSIDA study following 3-months intervention. 












Variance explained (%) 19.6 18.0 13.0 10.2 7.3 





 16:0 -0.272 0.215 -0.814 0.002 -0.142 
18:0 0.112 -0.072 -0.216 0.725 0.280 
MUFA 
     16:1n-7 0.099 -0.178 -0.449 0.135 -0.665 
18:1n-9 -0.019 -0.892 0.016 -0.061 -0.050 
18:1n-7 -0.148 0.868 -0.129 -0.037 -0.044 
TFA 
     18:1 trans 0.048 -0.026 -0.120 0.174 0.578 
PUFA 
     n-6 
     18:2n-6 -0.047 -0.077 -0.109 -0.672 0.336 
20:3n-6 0.599 0.053 0.120 0.190 -0.206 
20:4n-6 0.556 0.067 0.485 -0.058 0.255 
22:4n-6 0.803 -0.152 0.335 0.191 0.103 
22:5n-6 0.372 0.792 0.040 -0.126 0.057 
n-3 
     18:3n-3 -0.013 0.061 -0.237 -0.701 -0.141 
20:5n-3 -0.849 -0.151 0.230 0.157 -0.049 
22:5n-3 0.001 0.026 0.761 0.204 -0.223 
22:6n-3 -0.475 -0.076 0.496 0.498 0.054 





Components 1, 3 and 5 from the total plasma differed significantly between the two 




 respectively. While 
components 1 and 2 from the erythrocyte phospholipids differed significantly between 
the two groups with P value of 2.8x10
-7
 and 0.043 respectively as summarised in Table 
3.11 and Table 3.12. 
 
Table ‎3.11 Comparison of the generated components from plasma fatty acids between the two 
groups after 3 months intervention. 
  
Control             Intervention P
1 
      (n= 82) (n= 80) 
Component-1 0.14 (-0.05,0.33) -0.14 (-0.33,0.05) 0.045 
Component-2 0.02 (-0.20,0.25) -0.02 (-0.25,0.20) 0.767 
Component-3 -0.35 (-0.55,-0.14) 0.36 (0.15,0.56) 4.80x10
-6
 
Component-4 0.10 (-0.12,0.32) -0.10 (-0.32,0.12) 0.203 
Component-5 0.37 (0.18,0.56) -0.38 (-0.58,-0.19) 2.70x10
-7
 
Component-6 0.08 (-0.15,0.30) -0.08 (-0.30,0.15) 0.342 
Univariate analysis of variance was used to perform the comparison. 
1





Table ‎3.12 Comparison of the generated components from erythrocyte phospholipids fatty acids 





 (n= 82) (n= 80) 
Component-1 0.40 (0.19,0.61) -0.45 (-0.67,-0.23) 2.80x10
-7
 
Component-2 0.17 (-0.07,0.41) -0.19 (-0.44,0.06) 0.043 
Component-3 -0.10 (-0.34,0.13) 0.12 (-0.14,0.37) 0.215 
Component-4 -0.08 (-0.30,0.14) 0.09 (-0.15,0.33) 0.309 
Component-5 -0.01 (-0.25,0.23) 0.01 (-0.24,0.26) 0.922 
Univariate analysis of variance was used to perform the comparison. 
1





Figure 3.5 shows the ROC curves for the plasma PCA components and Figure 3.6 for 
the erythrocyte lipid components. Component 5 for plasma was the most powerful at 
discriminating between diets whereas component 1 for erythrocytes was most powerful 




Figure ‎3.3 Receiver operator characteristics for components from PCA of plasma according to 





Table ‎3.13 Area under the curve of the ROC analysis for plasma PCA component. 
Area Under the Curve 









Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
REGR factor score   
1_P_3m 
0.607 0.044 0.018 0.521 0.694 
REGR factor score   
2_P_3m 
0.510 0.046 0.828 0.420 0.600 
REGR factor score   
3_P_3m 
0.297 0.041 0.000 0.216 0.378 
REGR factor score   
4_P_3m 
0.557 0.045 0.208 0.468 0.646 
REGR factor score   
5_P_3m 
0.733 0.039 0.000 0.656 0.809 
REGR factor score   
6_P_3m 
0.506 0.046 0.901 0.416 0.596 
a
Under the nonparametric assumption. 
b












Table ‎3.14 Area under the curve of the ROC analysis for RBC PCA component  
Area Under the Curve 








Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
REGR factor score   
1_RBC_3m 
 
0.756 0.043 0.000 0.672 0.840 
REGR factor score   
2_RBC_3m 
 
0.616 0.049 0.022 0.521 0.712 
REGR factor score   
3_RBC_3m 
 
0.441 0.050 0.243 0.343 0.539 
REGR factor score   
4_RBC_3m 
 
0.490 0.051 0.845 0.391 0.589 
REGR factor score   
5_RBC_3m 
 
0.445 0.050 0.280 0.347 0.544 
a
Under the nonparametric assumption. 
b
















3.7.7 Relationship of biomarkers to carotid intima-medial thickness (CIMT).  
Baseline carotid diameter, intima-media thickness (IMT) and presence of atherosclerotic 
plaque in participants as detected by high resolution ultrasound stratified by gender are 
illustrated in Table 3.15. Left and right minimal carotid diameters were higher in males 
than females. The same applies to left and right maximal carotid diameters. Left and 
right anterior IMT and posterior IMT were also higher in males than females. 
Table 3.16 summarizes the CIMT thickness stratified by omega-3 tertiles. There was no 
significant difference between the three levels of omega-3 index for the posterior or the 






Table ‎3.15. Carotid diameter, intima-media thickness (IMT) and presence of atherosclerotic 
plaque in participants as detected by high resolution ultrasound. 
    Left   Right 
 
  Males Females   Males Females 
   n=59 n=91   n=59 n=91 
Minimal carotid diameter (mm)  6.86±0.49 6.32±0.66 
 
7.08±0.60 6.47±0.61 




     Anterior IMT (mm)  0.61±0.10 0.60±0.11 
 
0.63±0.11 0.61±0.10 




     Carotid plaque (%)
1




% of total number. 








Table ‎3.16  CIMT thickness stratified by erythrocytes omega-3 index tertiles. 
 
Omega-3 index  
 
IMT Low Medium High 
P-value 
for trend 
Left anterior 0.61 (0.58,0.63) 0.60 (0.58,0.63) 0.60 (0.57,0.63) 0.875 
Left posterior 0.57 (0.54,0.60) 0.56 (0.53,0.59) 0.60 (0.56,0.63) 0.288 
Right anterior 0.63 (0.60,0.65) 0.61 (0.58,0.63) 0.62 (0.59,0.65) 0.765 
Right posterior 0.53 (0.51,0.56) 0.52 (0.50,0.54) 0.55 (0.52,0.58) 0.309 
Values are mean (95% CI). 
   Analysis adjusted for age, gender, SBP, TC:HDL, carotid diameter. 





The aim of the present study was to investigate the influence of adherence to dietary 
modification approach versus habitual UK diet on CVD risk and to develop an overall 
biomarker of compliance to dietary fat modification using fatty acid proportions of 
erythrocyte phospholipids and total plasma as indicators of intake. The distribution of 
fatty acids in our study was in the range expected based on other published reports for 
both erythrocytes and plasma. Among all the SFA, palmitic and stearic acids showed 
weak, but significant correlation, 0.197 and 0.179 respectively. A substantial proportion 
of palmitic and stearic acids may be converted to oleic acid. The other SFA, myristic 
(C14:0) and arachidic (C20:0) acids were not detected in the erythrocytes. Dietary 
contribution of palmitoleic acid is known to be negligible, with the exception of 
macadamia nut and fish oil, and endogenous synthesis in the liver (delta-9 desaturation 
of palmitic acid) is responsible for the circulating levels of this fatty acid. Its synthesis 
is known to be suppressed when PUFA intake is high (Sanders, 1988). However, all 
PUFAs from the n-6 and n-3 families showed a significant correlation with the 
exception of (18:3n-3). It appeared that the control diet, which had a greater intake of 
dairy fat (butter spread, full-fat milk and unrestricted cheese intake), may have resulted 
in a slightly greater intake of LA. This would explain why component 5, which was also 
driven by the level of DGLA and AA, could be used to discriminate the intervention 
from control diets. TFA showed a very strong significant correlation between the two 




group, which might be explained by the selective uptake by the erythrocytes, showed 
higher levels of TFA. TFAs are known to be atherogenic and proportions of TFA in 
erythrocyte phospholipids might be used as a long term indicator of intake. 
After three months following an integrated dietary approach, 16:1n-7, 18:1n-7, TFA and 
18:3n-3 in erythrocyte phospholipids and 20:0, 18:1n-7, 18:2n-6 and 22:4n-6 in plasma 
did not differ between the two study groups. Palmitoleic acid was lower in the plasma 
of the intervention group. 
LA was significantly lower in erythrocytes, but not in the plasma of the intervention group. 
ALA was significantly lower in the plasma, but showed no difference in erythrocyte 
phospholipids. EPA and DHA were significantly higher in the two biomarkers, which indicate 
adherence to the dietary intervention. Levels of EPA and DHA reflect dietary intake of food 
items rich in these fatty acids such as oily fish in addition to active elongation and desaturation 
of precursor fatty acids. Using the plasma fatty acid composition to estimate the intake of EPA 
and DHA based on the dose response relationships in the MARINA study suggested an 
estimated intake of 0.3 g/d for EPA vs an estimated dietary intake 0f 0.4 g/d. However, the 
mean estimated intake of DHA was 0.2 g vs a measured intake of 0.8 g from the food diaries. It 
is possible that the slightly higher intake of dairy fat and meat products and the slightly lower 
intake of LA on the control diet resulting in smaller differences in DHA in plasma. High levels 
of DHA have been found in animals fed a mixture of butter and lard compared with diet high in 
polyunsaturated margarine (Sanders et al. 1984). 
Performance of PCA on fatty acid proportions after three months on the diets enabled 




between diets. These components provide a more concise indicator of change in fatty 
acid profile instead of changes in individual fatty acids. In plasma component 5 was 
most informative and component 1 for erythrocytes. The proportion of total SFA in 
plasma was also able to discriminate between the control and intervention diet but the 
proportion of SFA in erythrocytes lacked that capacity. 
3.9 Conclusion 
This dietary intervention study was successful in achieving its dietary targets. Changes 
in EPA seemed to be more sensitive to diet than DHA. The proportion of total SFA did 
enable discrimination between the control and intervention group probably because it is 
sensitive to reductions in PUFA intake. The results of the fatty acid analysis indicated 
that PCA analysis could be useful in identifying individuals who have made changes in 
their dietary fat intake that are consistent with advice to modify fat intake.  











 Chapter 4: Heritability of fatty acid composition of adipose tissue 






It is is uncertain to what extent genetic factors influence the fatty acid composition of 
lipids. Twin studies can be used to investigate the genetic and environmental influences 
on traits and diseases in the population. The genotype is determined by differences in 
the sequences of DNA whereas the phenotype is what is expressed. The phenotype 
expressed is dependent on the genotype and is also influenced by epigenetic effects 
which appear to have their greatest effects in early growth and development. Twin 
studies utilize the unique degree of shared genetic and environmental factors among the 
two kinds of twin pairs, monozygotic (MZ) and dizygotic (DZ) twins. MZ or identical 
twins are characterised by sharing common set of genes, while DZ or non-identical 
twins share 50% of their genes on average. Furthermore, both types of twins share the 
same uterine environment, age and features of early and late environment. These 
characteristics enable an estimation of the variation of traits into genetic, shared 
environmental and random environmental components. Estimation of the amount of the 
contribution of individual component of variation can be achieved by using quantitative 
analytical techniques to twin data. This gives an estimate of heritability, which has been 
defined as “a measure of the extent to which phenotypic variation in the population can 
be explained by genetic variation” (MacGregor et al. 2000).   
Twin studies have been utilized in association and linkage studies, gene expression 
studies and gene-environment interactions. As far as could be ascertained no previous 




adipose tissue and plasma. Two studies were found where heritability of fatty acids was 
investigated. One study explored the effect of heritability on proportions of branched 
chain fatty acids in co-twin study design, which estimated heritability by comparing the 
associations of traits within dizygotic and monozygotic twins (Stewart et al. 1986). 
Heritability of metabolites was also investigated (Shah et al. 2009). This chapter 
presents evidence for a significant independent effect of heritability on adipose tissue 
and plasma fatty acid composition in a subset of 570 healthy female twins of European 





4.2 Purpose of the study 
The aim of this study was to determine the influence of environmental (dietary intake) 
and additive genetic factors (heritability) on adipose and plasma lipids biomarkers of 
fatty acid intake using a co-twin design. These aims were achieved by the following 
objecives: 
1. To conduct detailed measurements of fatty acid composition of samples of 
adipose tissue and plasma from pairs of monozygotic and dizygotic twins 
recruited to the TwinsUK cohort.  
2. To calculate heritability of plasma and adipose tissue fatty acid composition. 
3. To assess the relationship between dietary estimates of fatty acid intake from 
FFQ with these biomarkers. 
4. To estimate dietary intake of long chain PUFA (LC-PUFA), eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA) from the plasma fatty acid 
composition based on calibration from a long-term dose response study 
(MARINA).  
5. To investigate the influence of variants in candidate SNPs for the for FADS1, 








Additive genetic factors (A) have a significant influence on fatty acid composition of 
adipose tissue and plasma of twins. 
Hypothesis (2) 
SNPs at SCD-1 gene and FADS1 gene cluster influence plasma and adipose tissue 





4.3 Study participants and design 
The present study was a cross-sectional observational study and took advantage of the 
fact that a subgroup of female twin participants were invited to provide samples of 
adipose tissue for gene expression studies. During the collection of biopsies, samples 
were set aside specifically for fatty acid analysis. All participants were twins enlisted in 
the TwinsUK registry, which is a national register of adult twins. The recruitment 
methodology has been described in detail by Spector and Williams. (2006). Twins were 
recruited to the registry as volunteers through a series of media campaigns and were not 
chosen for disease-specific investigations. The participant attended St Thomas‟ Hospital 
for initial clinical assessment between 1993 and 2004. Food frequency questionnaires 
were completed between 1995 and 2007 with most (84%) being completed in 2007 with 
the remainder being completed between 1995 and 2001. There were no differences in % 
energy from total fat between years but SFA and TFA intake were marginally lower 
(0.48% and 0.06% energy respectively) and PUFA higher (0.39% energy) in FFQs 
completed in 2007. In this study, adipose tissue biopsies were obtained in 2008 from 
MZ (n= 230) and DZ (n= 340) pairs of twins with majority being postmenopausal 
women (UK residents) without metabolic disorders that were likely to alter the dietary 






4.4.1 Analytical methods 
Adipose tissue was collected from participants by biopsies where a small incision was 
made under local anaesthesia and samples of up to 0.5g were obtained from the 
abdominal subcutaneous tissue. Approximately, 50mg were set aside for lipid analysis, 
wrapped in aluminium foil and stored at -80˚C until analysed. Fasting blood samples 
were collected in an EDTA containing tubes and centrifuged and the plasma sample was 
separated and stored at -80˚C. Up to 5mg adipose tissue was incubated with 2ml 
mixture of 1.25mol HCL/L methanol: toluene (4:1 by volume) in a glass culture tube 
fitted with a Teflon lined screw cap and incubated at 60˚C for 2hrs. After which 5ml of 
60g potassium carbonate/L water was added, the sample vortex mixed and centrifuged 
at 1500rpm for 10min to enable clear phase separation. Upper toluene phase was 
carefully collected using a glass pipette or a Hamilton syringe and transferred into an 
amber glass GLC vial and diluted with 500µl toluene. Fatty acid methyl esters (FAME) 
were separated on an Agilent 7890 Gas Chromatograph (Agilent Technologies) fitted 
with a flame ionisation detector with a 60m BPX70 SGE fused silica column and 
0.25mm diameter (SGE, Cat no. 054623 Milton Keynes, UK) in split mode 50:1 with 
hydrogen as carrier gas (1ml/min). Injector and oven temperatures were at 250°C and at 
180°C respectively.  FAME standards were obtained from Sigma Aldrich (Cat no.1891-
1, 189-2 and 189-3) and secondary reference standards of methyl esters of fish oil 




identity of fatty acids for which standards were not available was estimated using plots 
of the retention times as described by Christie. W (1990) to obtain the equivalent chain 
lengths and n-9/n-6/n-3 ratios.  Quality control was maintained by running a matrix 
standard of sample of adipose tissue FAME with each run. Chromatograms were 
evaluated using ChemStation software (version 8.04) and the output exports via visual 
basic application into excel for data analysis. 
Plasma total fatty acids were methylated using a modification method of Lepage & Roy 
as described by Sanders et al. (2006a), substituting toluene for benzene and using 
pentadecanoic acid (C15:0) as an internal standard. FAME were separated on a BPX70 
column 25m x 220µm film thickness x0.25µm internal diameter (SGE, Cat no. 054602 
Milton Keynes, UK) on an Agilent 7890 (Agilent Technologies, Cheshire, United 
Kingdom). Chromatograms were integrated using ChemStation software and exported 
into Microsoft Excel. 
4.4.2 Dietary assessment 
Participants completed 131-items FFQ described elsewhere (Teucher et al. 2007). 
Briefly, the FFQ was used earlier in the EPIC study and an established database of 
nutrients composition used to derive dietary intake. Nutrient intakes were calculated  
based on data from the 5
th
 Edition of McCance & Widdowson‟s The Composition of 
Foods (Holland et al. 1991) and the seventh supplement (MAFF, 1998). Participants 
were excluded if answers for more than 10 food items were left blank and if the ratio of 




exceeds 2 standard deviations from the mean of that ratio (<0.52 or >2.58) (Teucher et 
al. 2007). Nutrient intake data were available from the TwinsUK Registry at St 
Thomas‟ Hospital. 
4.4.3 Zygosity, body composition, biochemical analyses and SNPs genotyping 
Information on zygosity was determined by standardized questionnaire and confirmed 
by DNA fingerprinting. Height was measured to the closest 0.5cm using a wall-
mounted stadiometer. Weight (only light clothing allowed) was measured to the closest 
0.1 kg using digital scales. Fasting blood samples were collected from subjects after a 
minimum 8hrs overnight fast for determination of fasting blood lipids, glucose and 
insulin. Serum samples were stored at −45°C until analyzed using a CobasFara machine 
(RocheDiagnostics, Lewes, UK). A colorimetric enzymatic method was used to 
determine total cholesterol (TC), triacylglycerols (TAG), and high density lipoprotein 
(HDL-C) cholesterol levels. The latter was measured after precipitation from 
chylomicron, low density lipoprotein (LDL), and very low-density lipoprotein (VLDL) 
particles by magnesium and dextransulphate and LDL cholesterol was estimated using 
the Friedewald equation (total cholesterol – HDL cholesterol-TAG/2.2). Insulin was 
measured by immunoassay (Abbott Laboratories, Maidenhead, UK) and glucose was 
measured on an Ektachem 700 multichannel analyzer using an enzymatic colorimetric 
slide assay (Johnson and Johnson ClinicalDiagnostic Systems, Amersham, UK) in an 




Assessment (HOMA), a software implementation of the HOMA2 model developed by 
Diabetes Trials Unit, University of Oxford (http://www.dtu.ox.ac.uk/homacalculator/)  
Genotypes were extracted from whole genome analysis. These were provided by the St 
Thomas‟ TwinsUK study group. SNPs were genotyped using Illumina 610k and 
Illumina 317K arrays as described elsewhere (Illig et al. 2010). 
4.5 Statistical analysis 
Standard distributional checks were made using Q-Q plots in SPSS and where the data 
did not follow a normal distribution a natural logarithmic transformation was attempted 
and the distribution checked. Statistical analysis was performed using SPSS version 
20.0 for Windows (SPSS Inc, Chicago, IL, USA). Spearman‟s correlation was used to 
assess the associations. Data reduction conducted using principal component analysis 
(PCA). Obtained components were then subjected to varimax rotation to calculate 
orthogonal solutions. 
In order to estimate intakes of EPA and DHA in the samples, data was used from a dose 
response study (MARINA study, see Chapter 5). In that study participants had been 
randomly allocated different doses of EPA+DHA and measurements of EPA and DHA 
in plasma following supplementation had been made. The data were fitted using a linear 





Linear structural equation modelling was used to estimate the genetic and 
environmental components of variance which decays variations in a given phenotype 
into additive genetic effects (A), environmental effects shared in common (C) and non-
shared environmental effects (E) using the Mx software package (Neale et al. 2002). 
The goodness-of-fit analysis was completed by calculating the difference between the 
model fitted and the fully saturated model (Mohammed et al. 2005; Teucher et al. 
2007). Adjustment allowing for differences in age and BMI were done using the linear 
regression analysis module within SPSS and save the residuals as a new variable. The 
distribution of the residual was then checked for normality and where appropriate was 
log-normalised before further analysis. Figure 4.1 illustrates the mathematical concept 
used to estimate heritability by ACE model 
All genotype distributions were tested for deviation from the Hardy-Weinberg 
equilibrium by a χ2 test with 1 df (P > 0.05). Owing to the relatively small sample size, 
SNP genotype association analyses were based on a dominant model. Data are 
presented as means or geometric means ± SD adjusted for confounding effect of age, 
BMI and ethnicity. Multivariate analysis of variance was used to examine the genotype 
associations with proportions of fatty acids and plasma lipids to allow adjustment for 
multiple testing, while univariate analysis of variance was used to test genotype 
associations with surrogate measures of indices of desaturases activities. The adjustment 




for Rapid Likelihood Inference) software which was download from the website 





Figure ‎4.1 ACE path modelling. Path model for univariate analysis of a twin study. The 
observed phenotypes of twin 1 and twin 2 (score 1 and score 2) are represented in squares. 
Latent factors are represented in circles: A, C, D, and E are the additive genetic, dominant 
genetic, and common and individual environmental influences common to Score 1 and Score 2. 
A and D are correlated by a factor of 1.0 for MZ twins and 0.5 and 0.25, respectively, for DZ 
twins; C is correlated by a factor of 1.0 for both MZ and DZ twins (the equal environment 
assumption). Regression coefficients of the observed variables on the different latent factors are 
also shown in lowercase: for example, h is the regression coefficient of the additive genetic 






4.6.1 Characteristics of the study participants 
The characteristics of the female study participants are shown in Table 4.1. The 
estimated intakes of SFA, MUFA, PUFA and TFA from the FFQ were 11.5%, 10.5%, 
7.2% and 0.9% dietary energy respectively and comparable to UK women reported 
elsewhere using the same methodology in the Oxford and Norfolk cohorts of the EPIC 
study (Davey et al. 2003; Bingham et al. 2001). Plasma total and LDL-C were 
moderately elevated and similar to values reported in nationwide surveys for women of 




Table ‎4.1 Details of the female twins participating in the study. 
  Monozygotic  (n= 230) Dizygotic  (n= 340) P-value
1
 
Age  60.2 ± 8.2 57.5 ± 9.4 <0.001 
Height (cm) 160.9 ± 6.2 161.8 ± 5.7 0.174 
Weight (kg) 68.1 ± 14.7 69.3 ± 14.2 0.232 
BMI (kg/m2) 26.3 ± 5.1 26.4 ± 5.0 0.975 
Birth weight 2.2 ± 0.5 2.4 ± 0.6 0.001 
Omega-3 supplement use 44 (19.1%)  66 (19.4%) 0.512 
Energy (MJ/d) 8.32 ± 2.62 8.09 ± 2.37 0.355 
Protein ( % energy) 17.3 ± 2.3 17.3 ± 2.4 0.994 
Carbohydrates ( % energy) 50.8 ± 5.4 50.5 ± 6.3 0.790 
Fat ( % energy) 31.8 ± 4.8 31.7 ± 5.1 0.736 
SFA ( % energy) 11.8 ± 2.6 11.4 ± 2.8 0.141 
MUFA ( % energy) 10.5 ± 1.8 10.5 ± 2.0 0.648 
PUFA  ( % energy) 7.1 ± 1.7 7.3 ± 1.8 0.107 
TFA ( % energy) 0.9 ± 0.3 0.8 ± 0.4 0.137 
TC (mmol/L) 5.61 ± 1.08 5.61 ± 1.04 0.474 
LDL-C (mmol/L) 3.21 ± 1.01 3.29 ± 0.96 0.160 
HDL-C (mmol/L) 1.86 ± 0.47 1.83 ± 0.43 0.615 
TC:HDL-C  3.20 ± 1.08 3.20 ± 0.85 0.723 
Non HDL-C (mmol/L) 3.74 ± 1.12 3.78 ± 1.04 0.365 
TAG (mmol/L)
2
 1.16 ± 0.59 1.08 ± 0.51 0.186 
Insulin (pmol/L)
2
 55 ± 44 49 ± 68 0.202 
Glucose (mmol/L)
2
 5.1 ± 0.6 4.9 ± 0.7 0.042 
HOMA2 IR 1.03 ± 0.80 0.91 ± 1.09 0.100 
Values are mean ± SD or number of subjects (% ). 
1
 Probabilities are from analysis of covariance adjusted for age, BMI, ethnicity or Chi-squared 
test for frequencies. 
2
Non fasting values from 9 participants were excluded. 
MZ: monozygotic twins; DZ: dizygotic twins; BMI: body mass index; SFA: saturated fatty 
acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; TFA: trans-
fatty acids; TC: total cholesterol; LDL-C: LDL cholesterol; HDL-C: HDL cholesterol; 
TC:HDL-C: ratio of total to HDL cholesterol; Non HDL-C: non HDL cholesterol; TAG: 
triacylglycerol; HOMA2: The Homeostasis Model Assessment calculated using a software 






4.6.2 Fatty acid composition of adipose tissue: A comparison with published 
reports 
Figure 4.2 shows a typical GLC trace of the adipose tissue. The analyses illustrated 
clear separation of cis and trans isomers of 18:1 and a significant number of minor 
components. The mean values with SD are shown in Table 4.2 and for comparison data 
from two earlier studies in UK subjects (Craig et al. 2009) which did not specify the site 
of biopsy and Bolton-Smith et al. (1997) who used upper arm biopsies. The proportion 
of palmitic acid (16:0) and other SFA (14:0, 18:0) and palmitoleic acid (16:1n-7) in the 
TwinsUK cohort were similar to that in women previously by Bolton-Smith et al. 
(1997). The proportion of LA was greater in the TwinsUK cohort than the women 
studied by Bolton-Smith but was comparable to the more recent data of Craig et al. 
(2009) probably reflecting the generally higher dietary LA (18:2n-6) intake in 2009 vs. 
1997. This finding would fit in with the observation of a slightly lower proportion of 
oleic acid in the more recent data. Palmitoleic acid (16:1n-7) was present in similar 
proportions to that reported by Craig et al. (2009) but was about one third lower than 
that reported by Bolton-Smith et al. (1997). 
A GLC trace of plasma fatty acids is shown in Figure 4.3. Good separation of the major 
fatty acids was obtained. Table 4.3 summarizes the mean values with their SD and 
comparisons with women recruited into the MARINA study measured in the same 




lower PUFA were found in the plasma of the TwinsUK compared to participants in 















Figure 4.2 A typical chromatogram of the fatty acids methyl esters from 
adipose tissue. The detector response is shown in picoamps against time in 





Table ‎4.2 Comparison of fatty acid proportions (wt%) in adipose tissue with other reports from 
the United Kingdom. 
Fatty acid 
Twins 
F (n= 570) 
Craig et al. 2009 
M (n= 9), F (n= 24) 
Bolton-Smith et al. 1997 




Mean ± SD Median IQR Mean ± SD 
10:0 0.32 ± 0.36 - - - 
12:0 0.61 ± 0.73 0.5 0.4, 0.6 - 
14:0 2.02 ± 0.88 2.8 2.3, 3.2 2.24 ±  0.76 
16:0 19.24 ± 2.06 22.2 20.6, 22.9 19.43 ± 2.4 
18:0 3.21 ± 0.95 3.7 2.6, 4.5 3.48 ± 1.20 
20:0 0.35 ± 0.16 - - - 
ΣSFA 25.76 ± 3.03 29.4 27.2, 31.4 - 
16:1n-7 5.76 ± 1.70 6.4 5.2, 7.6 9.40 ± 2.02 
18:1n-9 46.54 ± 3.05 50.4 47.3, 51.8 51.40 ± 2.92 
18:1n-7 0.78 ± 0.93 - - - 
ΣMUFA 53.08 ± 3.44 56.7 54.2, 59.3 - 
18:1 trans  0.46 ± 0.33 - - - 
ΣTFA 0.46 ± 0.33 - - - 
18:2n-6 12.03 ± 2.42 11.9 10.8, 13.0 9.35 ± 2.50 
18:3n-6 - 0.02 0.01, 0.03 0.18 ± 0.09 
20:3n-6 0.32 ± 0.18 0.17 0.10, 0.21 0.15 ± 0.06 
20:4n-6 0.56 ± 0.19 0.30 0.23, 0.39 0.61 ± 0.15 
22:4n-6 0.25 ± 0.17 - - - 
Σn-6 13.16 ± 2.49 12.4 11.2, 13.6 - 
18:3n-3 0.84 ± 0.24 1.1 1.0, 1.3 - 
20:5n-3 0.21 ± 0.16 0.02 0.02, 0.07 - 
22:5n-3 0.38 ± 0.18 - - - 
22:6n-3 0.36 ± 0.22 0.09 0.05, 0.20 0.48 ± 0.164* 
Σn-3 1.79 ± 0.53 1.4 1.1, 1.7 - 
ΣPUFA 14.95 ± 2.71 13.9 12.9, 14.8 - 
n-6:n-3 7.75 ± 2.32 0.10 





Table ‎4.3 Comparison of total plasma fatty acids in the female twins compared with female 
participants recruited into the MARINA study (see Chapter 5). 
Fatty acid 
Twins MARINA 
(n= 208) (n= 210) 
10:0 - - 
12:0 - - 
14:0 0.82 ± 0.24 0.75±0.25 
16:0 20.94 ± 1.35 20.06±1.29 
18:0 7.08 ± 0.58 6.53±0.53 
20:0 0.22 ± 0.05 0.24±0.06 
ΣSFA 29.07 ± 1.62 27.58±1.36 
16:1n-7 2.50 ± 0.73 2.31±0.92 
18:1n-9 19.49 ± 2.05 20.43±2.46 
18:1n-7 1.54 ± 0.23 1.61±0.26 
ΣMUFA 23.53 ± 2.54 24.34±3.20 
18:1 trans  0.13 ± 0.06 0.07±0.06 
ΣTFA 0.13 ± 0.06 0.07±0.06 
18:2n-6 26.76 ± 3.65 27.75±4.00 
18:3n-6 0.46 ± 0.16 0.46±0.17 
20:3n-6 1.60 ± 0.37 1.60±0.35 
20:4n-6 6.37 ± 1.32 6.91±1.55 
22:4n-6 0.53 ± 0.15 0.58±0.15 
22:5n-6 1.06 ± 0.22 1.04±0.31 
Σn-6 36.78 ± 3.54 38.34±3.95 
18:3n-3 0.62 ± 0.16 0.65±0.20 
20:5n-3 1.49 ± 0.83 1.17±0.65 
22:5n-3 0.61 ± 0.12 0.64±0.13 
22:6n-3  2.48 ± 0.87 2.53±0.69 
Σn-3 5.21 ± 1.69 4.99±1.34 
ΣPUFA 42.00 ± 3.64 43.32±3.96 
n-6:n-3 7.77 ± 2.50 8.20±2.28 
Mean values ± SD in wt %. 





































































































































































































































































Figure 4.3 Typical chromatogram of fatty acid methyl esters from total plasma lipids The detector 





4.6.3 Estimation of EPA and DHA intake 
Using known data on EPA and DHA intake and proportions in their plasma from the 
female participants from the MARINA study (see Chapter 5), intakes of EPA and DHA 
were estimated in the female twins. The proportion of EPA and DHA were plotted 
against their levels in diet using a linear regression curve fitting equation in PRISM 
GraphPad version 5.04 (GraphPad.Com; California). Values of the proportions of fatty 















































































Estimated intakes of EPA and DHA are shown in Figure 4.4 and Figure 4.5 
respectively. The mean ± SD intakes of EPA and DHA in female twin participants were 
176 ± 28 mg/d and 131 ± 23 mg/d respectively. Thus, total intake of EPA + DHA in this 
cohort of female twin was estimated to be 307 ± 48 mg/d. Stratification by zygosity did 
not show any significant difference between the two groups.  A comparison of the levels 
in participants who reported taking dietary supplements was made (Table 4.4). The 
estimated intake of DHA was greater (P<0.05) in those reporting taking supplement 
than in those who did not. The difference in estimated intakes of EPA did not differ. 
Cod-liver oil is the most widely used omega-3 supplement and this contains more DHA 
than EPA. A typical one a day cod-liver oil capsule contains about 0.2-0.3 g of 
EPA+DHA. Furthermore, EPA levels are more readily influenced by the intake of ALA 












Table ‎4.4 Estimates of intake of EPA and DHA based on plasma concentrations. 
   Omega-3 supplement use 
Non-users (n= 171) Supplement users (n= 37) 
Mean SD Mean SD 
20:5n-3 163 239 235 401 
22:6n-3 116 205 201 334* 







4.6.4 Fatty acid proportions in adipose tissue and plasma 
The fatty acid composition of the adipose tissue of the study participants stratified by 
zygosity is summarized in Table 4.5. There were no significant differences between 
MZ and DZ twins in fatty acid proportions. Oleic acid (18:1n-9) was the dominant fatty 
acid accounting for 46.5% of the total, palmitic acid (16:0) accounted for 19.2% of the 
fatty acids and only small amounts (3.2%) of stearic acid (18:0) were present. Only 
traces of trans isomeric fatty acids (mainly 18:1 trans isomers) were found in the 
samples. Palmitoleic acid (16:1n-7) presumably derived by desaturation of palmitic acid 
in adipose tissue accounted for 5.7% of the total fatty acids. Linoleic acid (18:2n-6, LA) 
and α-linolenic acid (18:3n-3, ALA) accounted for 12.1% and 0.85% of the fatty acids 
respectively. Small amounts of their more unsaturated derivatives notably 
gammalinolenic acid (18:3n-6; GLA, 0.46%), dihomogammalinolenic (20:3n-6, DGLA; 
0.28%), arachidonic (20:4n-6; AA; 0.56%), adrenic (22:4n-6; 0.22%) acids in the n-6 
series and  eicosapentaenoic (20:5n-3; EPA;0.18%), docosapentaenoic (22:5n-3, DPA ; 
0.35%) and docosahexaenoic (22:6n-3, DHA; 0.31%) acids in the n-3 series were 
present. 
 The present data set indicates minimal amounts of trans fatty acids and provides 
detailed information on the proportion of LC n-6 and n-3 PUFA in adipose tissue. 
Table 4.6 shows the fatty acid proportions of the plasma. There were no significant 
differences between MZ and DZ. PUFA account for about 42% of the total fatty acids 




26.75% of all fatty acids followed by AA and DHA, 6.36% and 2.49% respectively. The 
rest of the PUFA ranged from 1.60% for DGLA, 1.06% for osbond acid (22:5n-6), 
1.32% for EPA, 0.62% for ALA, 0.61% for DPA, 0.51% for adrenic acid and 0.46% for 
GLA. This was followed by SFA, which constituted 29.02% and palmitic acid was the 
most abundant fatty acid with 20.93% of all SFA. Followed by stearic (7.08%), myristic 
(0.82%) and trace amounts of arachidic (0.22%) acids. MUFA accounted for 23.43% 
with highest proportions of oleic acid (19.50%) proceeded by palmitoleic (2.50%) and 
vaccinic (1.54%) acids. Only trace amounts of TFA were detected and these were 
mainly 18:1 isomers (0.13%). Other minor components included branched chain fatty 




Table ‎4.5 Fatty acid composition of adipose tissue of female twins 







SFA 25.75 ± 3.02 25.82 ± 3.02 25.71 ± 3.03 
10:0
§
 0.19 ± 0.36 0.21 ± 0.30 0.17 ± 0.40 
12:0
§
 0.41 ± 0.73 0.42 ± 0.75 0.40 ± 0.73 
14:0 2.03 ± 0.87 2.02 ± 0.89 2.03 ± 0.85 
16:0 19.24 ± 2.06 19.26 ± 2.02 19.23 ± 2.09 
18:0 3.21 ± 0.95 3.21 ± 1.00 3.22 ± 0.91 
20:0 0.36 ± 0.16 0.36 ± 0.15 0.35 ± 0.16 
MUFA 53.09 ± 3.44 52.99 ± 3.52 53.16 ± 3.39 
16:1n-7
§
 5.79 ± 1.66 5.71 ± 1.73 5.84 ± 1.62 
18:1n-9 46.54 ± 3.05 46.47 ± 2.97 46.60 ± 3.10 
18:1n-7 0.43 ± 0.94 0.43 ± 0.97 0.43 ± 0.92 
TFA 
   18:1 trans isomers
§
 0.45 ± 0.30 0.45 ± 0.33 0.45 ± 0.27 
PUFA  14.95 ± 2.71 14.75 ± 2.76 15.08 ± 2.67 
18:2n-6 12.05 ± 2.37 11.92 ± 2.31 12.14 ± 2.40 
20:3n-6
§
 0.28 ± 0.18 0.29 ± 0.17 0.28 ± 0.18 
20:4n-6 0.32 ± 0.18 0.56 ± 0.18 0.57 ± 0.19 
22:4n-6
§
 0.22 ± 0.17 0.21 ± 0.18 0.22 ± 0.17 
18:3n-3 0.85 ± 0.23 0.83 ± 0.21 0.86 ± 0.23 
20:5n-3
§
 0.18 ± 0.15 0.17 ± 0.16 0.18 ± 0.15 
22:5n-3
§
 0.35 ± 0.18 0.35 ± 0.18 0.35 ± 0.18 
22:6n-3
§







  Values are mean ± SD or GM ± SD (for logged variables) wt % total fatty acids. 
Values were log-transformed for 10:0, 12:0, 18:1trans, 18:1n-7, 20:3n-6, 22:4n-6, 20:5n-3, 
22:5n-3, 22:6n-3. 
§ 
Indicates data were transformed using natural logarithms. 
No significant difference between monozygotic and dizygotic twins from analysis of 
variance adjusted for age, gender, BMI and ethnicity. 
SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated 






Table ‎4.6 Fatty acid composition of plasma of female twins. 









  29.02 ± 2.58 28.76 ± 3.55 29.00 ± 1.57 
14:0 0.82 ± 0.24 0.80 ± 0.23 0.84 ± 0.24 
16:0 20.93 ± 1.35 20.93 ± 1.38 20.94 ± 1.34 
18:0 7.08 ± 0.58 7.14 ± 0.57 7.04 ± 0.59 
20:0
§
 0.22 ± 0.05 0.23 ± 0.04 0.22 ± 0.06 
MUFA 23.43 ± 3.01 23.23 ± 3.60 23.57 ± 2.52 
16:1n-7 2.50 ± 0.73 2.40 ± 0.68 2.57 ± 0.76 
18:1n-9 19.50 ± 2.05 19.55 ± 2.11 19.46 ± 2.02 
18:1n-7 1.54 ± 0.23 1.55 ± 0.24 1.54 ± 0.23 
TFA 
   18:1 trans isomers 0.13 ± 0.06 0.13 ± 0.07 0.13 ± 0.06 
PUFA  41.79 ± 4.66 41.54 ± 5.86 41.96 ± 3.58 
18:2n-6 26.75 ± 3.66 26.88 ± 3.47 26.66 ± 3.80 
18:3n-6 0.46 ± 0.16 0.44 ± 0.15 0.48 ± 0.16 
20:3n-6 1.60 ± 0.37 1.59 ± 0.40 1.61 ± 0.35 
20:4n-6 6.36 ± 1.32 6.32 ± 1.27 6.39 ± 1.36 
22:4n-6
§
 0.51 ± 0.15 0.49 ± 0.11 0.53 ± 0.17 
22:5n-6 1.06 ± 0.22 1.09 ± 0.24 1.04 ± 0.20 
18:3n-3 0.62 ± 0.16 0.63 ± 0.18 0.62 ± 0.14 
20:5n-3
§
 1.32 ± 0.83 1.30 ± 0.86 1.33 ± 0.81 
22:5n-3 0.61 ± 0.12 0.60 ± 0.11 0.62 ± 0.12 




 n= 86, 
3
 n= 122 
  Mean ± SD or GM ± SD (for logged variables)in wt % total fatty acids. 
Values for 20:0, 18:1trans, 22:4n-6, 20:5n-3, SFA were log transformed prior to analysis. 
§ 
Indicates data were transformed using natural logarithms. 
No significant difference between monozygotic and dizygotic twins from analysis of variance 
adjusted for age, gender, BMI and ethnicity. 
SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated 





4.6.5 Correlations between fatty acids proportions in adipose tissue and plasma 
and those in diet 
Table 4.7 shows the correlations between dietary intake and proportions of different 
fatty acid classes in adipose tissue. No relationships were seen with SFA and MUFA 
intakes expressed as percentage of the dietary energy intake but significant positive 
relationships were seen with TFA (ρ= 0.174, P= 1.85x10-4) and PUFA (ρ= 0.287, P= 
1.67x10
-11
) and an even stronger relationship was seen for the ratio of PUFA to SFA 
(P:S ratio; ρ= 0.331, P= 5.5x10-15) in diet with that of the proportions in adipose tissue. 
No association could be found between estimates of dietary SFA intake or the level in 
adipose tissue with serum cholesterol or LDL-C. 
Correlations between proportions of plasma fatty acids and those of dietary intake are 
summarized in Table 4.8. Highest associations were found for PUFA (ρ= 0.162, P= 
0.023) and TFA (ρ= 0.165, P= 0.020), while no association could be found with SFA 
and MUFA intakes. However, a more significant relationship was seen for the P:S ratio 
(ρ= 0.195, P= 0.006). 
Spearman‟s correlations between plasma fatty acid proportions and those from adipose 
tissue are illustrated in Table 4.9. Significant relationships were seen for total SFA (ρ= 
0.145, P= 0.037), MUFA (ρ= 0.378, P= 2.89x10-5) and PUFA (ρ= 0.318, P= 2.66x10-6). 
No association was found for myristic and stearic acids, but a strong association was 
found for palmitic acid (ρ= 0.338, P= 5.91x10-7). Palmitoleic (ρ= 0.641, P= 2.26x10-25) 




and adipose tissue. All PUFA showed a strong significant correlation between plasma 




Table ‎4.7 Correlations between the proportions of different classes of fatty acid in adipose 
tissue of female twins compared with estimates from dietary intake (n= 570). 
  Adipose tissue wt %  Diet % energy ρ1 P 
SFA 25.75±3.02 11.55±2.74 0.084 0.053 
MUFA 53.09±3.44 10.50±1.93 -0.006 0.86 
PUFA 14.95±2.71 7.21±1.74 0.287 1.67x10
-11
 
P:S 0.59 ± 0.15 0.66 ± 0.26 0.331 5.5x10
-15
 
TFA 0.53±0.30 0.86±0.38 0.174 1.85x10
-4
 
Mean values  ± SD for 570 twins. 
   SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty 
acids; TFA: trans-fatty acids. 
1
Spearman's correlation coefficient. 





Table ‎4.8 Correlations between proportions of different classes of fatty acid in plasma of female 
twins compared with estimates from dietary intake (n= 570). 
  Plasma  wt %  Diet % energy ρ1 P 
SFA 29.02 ± 2.58 11.55 ± 2.74 0.107 0.131 
MUFA 23.43 ± 3.01 10.50 ± 1.93 0.121 0.088 
PUFA 41.79 ± 4.66 7.21 ± 1.74 0.162 0.023 
P:S 1.45 ± 0.19 0.66 ± 0.26 0.195 0.006 
TFA 0.13 ± 0.06 0.86 ± 0.38 0.165 0.020 
Mean values  ± SD for 570 twins. 
   SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty 
acids; P:S: ratio of PUFA to SFA TFA: trans-fatty acids. 
1
Spearman's correlation coefficient. 






Table ‎4.9 Correlations between proportions of different classes of fatty acid in plasma of female 
twins compared with those of adipose tissue. 
Fatty Acid               ρ                P 
SFA 0.145 0.037 














18:1n-7 0.027 0.718 
TFA 














20:4n-6 0.209 0.003 














n-6:n-3 ratio 0.362 8.00x10
-8
 
P:S ratio 0.263 1.23x10
-4
 





4.6.6 Principal component analysis 
Data reduction was attempted using principal component analysis on the adipose tissue 
fatty acids. Table 4.10 shows the components from the analysis and the scree plot 
(Figure 4.6) generated. Component 1 (high P:S ratio), which explained 22% of the 
variance, appeared to be determined by higher proportions of LCPUFA and lower 
proportions of SFA. This is likely to indicate a higher conversion of LA and ALA to 
LCPUFA or a significant intake of the preformed LC-PUFA. Component 2, which 
explained 12.28% of the variance, showed a strong correlation with MUFA and AA and 
negative correlation with SFA and may indicate higher intake of MUFA and active 
desaturation to AA as its precursor essential fatty acid (EFA) is weakly correlated.  
Component 3 was found to explain 11.02% of the variance and correlates well with 
myristic, palmitic and TFA and negatively correlated with capric and lauric acids. 
Component 4 explained 10.8% of the variance and was associated with higher 
proportions of palmitic, arachidic and palmitoleic acids, but negatively with EFA, LA 
and ALA which might suggest that intakes of these fatty acids are very low in addition 
to their long chain metabolites. The generated components showed no significant 






Figure ‎4.6 Scree plot of the generated components from the application of PCA on the 18 





Table ‎4.10 Association between proportions of 18 adipose tissue fatty acids and 4 identified 
components. 
  Component 
 
1 2 3 4 
 




high SFA, high 
TFA,  low PUFA 
High SFA, 
low PUFA   
Variance explained 
(%) 22.8 12.28 11.02 10.8 
Eigen value  4.1 2.21 1.98 1.94 
10:0 0.016 0.050 -0.213 0.113 
12:0 -0.242 -0.266 -0.785 0.084 
14:0 0.037 -0.137 0.896 0.124 
16:0 -0.138 -0.558 0.212 0.445 
18:0 -0.046 -0.891 -0.002 0.075 
20:0 0.195 -0.072 -0.022 0.244 
16:1n-7 -0.072 0.739 0.087 0.358 
18:1n-7 -0.116 0.215 -0.147 0.030 
18:1n-9 -0.065 0.342 0.068 -0.045 
18:1trans -0.006 0.103 0.467 0.054 
18:2n-6 0.098 -0.063 -0.100 -0.862 
20:3n-6 0.684 0.154 -0.082 0.137 
20:4n-6 0.430 0.611 0.062 0.069 
22:4n-6 0.802 0.090 -0.047 0.075 
18:3n-3 -0.270 -0.067 0.042 -0.777 
20:5n-3 0.861 -0.040 0.040 0.067 
22:5n-3 0.860 0.123 0.169 -0.018 
22:6n-3 0.816 -0.070 0.170 -0.134 





Table ‎4.11 Comparison of the generated components from adipose tissue fatty acids between 
MZ and DZ twins. 
Component  MZ DZ P-value 
1 -0.01(-0.15,0.13) 0.01(-0.11,0.13) 0.83 
2 -0.03(-0.16,0.10) 0.03(-0.09,0.14) 0.50 
3 -0.03(-0.17,0.11) 0.02(-0.10,0.14) 0.60 
4 0.07(-0.07,0.21) -0.05(-0.17,0.07) 0.23 
5 -0.02(-0.16,0.12) 0.01(-0.11,0.13) 0.75 
6 -0.06(-0.20,0.09) 0.04(-0.08,0.16) 0.31 
Univariate analysis of variance was used to perform the 
comparison. 
1
P-value adjusted for age, BMI and ethnicity. 
 
 
Table 4.12 summarises the generated components from the PCA analysis of plasma 
fatty acids and scree plot (Figure 4.7). Analysis revealed 6 components. Component 1 
appeared to reflect a high MUFA+SFA with low LA. Component 2 appeared to reflect 
the intake of n-3 LCPUFA. Component 4 appeared to reflect a higher proportion of 
trans fatty acids. Component 5 might reflect a low P:S ratio and component 6 higher 




Table ‎4.12 Association between proportions of 18 plasma fatty acids and the 6 identified 
components. 
  Components 
 




















desaturation   
Variance (%) 22.48 15.67 11.99 9.40 7.88 6.64 
Eigen value    4.05 2.82 2.16 1.69 1.42 1.20 
14:0 0.674 -0.049 -0.149 -0.409 0.344 0.120 
16:0 0.694 -0.080 -0.253 -0.075 0.126 -0.041 
18:0 0.089 -0.030 0.302 0.272 0.683 -0.088 
20:0 -0.044 -0.067 0.940 0.053 0.075 -0.032 
16:1n-7 0.836 0.023 -0.036 -0.005 -0.229 0.255 
18:1n-9 0.663 -0.289 -0.035 0.013 -0.187 -0.142 
18:1n-7 0.347 0.026 -0.009 0.320 -0.755 -0.068 
18:1trans 0.334 -0.341 -0.037 0.110 0.175 -0.589 
18:2n-6 -0.885 -0.240 0.029 -0.292 0.022 -0.076 
18:3n-6 0.385 -0.089 -0.005 0.215 0.372 0.604 
20:3n-6 0.193 -0.410 0.038 0.030 -0.027 0.753 
20:4n-6 -0.059 0.160 -0.031 0.842 0.065 0.258 
22:4n-6 -0.182 -0.029 0.855 -0.027 0.199 0.122 
22:5n-6 -0.374 0.269 0.536 0.187 -0.386 -0.104 
18:3n-3 -0.043 0.075 -0.075 -0.649 0.041 0.109 
20:5n-3 -0.029 0.917 0.048 -0.077 0.014 -0.150 
22:5n-3 0.074 0.828 0.027 0.098 0.049 0.104 
22:6n-3 -0.126 0.873 -0.113 0.041 -0.183 -0.113 






Figure ‎4.7 Scree plot of the generated components from the application of PCA on the 18 










4.6.7 Results from heritability analysis 
The results of genetic modelling analysis for adipose tissue fatty acids are shown in 
Table 4.13. Heritability is estimated based on Falconer‟a formula h2=2 (r MZ - r DZ), 
where r is the correlation coefficient, with adjustment for covariates using structured 
equation modelling. Model fitting revealed that additive genetic effects (A) could be 
dropped from the model without significantly deteriorating the Chi-squared goodness-
of-fit statistics for all fatty acids except for stearic acid (18:0; 60%) and arachidonic acid 
(AA; 65%).  Most of the variance between subjects in proportions of stearic acid and 
AA was largely governed by genetic factors. Proportions of the remaining fatty acids 
appeared to be governed by either contribution from shared (C) or unique (E) 
environmental factors. Common or shared environmental factors were the main 
determinant of proportions of lauric, myristic, palmitic and vaccinic acids. Proportions 
of capric, arachidic, palmitoleic, oleic, TFA, all the n-6 and n-3 fatty acids, with the 





Table ‎4.13 Genetic modelling analysis for adipose tissue fatty acid composition showing estimates with 95% CI of the proportions of variation within subjects from genetics, 
common environment and unique environment 
  Correlation r (95% CI) 
 












10:0 0.23(0.04,0.40) 0.53(0.40,0.63) 
 
0.00(0.00,0.13) 0.41(0.28,0.51)* 0.59(0.49,0.70) 
12:0 0.64(0.51,0.74) 0.67(0.56,0.75) 
 
0.00(0.00,0.18) 0.66(0.50,0.72)* 0.34(0.27,0.42) 
14:0 0.65(0.52,0.75) 0.72(0.63,0.79) 
 
0.00(0.00,0.12) 0.69(0.58,0.75)* 0.31(0.25,0.38) 
16:0 0.62(0.49,0.72) 0.54(0.39,0.65) 
 
0.20(0.00,0.51) 0.44(0.16,0.64)* 0.36(0.27,0.49) 
18:0 0.71(0.59,0.79) 0.34(0.18,0.48) 
 
0.60(0.27,0.75)* 0.07(0.00,0.35) 0.33(0.25,0.44) 
20:0 0.38(0.21,0.53) 0.48(0.33,0.60) 
 
0.00(0.00,0.29) 0.44(0.20,0.54)* 0.56(0.45,0.67) 
16:1n-7 0.35(0.17,0.51) 0.32(0.17,0.46) 
 
0.00(0.00,0.42) 0.33(0.00,0.44) 0.67(0.52,0.78) 
18:1n-7 0.79(0.70,0.85) 0.73(0.64,0.80) 
 
0.08(0.00,0.27) 0.70(0.53,0.80)* 0.22(0.16,0.30) 
18:1n-9 0.41(0.25,0.56) 0.42(0.28,0.54) 
 
0.03(0.00,0.41) 0.39(0.09,0.51)* 0.58(0.44,0.69) 
TFA 0.59(0.44,0.71) 0.38(0.22,0.52) 
 
0.32(0.00,0.65) 0.24(0.00,0.53) 0.44(0.33,0.58) 
18:2n-6 0.51(0.35,0.64) 0.46(0.29,0.59) 
 
0.17(0.00,0.55) 0.37(0.03,0.58)* 0.47(0.35,0.61) 
20:3n-6 0.52(0.36,0.64) 0.46(0.31,0.58) 
 
0.18(0.00,0.54) 0.36(0.05,0.56)* 0.47(0.35,0.61) 
20:4n-6 0.64(0.52,0.74) 0.26(0.09,0.40) 
 
0.65(0.43,0.74)* 0.00(0.00,0.17) 0.35(0.26,0.47) 
22:4n-6 0.52(0.37,0.64) 0.44(0.28,0.57) 
 
0.20(0.00,0.57) 0.33(0.01,0.55)* 0.47(0.36,0.61) 
18:3n-3 0.39(0.22,0.54) 0.29(0.11,0.45) 
 
0.30(0.00,0.56) 0.11(0.00,0.41) 0.58(0.44,0.76) 
20:5n-3 0.39(0.22,0.54) 0.47(0.31,0.60) 
 
0.00(0.00,0.26) 0.43(0.20,0.53)* 0.57(0.46,0.68) 
22:5n-3 0.54(0.39,0.66) 0.51(0.38,0.62) 
 
0.15(0.00,0.48) 0.41(0.14,0.60)* 0.43(0.33,0.56) 
22:6n-3 0.37(0.20,0.52) 0.50(0.36,0.61)   0.00(0.00,0.20) 0.44(0.25,0.53)* 0.56(0.47,0.67) 
1
Correlation (95% CI) between subjects in monozygotic twin pairs  n= 230 and dizygotic twin pairs n= 340. 
 
2
A is Additive genetic, C is common environment, E is unique environment. 
  Data were analysed using co-twin model adjusted for age and BMI.  
  *indicate significance (P<0.05). 




The intake of SFA is believed to have a significant influence on non-HDL cholesterol (NHDL-
C). In order to investigate whether levels of SFA in adipose tissue or the ratio of PUFA:SFA 
(P/S) in adipose tissue were related to NHDL-C concentration, the following analyses were 
conducted. ACE modelling was performed with and without adjustment for age, BMI, SFA in 
adipose tissue and P/S ratio in adipose tissue (Tables 4.14). This analysis suggested a strong 
additive genetic effect on NHDL-C explaining about 45% of the variance. This estimate did not 
change substantially with adjustment for age, BMI or levels of fatty acids. A regression analysis 
of NHDL-C with age, BMI, and proportions of SFA and P/S ratio indicated that most of the 






Figure ‎4.8  Major non-genetic determinants of non-HDL cholesterol in the female twin 
participants determined by the automated regression analysis module of SPSS. 
 
 
Table 4.15 summarises genetic modelling analysis for the 6 generated components from 
adipose tissue fatty acid showing estimates with 95% CI of the proportions of variation 
within subjects from additive genetics, common environment and unique environmental 
factors. This indicated a possibly genetic influence for component 2, which was 




Table ‎4.14 Genetic modelling analysis for NHDL-C showing estimates with 95% CI of the proportions of variation within subjects from genetics, common 
environment and unique environment. 




 Genetic  Common environment  Unique environment 
Non-HDL-C           
Adjusted for age & BMI 0.47(0.31,0.61) 0.17(-0.01,0.34) 0.44(0.06,0.56)* 0.00(0.00,0.30) 0.56(0.44,0.71) 
Adjusted  for age, BMI & adipose SFA 0.48(0.32,0.61) 0.19(0.01,0.35) 0.45(0.06,0.57)* 0.00(0.00,0.31) 0.55(0.43,0.70) 
Adjusted for age, BMI & adipose P:S 0.48(0.32,0.61) 0.19(0.01,0.35) 0.45(0.06,0.57)* 0.00(0.00,0.31) 0.55(0.43,0.70) 
1
Correlation (r) with 95% CI in parenthesis in monozygotic twins  n= 230 and dizygotic twins n= 340. 
 Data were analysed using co-twin model adjusted for age and BMI.  




Table ‎4.15 Genetic modelling analysis for the 6 generated components from adipose tissue fatty acid showing estimates with 95% CI of the proportions of 





 Genetic  Common environment  Unique environment 
Component-1 0.35(0.15,0.51) 0.58(0.41,0.70) 0.00(0.00,0.18) 0.45(0.26,0.56) 0.55(0.44,0.68) 
Component-2 0.73(0.61,0.81) 0.45(0.28,0.59) 0.36(0.04,0.73)* 0.32(0.00,0.59) 0.32(0.24,0.43) 
Component-3 0.63(0.47,0.74) 0.74(0.64,0.81) 0.00(0.00,0.10) 0.69(0.58,0.75) 0.31(0.25,0.40) 
Component-4 0.52(0.34,0.65) 0.44(0.25,0.59) 0.25(0.00,0.64) 0.30(0.00,0.56) 0.45(0.33,0.62) 
Component-5 0.73(0.62,0.81) 0.62(0.50,0.72) 0.20(0.00,0.48) 0.52(0.28,0.72) 0.27(0.20,0.38) 
Component-6 0.51(0.32,0.66) 0.56(0.42,0.67) 0.00(0.00,0.20) 0.53(0.34,0.62) 0.47(0.38,0.58) 
1
Correlation (r) with 95% CI in parenthesis in monozygotic twins  n= 230 and dizygotic twins n= 340. 
Data were analysed using co-twin model adjusted for age and BMI.  




The results of genetic modelling analysis for plasma fatty acids are shown in Table 
4.16. Model fitting revealed that additive genetic effects (A) could not be dropped from 
the model without significantly deteriorating the Chi-squared goodness-of-fit statistics 
for all fatty acids except for myristic acid, oleic acid, TFA and DPA. The remaining 
fatty acids were shown to be manipulated by additive genetic factors (A), which 
represent the combined effects of alleles at different loci that influence the trait (Bartels 
et al. 2013). 
Among SFA, the highest genetic effects appeared to influence proportions of arachidic 
acid (60%) and a non-significant effect on proportions of palmitic (43%) and stearic 
(40%) acids. A non-significant genetic effect was also found for palmitoleic (59%) and 
vaccinic (55%) acids, while variance in proportions of oleic acid (22%) was influenced 
by minor genetic factors. A finding consistent with our knowledge that oleic acid is 
derived from both dietary fat and de novo lipogenesis. All n-6 PUFA were found to be 
governed by a significant genetic effect (adrenic acid (66%); LA (63%); AA (61%); 
DGLA (54%); GLA (52%)). Proportion of DHA (65%) and EPA (55%) were the only 
n-3 PUFA that emerged with significant genetic effect. ALA was influenced by 48% 
genetic effects, but not significant. In contrast, genetic effects explained 21% of the 




Table ‎4.16 Genetic modelling analysis for plasma fatty acid composition showing estimates with 95% CI of the proportions of variation within subjects from genetics, 
common environment and unique environment (n= 208). 
  Correlation r (95% C) 
 












14:0 0.40(0.06,0.65) 0.30(0.05,0.51) 
 
0.27(0.00,0.65) 0.16(0.00,0.50) 0.57(0.35,0.85)* 
16:0 0.66(0.43,0.80) 0.44(0.19,0.63) 
 
0.43(0.00,0.78) 0.22(0.00,0.61) 0.34(0.21,0.56)* 
18:0 0.50(0.22,0.70) 0.37(0.11,0.57) 
 
0.40(0.00,0.72) 0.15(0.00,0.54) 0.45(0.28,0.73)* 
20:0 0.62(0.38,0.78) 0.26(-0.05,0.51) 
 
0.60(0.13,0.75)* 0.00(0.00,0.35) 0.40(0.25,0.63)* 
16:1n-7 0.51(0.22,0.71) 0.30(0.04,0.52) 
 
0.59(0.00,0.75) 0.00(0.00,0.43) 0.41(0.25,0.70)* 
18:1n-7 0.58(0.31,0.75) 0.26(0.01,0.49) 
 
0.55(0.00,0.71) 0.00(0.00,0.47) 0.45(0.29,0.70)* 
18:1n-9 0.60(0.34,0.77) 0.43(0.17,0.63) 
 
0.22(0.00,0.70) 0.33(0.00,0.63) 0.45(0.29,0.67)* 
TFA 0.47(0.10,0.71) 0.45(0.18,0.65) 
 
0.16(0.00,0.71) 0.36(0.00,0.63) 0.48(0.28,0.73)* 
18:2n-6 0.65(0.43,0.80) 0.41(0.14,0.62) 
 
0.63(0.11,0.82)* 0.08(0.00,0.49) 0.29(0.18,0.49)* 
18:3n-6 0.56(0.30,0.74) -0.01(-0.33,0.32) 
 
0.52(0.10,0.72)* 0.00(0.00,0.27) 0.48(0.29,0.78)* 
20:3n-6 0.63(0.39,0.78) -0.09(-0.42,0.26) 
 
0.54(0.17,0.71)* 0.00(0.00,0.28) 0.46(0.29,0.70)* 
20:4n-6 0.59(0.34,0.76) 0.28(-0.02,0.52) 
 
0.61(0.08,0.76)* 0.00(0.00,0.40) 0.39(0.24,0.63)* 
22:4n-6 0.75(0.58,0.85) 0.22(-0.06,0.46) 
 
0.66(0.28,0.78)* 0.00(0.00,0.32) 0.34(0.22,0.51)* 
18:3n-3 0.55(0.22,0.75) 0.15(-0.13,0.40) 
 
0.48(0.00,0.67) 0.00(0.00,0.47) 0.52(0.33,0.81)* 
20:5n-3 0.57(0.32,0.74) 0.20(-0.09,0.46) 
 
0.55(0.03,0.71)* 0.00(0.00,0.39) 0.45(0.29,0.69)* 
22:5n-3 0.54(0.27,0.73) 0.45(0.17,0.65) 
 
0.21(0.00,0.70) 0.33(0.00,0.62) 0.46(0.29,0.70)* 
22:6n-3 0.75(0.56,0.86) 0.47(0.16,0.67) 
 
0.65(0.19,0.86)* 0.13(0.00,0.52) 0.22(0.14,0.38)* 
1
Correlation (95% CI) between subjects in monozygotic twin pairs n= 86 and dizygotic twin pairs n= 122. 
 2A is Additive genetic, C is common environment, E is unique environment. 
  Data were analysed using co-twin model adjusted for age and BMI  
  *indicate significance (P<0.05). 




4.7 Effect of single nucleotide polymorphism in the FADS1 and SCD-1 
genes on desaturase activities and proportions of LC-PUFA, SFA and 
MUFA 
In order to further investigate the genetic influences on proportions of MUFA and LC-
PUFA in adipose tissue and plasma, the rate limiting enzymes in their synthesis, 
particularly the desaturases, were investigated.  
4.7.1 Selection of SNPs 
rs174537 (G/T), which is located 14 kb upstream of the FADS1 gene, is linked with the 
strongest GWA signal and explains for up to 19% of the differences in plasma 
arachidonic acid (AA, 20:4n-6) (Tanaka et al. 2009). Whereas, rs7849 (C/T) in SCD-1 
was found to have a strong association with insulin sensitivity and waist circumference 
(Warensjö et al. 2007) 
4.7.2 Statistical analysis 
4.7.2.1 SNP allele and genotype frequencies 
Two SNPs rs174537 upstream of the FADS1 and rs7849 in the SCD-1 gene were 
genotyped. Table 4.17 summarises the minor allele and genotype frequencies in all 
female subjects participanting in the study. Genotype distributions did not deviate from 




with those listed for Europeans on the NCBI SNP database 
(http://www.ncbi.nlm.nih.gov/projects/SNP/, accessed August 2010). 
 
 
Table ‎4.17 FADS1 and SCD-1 SNP alleles and genotype frequencies. 












FADS1       
rs174537 MAF 0.34 
  GG 222 (43) 
  GT 238 (46) 
  TT 59 (11) 
  All 519 (100) 0.689 
   
 SCD-1   
 rs7849 MAF 0.18 
  TT 334 (66) 
  CT 156 (31) 
 
 
CC 14 (3) 
  All 504 (100) 0.404 
MAF, minor allele frequency. 
 1Number of subjects for each genotype (% total). 
2





4.7.2.2 FADS1 SNP genotype associations with plasma and adipose tissue 
variables  
Table 4.18 shows total LC-PUFA composition and activities of D5D and D6D 
estimated in adipose tissue stratified by rs174537 genotypes. There were significant 
associations between SNP genotype and proportions of adipose tissue fatty acids based 
on a dominant model after adjustment for age and BMI and within pair effects. For 
related individuals, conventional statistical analyses lead to inflated significance. 
Dependency of the observations within pairs was accounted for by the use of the 
Generalized Estimating Equations (GEE) procedure (Trégouët et al. 1997) in which 
both MZ and DZ twins can be used in tests of association. The approach accounts for 
dependency of the observations within pairs and yields unbiased standard errors and P-
values.  
Carriers of the minor allele had significantly lower proportions of AA (FADS1 product). 
Proportions of LA were lower, but not significantly, while those of DGLA were higher 
in the carriers of the minor allele. In the n-3 family, significantly lower levels of DPA 
were found in the carriers of the minor allele and non-significantly lower levels of EPA 
and DHA were noted in the adipose tissue of the carriers of the minor allele, while 
proportions of ALA were similar in the two groups. This was illustrated by a 
significantly lower estimated activity of D5D in the carriers of the minor allele 




Table ‎4.18 Proportions of fatty acids, estimated desaturase activities in adipose tissue stratified 
by FADS SNP genotypes (n= 519). 






    n = 222 n = 297   
Fatty acid % total 
 
   18:2n-6 
 
12.12 (11.81,12.43) 12.06 (11.79,12.33) 0.937
20:3n-6 
 
0.27 (0.26,0.29) 0.28 (0.27,0.30) 0.457 
20:4n-6 
 





0.23 (0.21,0.25) 0.21(0.20,0.22) 0.088 
18:3n-3 
 




















0.60 (0.58,0.62) 0.59 (0.58,0.61) 0.646 
Desaturase activity 




2.20 (2.10,2.30) 1.89 (1.81,1.98) 2.59x10
-6
 
Data show mean (95% CI) for each LC-PUFA as a % of total fatty acids, mean surrogate 
estimates of D5D, D6D and D9D activity based on ratio of product:substrate (95% CI). Mean 
values adjusted for age and BMI.  
1
P-value adjusted for within pair effects. 
1
P-values corrected for multiple testing. 
§




In the plasma, on the other hand, proportions of GLA and AA in the n-6 series were 
significantly lower, whereas the levels of LA and DGLA were significantly higher in 
the carriers of the minor allele. Non-significantly lower levels of adrenic (22:4n-6) and 
higher levels of osbond (22:5n-6) acids were noted. Of the n-3 family, significantly 
lower levels of DPA and DHA were seen in the plasma of the carriers of the minor 
allele only. D5D and D6D estimated activities were significantly lower in the carriers of 
the minor allele. Results from the plasma stratified by rs174537 genotypes are shown in 




Table ‎4.19 Proportions of fatty acids (wt%), estimated desaturase activities and lipid 
concentrations in plasma stratified by FADS1 SNP genotypes (n= 185). 
    rs174537 
Phenotype 
 




25.72 (24.88,26.55) 27.32 (26.70,27.93) 0.0006 
18:3n-6 
 





1.55 (1.46,1.63) 1.66 (1.59,1.72) 0.01 
20:4n-6 
 








0.52 (0.49,0.55) 0.50 (0.48,0.53) 0.561 
22:5n-6 
 
1.04 (0.99,1.09) 1.07 (1.03,1.11) 0.596 
18:3n-3 
 





0.19 (0.17,0.20) 0.17 (0.16,0.18) 0.136 
22:5n-3 
 
0.64 (0.61,0.67) 0.59 (0.57,0.61) 0.002 
22:6n-3 
 





1.43 (1.39,1.48) 1.46 (1.43,1.49) 0.763 
Desaturase activity 
 

















   
TC  
 
5.61 (5.47,5.75) 5.58 (5.46,5.70) 0.775 
HDL-C  
 
1.83 (1.78,1.89) 1.85 (1.80,1.90) 0.585 
LDL-C  
 
3.27 (3.14,3.40) 3.21 (3.10,3.33) 0.516 
TAG 
 
1.01 (0.99,1.04) 1.01 (0.99,1.03) 0.85 
TC:HDL-C ratio 
 
3.21 (3.09,3.33) 3.17 (3.07,3.28) 0.618 
NHDL-C 
 





5.09 (4.93,5.26) 5.20 (5.06,5.35) 0.337 
Glucose
§
   2.03 (1.99,2.07) 2.03 (2.00,2.07) 0.891 
Data show mean (95% CI) for each LC-PUFA as a % of total fatty acids, mean surrogate 
estimates of D5D, D6D and D9D activity based on ratio of product:substrate (95% CI). Mean 
values adjusted for age and BMI. 
1
P-value adjusted for within pairs effect for MZ and DZ. 
1
P-values corrected for multiple testing. 






4.7.2.3 SCD-1 SNP genotype associations with plasma and adipose tissue 
variables  
Table 4.20 summarises the proportions of palmitoleic and oleic acids and their 
precursor fatty acids palmitic and stearic acids, respectively, and activities of D9D 
desaturases in adipose tissue stratified by rs7849 genotype. There were no significant 
effects of the SNP on proportions of these fatty acids, but minor allele carriage was 
associated with slightly higher proportions of palmitic, stearic and palmitoleic acids, 




Table ‎4.20 Proportions of fatty acids, estimated desaturase activities and lipid concentrations in 
adipose tissue stratified by SCD-1 SNP genotypes (n= 519). 





    n = 334 n = 170   





19.20 (18.98,19.43) 19.25 (18.94,19.56) 0.872 
18:0 
 
3.16 (3.07,3.26) 3.27 (3.14,3.40) 0.786 
16:1n-7 
 
5.80 (5.62,5.98)) 5.85 (5.60,6.09) 0.161 
18:1n-9 
 









    D9D  
    16:1n-7:16:0 
 
0.31 (0.30,0.32) 0.31 (0.29,0.32) 0.883 
18:1n-9:18:0 
 
16.17 (15.64,16.70) 15.82 (15.08,16.56) 0.453 
Data show mean (95% CI) for each LC-PUFA as a % of total fatty acids, mean surrogate 
estimates of D5D, D6D and D9D activity based on ratio of product:substrate (95% CI). Mean 
values adjusted for age and BMI. 
1
P-value adjusted for within pair effects. 
1






In plasma, the SNP in the SCD-1 gene did not show any significant effects either. Results of the 
plasma fatty acid proportions stratified by rs7849 genotype are summarised in Table 4.21.  
Minor allele carriage resulted in non-significantly higher levels of palmitic acid and its product, 
palmitoleic acid. On the other hand, stearic acid proportions were lower and those of its product, 
oleic acid, were higher in the carriers of the minor allele. This SNP showed no association with 





Table ‎4.21 Proportions of fatty acids (wt %), estimated desaturase activities and lipid 
concentrations in plasma stratified by SCD-1 SNP genotypes (n= 179). 
    rs7849 
Phenotype 
 




20.86 (20.62,21.09) 21.26 (20.89,21.63) 0.113 
18:0 
 
7.08 (6.98,7.19) 7.02 (6.85,7.18) 0.491 
16:1n-7 
 
2.50 (2.39,2.62) 2.55 (2.36,2.73) 0.127 
18:1n-9 
 
19.36 (19.01,19.70) 19.91 (19.37,20.45) 0.312 
P:S 
 
1.47 (1.43,1.50) 1.41 (1.36,1.46) 0.080 
Desaturase activity 
    D9D  
    16:1n-7:16:0 
 
0.12 (0.11,0.12) 0.12 (0.11,0.13) 0.989 
18:1n-9:18:0 
 
16.17 (15.64,16.70) 15.82 (15.08,16.56) 0.453 
Plasma lipids 
    TC  
 
5.59 (5.47,5.70) 5.59 (5.43,5.75) 0.967 
HDL-C  
 
1.84 (1.80,1.89) 1.84 (1.78,1.90) 0.968 
LDL-C  
 





1.01 (0.99,1.03) 1.00 (0.98,1.03) 0.575 
TC:HDL-C ratio 
 
3.20 (3.10,3.30) 3.17 (3.04,3.31) 0.758 
NHDL-C 
 










2.02 (1.98,2.05) 2.05 (2.01,2.10) 0.236 
BMI   5.59 (5.47,5.70) 5.59 (5.43,5.75) 0.967 
Data show mean (95% CI) for each LC-PUFA as a % of total fatty acids, mean surrogate 
estimates of D5D, D6D and D9D activity based on ratio of product:substrate (95% CI). Mean 
values adjusted for age and BMI. 
1
P-value adjusted for within pair effects. 
P-values corrected for multiple testing. 
§








As far as could be ascertained, this is the first study that has compared adipose tissue 
fatty acid composition between twins. The participants of the study were healthy 
women. Their dietary intakes and plasma lipid profiles were not unlike those of similar 
aged women in the National Diet and Nutrition Survey (Henderson et al. 2003). Dietary 
TFA and PUFA intakes showed significant correlations with proportions in adipose 
tissue. However, the estimated intake of SFA did not correlate with the levels in adipose 
tissue. Neither was there any association with MUFA intake and the proportion of 
MUFA in adipose tissue. In the latter case it was noted that the proportion of oleic acid 
was much higher than estimated in the diet indicating substantial synthesis of this fatty 
acid. Furthermore, the proportion of palmitic acid was lower and that of palmitoleic was 
higher which would suggest that a substantial proportion of palmitic acid is converted to 
palmitoleic acid and that a fraction of palmitic acid is converted to oleic acid. This 
might explain the lack of association between dietary intake and levels of MUFA and 
SFA in adipose tissue. A novel finding was the relatively substantial amounts of LC-
PUFA in adipose tissue, assuming about 20% of body weight is adipose tissue for a 
body weight of 68kg this would suggest that out of 13.6 kg, there would be a body pool 
of about 49g of DHA. Dietary intake of DHA was estimated from the level in plasma to 
be about 0.13g/d this would equate to about 0.18% of the dietary fatty acid intake. The 
proportion of DHA in adipose tissue was ~0.36% vs. 0.18%, which would imply that at 




Experimental studies (Mensink et al. 2003) have shown that SFA increase TC and 
particularly LDL-C. NHDL-C concentration is a surrogate measure for LDL-C and is 
widely used in epidemiological studies in relation to risk of CVD. This cross-sectional 
study was unable to find any relationship between dietary SFA intake and/or adipose 
tissue SFA content or that in serum NHDL-C concentration. However, ACE modelling 
indicated that 45% of the variance could be explained by additive genetics and the 
remaining variance was explained by environmental effects. Analysis of the non-genetic 
factors suggests age and BMI were the major determinants of NHDL-C. The range of 
SFA intakes estimated by the FFQ was not large with SD of about 2.8% energy. 
Furthermore, only 60-70% of the SFA intake is likely to be C12-C16 SFA and 
consequently the difference between 1 SD either side of the mean would only be about 
3.5% energy. Using the Keys equation, a 3.5% energy difference in SFA would predict 
a difference in serum cholesterol of a 0.2 mmol/L, which is below 5% of the variance 
and may be too small an effect to detect in a cross-sectional study. This failure to find a 
relationship between SFA intake and NHDL-C is consistent with the findings of the UK 
NDNS and most other reports from cohort studies. However, where differences in SFAs 
are large for example when comparing vegans with omnivores, it is possible in cross-
sectional studies to show a relationship with NHDL-C (Crowe et al. 2013).  
 The present study aimed to distinguish the possible effect of genetic factors from those 
of the environment, represented by dietary consumption and food choices, on 




analysis of data from 570 participants demonstrated that 60% and 63% of variation in 
the proportions of stearic acid and AA, respectively, was attributable to genetic factors. 
Two main factors determine variation of fatty acid proportions in adipose tissue. These 
are dietary intake and endogenous synthesis/remodelling, which involves enzymatic 
elongation and desaturation of precursor fatty acids. Both of these factors have been 
shown to have some degree of genetic control. Teucher et al. (2007) showed that food 
choice or dietary pattern is governed by genetic factors to some extent after analysis of 
the dietary intake of twin subjects. Endogenous synthesis of fatty acids depends on 
activities of enzymes subject to genetic variation. The high heritability of stearic acid 
may indicate variability of conversion to oleic acid by delta-9 desaturase. LA cannot be 
synthesised de novo but is converted to AA. Small amounts of preformed AA are 
present in meat and eggs but the amounts are very much smaller than the amounts of 
EPA and DHA provided by oily fish. It is likely, therefore that the higher amount is a 
consequence of differences in its synthesis from LA. The high heritability of AA was 
also confirmed by the plasma analysis. 
This work was then able to demonstrate that SNP rs174537 upstream of the FADS1 
gene is associated with proportions of AA in adipose tissue and plasma. On the other 
hand, SNP rs7849 in the SCD-1 gene was found to be associate with proportions of 
palmitic and stearic acids and their metabolites, palmitoleic and oleic acids, in plasma 
and adipose tissue, but not significantly. This might be due to the fact that the SCD-1 




of SCD-1 expressed in adipose tissue. Furthermore, the relatively small sample size has 
limitations with regard to power to detect significant differences.   
4.9 Conclusion 
In conclusion, the present study demonstrated that PUFA and TFA in both adipose 
tissue and plasma correlate and are good biomarkers of dietary intake but the 
proportions of SFA in adipose tissue are weak biomarkers of SFA intake. This work 
also revealed that adipose tissue is a significant reservoir of DHA and other LC-PUFA. 
It was demonstrated that it is possible to estimate intakes of EPA and DHA from the 
proportions in plasma. A significant additive genetic effect on the proportion of AA in 
adipose tissue and of AA in plasma was detected. Some of this variation could be 












 Chapter 5: MARINA study: Influence of genetic variation on 







EPA and DHA play a crucial role at cellular level. In addition to maintaining cell 
membrane fluidity and integrity, they are of importance for retinal and neurological 
functions.  Phosphlipids in the brain and retina contain 20-50% DHA. EPA and DHA 
can also act as ligands for PPARs and influence transcriptional events at a molecular 
level. For these reasons, consumption of dietary sources rich in these two fatty acids 
might be anti-inflammatory, cardio-protective and reduce risk to CVD (Burdge, 2004).  
While the essentiality of LA and its metabolites are well established, the physiological 
role of the n-3 series is less certain. The essentiality of the n-3 series appears to hinge on 
the conversion of ALA to DHA. Requirements for n-3 LC-PUFA can be probably met 
by ALA in most species including primates and studies on human infants have shown 
active conversion of ALA to DHA (Jensen et al. 1997). However, high intakes of LA 
may inhibit this conversion by competitive inhibition of delta-6 desaturase (D6D). 
Soybean oil and rapeseed oil are the chief dietary sources of ALA although milk fat 
(provides 1-1.5%) and walnuts are rich sources. ALA can be converted into EPA and 
DHA by alternating desaturation and chain elongation reactions. The liver is a major 
site of conversion (Burdge & Calder, 2005), but there is evidence that conversion takes 
place inside the brain (Sanders et al. 1984) and other tissues such as the testis (Leat et 
al. 1983). In the land-based food chain, the formation of DHA is dependent upon 
conversion from ALA and this is also influenced by the relative amount of LA in the 




especially offal, but including meat and eggs. However, the amount present in most 
human diets is small (50-100mg) and usually no more than 200mg/d. In the marine food 
chain significant amounts of preformed EPA and DHA are present especially in oily 
fish such as herring, mackerel, sardines, salmon and tuna. These fatty acids are derived 
from algae which make these fatty acids mainly by the polyketide synthase pathways 
(Metz et al. 2001). The consumption of EPA and DHA has a far more marked effect on 
the proportions of these fatty acids in plasma and membrane lipids than dietary ALA 
(Sanders, 2009a). Minimal requirements for n-3 LC-PUFA are in the range of 0.2%-
0.5% of the total energy intake and it is generally accepted that this requirement can be 
met by ALA. Some recent dietary guidelines have suggested a population intake of 
0.25g n-3 LC-PUFA (WHO/FAO 2010; EFSA 2010) because of the association of fish 
intake with a lower risk of CVD. However, no recommendations for intakes of n-3 LC-
PUFA were made in the Dietary Guidelines for Americans 2010 which were made on 
the basis of a meticulous systematic review of the evidence ( 
http://www.nutritionevidencelibrary.gov ) 
EPA and DHA are preferentially esterified into the sn-2 position of phospholipids 
(Flachs et al. 2009; Kopecky et al. 2009). Different phospholipids classes have 
specificity for different PUFA. For instance, AA is the dominant PUFA in 
phosphatidylinositol, while DHA is the principal fatty acid in retinal ethanolamine 
phosphoglycerides. Phospholipids, above and beyond being essential membrane 




LC-PUFA (Flachs et al. 2009). AA is the usual substrate for cyclo-oxygenases type 1 
and 2 (COX-1 and COX-2). EPA forms a series of metabolites that are generally 
inactive or less active than those derivatives of AA. DHA does not give rise to 
prostaglandins but inhibits the formation of prostaglandins derived from AA in a similar 
manner with EPA. More recently, metabolites called neuroprotectins and resolvins have 
been shown to be from EPA and DHA (Serhan et al. 2004). Eicosanoids derived from 
n-6 PUFA are vital for normal body functions and are usually synthesised by COX-1 
but extreme eicosanoid formation can be induced as a result of inflammation and injury 
via activation of COX-2 (Flachs et al. 2009; Kopecky et al. 2009; Sanders & Emery, 
2003). The replacement of AA with EPA and DHA can modulate inflammation. 
However, if EPA replaces too much AA it results in pathological changes. For example, 
parturition is inhibited (Sanders, 1988). The extent to which ALA is converted to EPA 
and DHA has been a topic of much debate. Groups of people such as vegans who have 
no dietary intakes of EPA and DHA have levels of EPA and DHA about 2/3 lower than 
that of omnivores (Sanders et al. 1978). Supplementation studies in adults have shown 
that ALA is converted into EPA but without influencing DHA (Sanderson et al. 2002). 
However, studies conducted on infants show that ALA is converted to DHA. There 
have been reports (Welch et al. 2010) suggesting that women may be more able to 
convent ALA to DHA. It has also been suggested that the capacity to desaturase besides 
being under hormonal control may also be influenced by genetic factors (Schaeffer et al. 
2006). Plasma lipids are believed to reflect short term changes in fatty acid intake 




This chapter reports on the effects of different doses of EPA and DHA on levels of 
these fatty acids in plasma and erythrocytes and the effects of polymorphisms in the 
FADS1 FADS2 gene cluster on proportions of LC-PUFA based on the analysis of 





5.2 Purpose of the study 
Dietary intake of fish is associated with a lower risk to CVD. It is thought that this 
protective effect is mediated, in part, by the presence of long-chain n-3 PUFA (LC-n-3-
PUFA) in fish particularly eicosapentaenoic (20:5n-3; EPA) and docosahexaenoic acids 
(22:6n-3; DHA). Levels of EPA and DHA in blood are strongly influenced by the 
consumption of dietary sources rich in these fatty acid, but may also be influenced by 
the intakes of linoleic (18:2n-6; LA) and α-linolenic (18:3n-3; ALA) acids and genetic 
factors. The dose-response relationship of increasing intakes of LC n-3 PUFA on levels 
in plasma and erythrocytes have been examined in short term studies but there is a lack 
of information from longer term studies of six months duration or longer.  
The aims were 
1.  To investigate the influence of single nucleotide polymorphism in the 
FADS1-FADS2 gene cluster on levels of PUFA and LC-PUFA in 
erythrocyte phospholipids and total plasma fatty acids at baseline and after 6 
months of graded intake of EPA+DHA (ratio of 1.51:1).  
2. Develop equations to predict intakes of EPA and DHA from analysis of 
plasma lipids in other studies. 
3. To identify possible post-intervention novel circulating fatty acid pattern 




4. To investigate whether the measures of n-3 PUFA in the participants at 
baseline is associated with in vivo measures of atherosclerosis determined by 
carotid intimal media thickness. 
The following objectives were set to meet the above aims: 
1. To measure fatty acid proportions in both erythrocyte phospholipids and 
total plasma at baseline and after 6-months following supplementation of 
graded intakes of EPA + DHA equivalent to intakes of 1, 2 or 4 servings of 
oily fish per week by gas chromatography. 
2. To perform PCA analysis on proportions of fatty acids after 6 months 
intervention to identify circulating pattern of fatty acids.  












Supplementation of graded intake of EPA + DHA for 6-months will modify fatty acid 
proportions of plasma and erythrocyte phospholipids in a linear dose dependent manner 
Hypothesis (2) 
Single nucleotide polymorphism in the FADS1-FADS2 gene cluster influences the 
proportions of parent essential fatty acid and their LC-PUFA in the erythrocyte 
phospholipids and total plasma fatty acids at baseline and after 6 months of 





5.3 Study participants and design 
The MARINA (Modulation of Atherosclerosis Risk by Increasing doses of N-3 fatty 
Acids) trial was a single-centre dietary intervention study of randomized double-blind 
parallel design, to test the effects of three daily doses of EPA and DHA on endothelial 
function and established CVD risk factors (Sanders et al. 2011). The study was 
approved by the St Thomas‟ Hospital NHS Research Ethics Committee (NREC 
08/H0802/3) and written informed consent was given by participants, who were healthy 
non-smoking men and women aged between 45-70y, recruited through media 
advertisements and screened as described previously (Sanders et al. 2011). A total of 
367 participants were randomized to treatment by computer-generated sequence, using 
the process of minimization to balance age, gender and ethnicity between treatment 
groups. During an initial run-in period of 4 weeks, participants took olive oil (BP 
specification) placebo capsules whilst restricting oily fish intake, after which baseline 
measurements of outcome variables were made. The dietary intervention phase involved 
supplementation with encapsulated EPA and DHA at three doses (0.45, 0.9 and 1.8 
g/day), compared with placebo. The dose range was selected to reflect the range of 
intakes likely to be encountered in human diet rather than extreme diets (SACN Advice 
of Fish Consumption 2004). Current UK dietary advice is to consume two portions of 
fish a week one of which is oily. The present investigation is based on measurements 
made at baseline and after 6 months. Compliance was determined by assessing the EPA 




participants were supplied with capsules at regular intervals and any unused were 
returned and their numbers recorded. The oil blends were supplied by Croda Chemicals 
Europe Ltd. (Hull, UK) and encapsulated in gelatine by Powerhealth (Pocklington, UK) 
as described previously (Sanders et al. 2011). Quality control analysis was performed 
by Croda Chemicals Europe Ltd. 
5.4 Blood sampling and analysis 
Erythrocyte lipids were extracted from washed cells within 3 days of blood collection as 
described in Chapter 2. Extracted lipids were stored at -20°C until analyzed. Blood 
samples for analysis were drawn after a minimum 8hrs overnight fast preceded by a 
low-fat evening meal (<10g fat, 3MJ) and serum was stored at -45°C until analyzed. 
Plasma total fatty acids were determined by capillary gas-liquid chromatography (GLC) 
as described in Chapter 2, substituting toluene for benzene and using pentadecanoic acid 
as an internal standard (Lepage & Roy, 1986). Measurements of plasma lipid 
concentrations were as described in Chapter 2 and inter- assay coefficients of variation 
were as previously reported (Sanders et al. 2011). Surrogate estimates of desaturase 
activity was based on product:substrate ratios of n-6 LC-PUFA measures available.  
AA:DGLA (20:4n-6:20:3n-6) was used to estimate D5D activity (FADS1) and GLA:LA 





5.5 Carotid intima-medial thickness (CIMT) assessed by high resolution 
ultrasound 
It is possible to assess the extent of atherosclerosis in vivo by measuring carotid intima 
medial thickness. With increase age, the intima thickens and this represents a measure 
of atherosclerosis. It can be measured by high-resolution ultrasound non-invasively and 
is regarded as a gold standard method for assessing atherosclerosis in healthy subjects. 
CIMT changes very slowly so value measured at the end of the study are likely to be 
similar to those at baseline. 
5.6 Selection and analysis of SNPs 
Selected SNPs were sited within FADS1 and FADS2 genes or potential 5‟ or 3‟ 
regulatory regions and in strong LD to enable haplotype analysis (r
2
>0.8). High minor 
allele frequencies (>10%) are required for investigation of diet-gene interaction. The 
rs174537 (G/T) located 14 kb upstream of the FADS1 gene is associated with the 
strongest GWA signal and accounts for up to 19% of the variation in plasma 
arachidonic acid (AA, 20:4n-6) (Tanaka et al. 2009). rs174561 (T/C) is located in intron 
1 of FADS1 and rs3834458 (T/del) is located in the promoter region of FADS2. 
5.6.1 DNA extraction and SNP genotyping 
Buffy coats removed from blood samples were stored in EDTA at -20°C. Genomic 




Healthcare, Amersham, UK) according to manufacturer‟s instructions. Genotyping was 
performed on the 310 participants for whom DNA was available by KBiosciences 
(Hoddesdon, UK), using the KASPar system. Genotype accuracy, as assessed by 
inclusion of duplicates in the array was 98% and negative controls (water blanks) were 
included on each plate. The mean genotyping success rate was 97.7% (95.8-99.7%). 
5.6.2 Haplotype analysis 
Haplotype analysis was performed using the graphical JAVA interface of the THESIAS 
software package (Tregouet & Garelle, 2007), (available online at 
http://ecgene.net/genecanvas ). This program is based on the maximum likelihood 
model linked to the SEM algorithm (Tregouet et al. 2004) and used to statistically 
reconstruct haplotypes in unrelated individuals and perform haplotype-based association 
analysis of phenotypes. Covariate-adjusted haplotype effects as well as interactions 
between haplotypes and covariates can be investigated. 
5.7 Statistical analysis 
All genotype distributions were tested for deviation from Hardy-Weinberg equilibrium 
using a χ2 test with 1 df (P> 0.05). Inter-locus linkage disequilibrium based on observed 
numbers of diplotypes was established using CubeX software (Gaunt et al. 2007), 
(available online at http://www.oege.org/software/cubex/ ) and represented in a 
correlation matrix as Lewontin's D′ and squared correlation r2 measures between each 




Statistical analyses were carried out using the SPSS version 17.0 for Windows (SPSS 
Inc, Chicago, IL, USA). Normal distribution of outcome variables was evaluated by Q-
Q plots. Where needed, variables were log transformed to obtain better approximations 
of the normal distribution prior to analysis. Due to the limited sample size, especially 
after stratification for dietary intake, SNP genotype association analyses were based on 
a dominant inheritance model. The presence of any significant difference in three SNP 
genotype frequencies between the four treatment groups was ascertained by χ2 test with 
6 df (P> 0.05). Linear regression was used to assess independent SNP and haplotype 
associations with phenotypes and interaction with dietary treatment. All data presented 
in text and tables are expressed as means or geometric means ± standard deviation (SD) 
or mean (95% CI). Ethnicity, sex, age and body mass index (BMI) were added to the 
models as covariates to adjust for possible confounding effects. Interaction between 
FADS SNP genotype and dosage of EPA+DHA was explored by adding interaction 
terms to the multiple linear regression models. Association between proportions of LC-
PUFAs in plasma and erythrocyte phosphoglycerides was evaluated by Spearman‟s 
correlation coefficient (ρ) with significance set at P< 0.01 (two-tailed test). Multivariate 
analysis of variance was used to allow for multiple testing of genotype associations with 
proportions of nine fatty acids and univariate analysis of variance to test genotype 
associations with surrogate measures of desaturase activities without adjustment for 
multiple comparisons. Significance was taken as P< 0.05 (as confirmed in the 





5.8.1 Characteristics of subjects 
Data was available for analysis of 310 out of 367 participants randomized to treatment. 
The number of participants allocated and drop-out rates did not differ significantly 
between treatment groups (Sanders et al. 2011). There were more women than men 
approximately 1.6:1 and ~20% of the sample was non-white, with similar proportions of 
Asian and Black participants. The average BMI was above the desirable range (20-25 
kg/m
2
) and the mean waist circumferences were greater than cut-offs indicating risk of 
metabolic syndrome (94 cm in men and 80 cm in women) (Sanders et al. 2011). Table 
5.1 shows the details of subjects after 4 week run-in on placebo, for whom DNA 
samples were available, and the PUFA in plasma and erythrocyte lipids. The proportion 
of LA was much higher in plasma than erythrocytes reflecting the higher proportions in 
cholesteryl esters and lecithin. There were no significant differences in these measures 




Table ‎5.1 Characteristics of the sample. 
  Placebo 0.45 g/day 0.9 g/day 1.8 g/day 
  n = 71  n = 82 n = 81 n = 82 
Male n (%) 31 (35) 31 (38) 30 (37) 31 (38) 
Female n (%) 42 (48) 51 (62) 51 (63) 51 (62) 
Age (y) 55.37±6.96 55.00±6.79 55.16±6.56 55.02±6.65 
BMI (kg/m
2
) 26.24±3.72 25.12±3.86 26.13±4 25.22±3.49 
     
Plasma fatty acid % total     
Linoleic acid (18:2n-6) 26.99±4.02 27.54±3.62 27.69±4.14 27.83±3.91 
γ-linolenic acid (18:3n-6) 0.47±0.16 0.43±0.18 0.45±0.16 0.46±0.18 
Dihomo-γ-linolenic acid (20:3n-6) 1.62±0.37 1.58±0.32 1.59±0.29 1.63±0.36 
Arachidonic acid (20:4n-6) 6.91±1.61 6.74±1.43 7.12±1.69 6.84±1.36 
Adrenic acid (22:4n-6) 0.60±0.15 0.57±0.13 0.61±0.14 0.60±0.14 
α-linolenic acid (18:3n-3) 0.67±0.25 0.61±0.17 0.66±0.20 0.64±0.20 
Eicosapentaenoic acid (20:5n-3) 1.22±0.74 1.10±0.60 1.12±0.57 1.10±0.56 
Docosapentaenoic acid (22:5n-3) 0.66±0.12 0.64±0.12 0.64±0.13 0.65±0.13 
Docosahexaenoic acid (22:6n-3) 2.40±0.79 2.42±0.78 2.36±0.67 2.45±0.68 
     
Plasma desaturase activity      
D5D (20:4n-6:20:3n-6)  4.47±1.33 4.44±1.32 4.64±1.46 4.39±1.28 
D6D (18:3n-6:18:2n-6) 0.17±0.01 0.16±0.01 0.16±0.01 0.16±0.01 
Erythrocyte fatty acid % total     
Linoleic acid (18:2n-6) 10.84±1.56 11.12±1.45 11.00±1.42 11.00±1.57 
γ-linolenic acid (18:3n-6) - - - - 
Dihomo-γ-linolenic acid (20:3n-6) 1.90±0.37 1.90±0.38 1.83±0.38 1.89±0.40 
Arachidonic acid (20:4n-6) 16.76±1.96 16.37±2.12 16.92±2.12 16.44±2.03 
Adrenic acid (22:4n-6) 2.78±1.01 2.91±1.03 2.99±2.18 2.79±0.66 
α-linolenic acid (18:3n-3) 0.19±0.12 0.20±0.20 0.18±0.10 0.18±0.13 
Eicosapentaenoic acid (20:5n-3) 1.30±0.47 1.26±0.46 1.36±0.55 1.31±0.50 
Docosapentaenoic acid (22:5n-3) 3.23±0.40 3.20±0.53 3.23±0.55 3.22±0.56 
Docosahexaenoic acid (22:6n-3) 6.52±1.57 6.47±1.34 6.32±1.50 6.48±1.51 
     
Erythrocyte desaturase activity      
D5D (20:4n-6:20:3n-6)  9.14±1.91 8.91±1.87 9.41±2.08 9.01±1.88 
D6D (18:3n-6:18:2n-6) - - - - 
Measurements made at baseline after 4-wk run-in on normal diet with placebo supplement are 
shown for each randomized EPA+DHA treatment group. Values are n (%) for Male/Female or 




5.8.2 SNP allele and genotype frequencies 
Three SNPs at the FADS1-FADS2 gene locus, rs174537, rs174561 and rs3834458 were 
genotyped. The minor allele and genotype frequencies in all subjects who completed the study 
(n= 310) are shown in Table 5.2. Genotype distributions did not deviate from Hardy- Weinberg 
expectations and minor allele frequencies were in close agreement with those listed for 
Europeans on the NCBI SNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/  [accessed 
August 2010]. 
 
Table ‎5.2 FADS1 and FADS2 SNP allele and genotype frequencies. 
SNP 
Genotype 






rs174537 MAF 0.30  
 GG 153 (45)  
 GT 126 (37)  
 TT 30 (9)  
 All 309 (100) 0.58 
    
rs174561 MAF 0.27  
 TT 162 (47)  
 TC 116 (34)  
 CC 25 (7)  
 All 303 (100) 0.51 
    
rs3834458 MAF 0.30  
 TT 151 (44)  
 T/- 115 (34)  
 -/- 31 (9)  
  All 297 (100) 0.19 
MAF, minor allele frequency.  
a
No. of subjects for each genotype (% total).  
b




5.8.3 SNP genotype associations with plasma and erythrocyte variables at 
baseline 
Erythrocyte measures previously confirmed establishment of similar levels of n-3 LC-
PUFA in all treatment groups during the run-in on placebo and compliance over the 
intervention period (Sanders et al. 2011). Proportions of fatty acids in plasma and 
erythrocyte phosphoglycerides were highly correlated (P< 0.01), except for adrenic acid 
(22:4n-6), which is rapidly taken up from plasma by erythrocytes (Table 5.3). 
 
Table ‎5.3 Spearman's correlation between proportions of fatty acids and indices of D5D activity 
estimations in plasma and erythrocytes at baseline 
  Plasma  Erythrocyte  ρ 
Fatty acid % total
a
    
18:2n-6 27.50 ± 3.95 11.01 ± 1.49 0.614
b
 
18:3n-6 0.46 ± 0.17 - - 
20:3n-6 1.61 ± 0.33 1.88 ± 0.39 0.564
b
 
20:4n-6 6.89 ± 1.54 16.54 ± 2.12 0.385
b
 
22:4n-6 0.58 ± 0.15 2.88 ± 1.34 -0.046 
18:3n-3 0.65 ± 0.20 0.19 ± 0.14 0.398
b
 
20:5n-3 1.13 ± 0.60 1.30 ± 0.50 0.628
b
 
22:5n-3 0.64 ± 0.12 3.22 ± 0.53 0.411
b
 





    
D5D
c




Mean ± SD. 
b
Correlation significant at the P = 0.01 level (2-tailed). 
c




Table 5.4 shows total LC-PUFA composition and activities of D5D and D6D estimated 
in plasma stratified by rs174537, rs174561 and rs3834458 genotypes, after a 4-week 
run-in on normal diet with placebo supplement. There were significant associations 
between SNP genotypes and proportions of plasma fatty acids based on a dominant 
model after adjustment for ethnicity, gender, age and BMI. In the n-6 series, the minor 
alleles of all SNPs were associated with a higher proportion of FADS1 substrate dihomo 
γ-linolenic acid (DGLA, 20:3n-6) and lower proportions of FADS2 product γ-linolenic 
acid (GLA, 18:3n-6), FADS1 product AA (20:4n-6) and its derivative adrenic acid. In 
the n-3 family, minor alleles were significantly associated with higher proportion of 
FADS1 substrate ALA (18:3n-3) and lower proportions of FADS2 product EPA (20:5n-
3) and its derivatives docosapentaenoic acid (DPA, 22:5n-3) and DHA (22:6n-3). 
Increased substrate and decreased downstream product proportions inferred a reduction 
in desaturase activities. In line with these observations, carriers of the minor alleles of 
all three SNPs showed highly significant associations with lower estimated activities of 





Table ‎5.4 Proportions of fatty acids and estimated indices of desaturase activities in plasma stratified by FADS1-FADS2 SNP genotype at baseline. 
  rs174537 rs174561 rs3834458 
Phenotype GG GT+TT P
a
 TT TC+CC P TT Tdel + deldel P 
  n = 151 n = 125   n = 160 n = 140   n = 160  n = 144   
18:2n-6 27.2 (26.5,27.8) 27.6 (26.9,28.2) 0.17 26.5 (25.6,27.4) 27.9 (27.2,28.5) 0.016 26.9 (26.0,27.9) 27.6 (26.9,28.2) 0.26 
18:3n-6 0.5 (0.5,0.5) 0.4 (0.4,0.4) 1.90 x 10
-8
 0.5 (0.5,0.6) 0.4 (0.4,0.4) 4.56 x 10
-8
 0.5 (0.5,0.6) 0.41 (0.39,0.44) 4.96 x 10
-8
 
20:3n-6 1.5 (1.5,1.6) 1.7 (1.7,1.8) 3.85 x 10
-6
 1.5 (1.5,1.6) 1.7 (1.7,1.8) 5.29 x 10
-6
 1.6 (1.5,1.6) 1.70 (1.65,1.75) 1.52 x 10
-5
 
20:4n-6 7.6 (7.4,7.8) 6.3 (6.1,6.5) 7.56 x 10
-16
 7.5 (7.2,7.9) 6.2 (5.9,6.4) 2.49 x 10
-16
 7.5 (7.2,7.9) 6.24 (6.01,6.47) 3.83 x 10
-16
 
22:4n-6 0.6 (0.6,0.6) 0.6 (0.5,0.6) 0.007 0.6 (0.6,0.6) 0.6 (0.5,0.6) 0.05 0.6 (0.6,0.6) 0.56 (0.54,0.58) 0.002 
18:3n-3 0.6 (0.6,0.7) 0.7 (0.6,0.7) 0.13 0.6 (0.6,0.7) 0.7 (0.6,0.7) 0.018 0.6 (0.6,0.7) 0.67 (0.64,0.70) 0.008 
20:5n-3 1.2 (1.1,1.3) 1.02 (0.9,1.1) 0.003 1.1 (0.9,1.2) 1.01 (0.9,1.1) 0.004 1.1 (0.9,1.2) 1.03 (0.93,1.12) 0.023 
22:5n-3 0.7 (0.7,0.7) 0.6 (0.6,0.6) 4.47 x10
-7
 0.7 (0.6,0.7) 0.6 (0.6,0.6) 2.69 x 10
-7
 0.7 (0.7,0.7) 0.61 (0.59,0.63) 3.14 x 10
-5
 
22:6n-3 2.5 (2.4,2.6) 2.3 (2.2,2.4) 0.001 2.3 (2.2,2.5) 2.2 (2.1,2.4) 2.18 x 10
-4
 2.3 (2.2,2.5) 2.27 (2.15,2.38) 0.003 
D5D
b
 5.1 (4.9,5.3) 3.8 (3.6,4.0) 1.38 x 10
-18
 5.1 (4.9,5.3) 3.8 (3.6,3.9) 5.84 x 10
-19





 0.18 (0.17,0.18) 0.16 (0.15,0.16) 3.26 x 10
-7
 0.18 (0.17,0.18) 0.16 (0.15,0.16) 6.05 x 10
-8
 0.17 (0.17,0.18)  0.16 (0.15,0.16) 4.20 x 10
-7
 
Mean values (95% CI) estimates of D5D and D6D activity based on ratio of n-6 product:substrate (95% CI).  
a
Genotype association with fatty acids and desaturase activitieswas tested respectively by multivariate and univariate analysis of variance based on a dominant model. P-
values adjusted for BMI, age, gender and ethnicity. 
b
Activity estimated by 20:4n-6:20:3n-6 ratio. 
      cActivity estimated by 18:3n-6:18:2n-6 ratio. 




In erythrocytes, DGLA was the only LC-PUFA showing associations with genotypes 
with significance comparable to those in plasma (2.97 x 10
-19
 ≤ P ≤ 6.03 x 10-15). D5D 
activity estimated in erythrocytes was much higher than in plasma, a reflection of the 
higher proportion of AA (16.5% versus 6.9%), but all minor alleles were associated 
with significantly lower activity (1.60 x 10
-21
 ≤ P ≤ 2.68 x 10-16). D6D activity was not 






Table ‎5.5 Proportions of fatty acids and indices of desaturase activities in erythrocytes stratified by FADS1-FADS2 SNP genotype at baseline. 
  rs174537 rs174561 rs3834458 
Phenotype GG GT+TT P
a
 TT TC+CC P TT Tdel + deldel P 
  n = 147 n = 151   n = 157 n = 136   n = 140  n = 130   
18:2n-6 10.8 (10.6,11.1) 11.1 (10.9,11.3) 0.112 10.8 (10.5,11.0) 11.1 (10.9,11.4) 0.02 10.8 (10.6,11.1) 11.1 (10.8,11.3) 0.171 
18:3n-6 - - - - - - - - - 
20:3n-6 1.7 (1.7,1.8) 2.0 (1.9,2.1) 4.9 x 10
-16
 1.71 (1.7,1.8) 2.1 (2.0,2.1) 2.9 x 10
-19
 1.7 (1.7,1.8) 2.05 (1.9,2.1) 6.0 x 10
-15
 
20:4n-6 16.9 (16.6,17.3) 16.3 (16.0,16.7) 0.019 16.9 (16.6,17.3) 16.1 (15.8,16.5) 8.00 x 10
-4
 16.9 (16.6,17.3) 16.3 (15.9,16.6) 0.006 
22:4n-6 2.1 (2.7,3.3) 2.8 (2.7,2.9) 0.441 2.9 (2.7,3.2) 2.9 (2.7,2.9) 0.319 2.9 (2.70,3.3) 2.8 (2.7,2.9) 0.356 
18:3n-3 0.2 (0.2,0.2) 0.2 (0.2,0.2) 0.472 0.2 (0.2,0.2) 0.2 (0.2,0.2) 0.057 0.2 (0.2,0.2) 0.2 (0.2,0.2) 0.29 
20:5n-3 1.3 (1.3,1.4) 1.2 (1.2,1.3) 0.034 1.4 (1.3,1.4) 1.2 (1.2,1.3) 0.038 1.3 (1.2,1.4) 1.2 (1.2,1.3) 0.096 
22:5n-3 3.3 (3.2,3.4) 3.2 (3.1,3.2) 0.032 3.3 (3.2,3.4) 3.1 (3.1,3.2) 0.024 3.3 (3.2,3.4) 3.2 (3.1,3.2) 0.053 
22:6n-3 6.5 (6.3,6.8) 6.2 (5.9,6.4) 0.041 6.6 (6.4,6.9) 6.1 (5.9,6.4) 0.008 6.5 (6.3,6.8) 6.2 (5.9,6.4) 0.054 
Desaturase activity 
        D5D
b
 9.9 (9.7,10.3) 8.3 (7.9,8.5) 2.7 x 10
-16
 10.0 (9.8,10.3) 8.0 (7.7,8.3) 1.6 x 10
-21
 9.9 (9.7,10.3) 8.2 (7.9,8.5) 1.9 x 10
-16
 
Data show mean (95% CI) for each LC-PUFA as a % of total fatty acids and mean surrogate estimates of D5D activity based on ratio of n-6 product:substrate (95% CI).  
a
Genotype association with fatty acids and desaturase activity was tested respectively by multivariate and univariate analysis of variance based on a dominant model. P-
values adjusted for BMI, age, gender and ethnicity. 
b
Activity estimated by 20:4n-6:20:3n-6 ratio. 





In view of observed associations with plasma LC-PUFA proportions, we examined 
associations with concentrations of plasma TC, LDL-C, HDL-C, TAG and TC:HDL-C 
ratio, but none were significant (P> 0.05). 
5.8.4 Haplotype reconstruction 
Any one of a set of SNPs in LD associated with a phenotype is potentially functional and could 
be the origin of associations seen with the others. Alternatively, all SNPs could be in LD with 
an unknown functional site. A third possibility exists, whereby an unknown variant on the same 
haplotype in LD with a functional site could be responsible for associations seen with analysed 
SNPs. Thus, if haplotypes show stronger associations than SNPs independently, an unknown 
variant(s) could be responsible for the observed association. 
Statistical reconstruction of haplotypes in unrelated individuals, for whom phase is unknown, is 
possible when SNPs are in strong LD. As only rs174537 has been genotyped in NCBI HapMap 
trios (http://hapmap.ncbi.nlm.nih.gov/ ), we could not use the NCBI Haploview program to 
establish pairwise LD between our SNPs. Instead we used the online program CubeX (see 
Methods Chapter) based on diplotypes available for 282 MARINA subjects. Strong LD was 
confirmed; the pairwise squared correlations r
2
 ranged from 0.83 to 0.99 and Lewontin's D' from 





Figure ‎5.1 Structure of the FADS1 FADS2 gene cluster, its location on chromosome 11 and 
pairwise LD D‟ and r2 plots of the 3 studied SNPs. 
 
Reconstruction of haplotypes of the three SNPs (rs174537- rs174561- rs3834458) was 
based on participants for whom all genotypes were available, to avoid errors resulting 
from missing data. In these, fatty acid composition in plasma and erythrocyte 
phosphoglycerides was available for respectively 250 and 244 and estimated desaturase 
activities for 254 subjects. Seven of the eight possible haplotypes were represented, 
with frequencies ranging from 0.2% to 69.3% (Table 5.6). The most common 














   rs174537 rs174561 rs3834458    
Haplotype 1 (Reference)  1 1 1  69.3 
Haplotype 2  2 2 2  25.8 
Haplotype 3  2 1 2  3.3 
Haplotype 4  2 1 1  0.6 
Haplotype 5  2 2 1  0.6 
Haplotype 6  1 2 1  0.2 
Haplotype 7  1 1 2  0.2 
Haplotype 8  1 2 2  - 
Estimated reconstructed haplotype frequencies under linkage disequilibrium based on 






5.8.5 Haplotype associations with plasma and erythrocyte variables at baseline 
The significance of haplotype associations with plasma and erythrocyte phenotypes and 
proportions of variance explained by the three most frequent haplotypes, accounting for 
98.4% of the total is shown in Table 5.7. Plasma LC-PUFAs associated with 
independent SNP genotypes (Table 5.4) were also associated with haplotype, with 
similar levels of significance. Variability in fatty acid proportions explained ranged 
from 26.06% for AA to 2.88% for ALA. The significance of the association between 
haplotype and estimated D5D activity (P= 2.19 x 10
-17
) was similar to that for the single 
SNPs (5.84 x 10
-19
 ≤ P ≤ 4.5 x 10-18) (Table 5.4). However, the significance of 
haplotype association with estimated D6D activity (P= 3.39 x 10
-28
) was far greater than 
those with the single SNPs (6.05 x 10
-8
 ≤ P ≤ 4.20 x 10-7). 
Among LC-PUFA in erythrocyte phosphoglycerides, DGLA showed by far the 
strongest association with haplotype, accounting for a much larger proportion of the 
variance than in plasma (34.6% compared to 10.9%). The significance of association 
between haplotype and D5D activity estimated in erythrocytes (P= 2.01 x 10
-19
) was 
similar to that for the single SNPs (1.60 x 10
-21
 ≤ P ≤ 2.68 x 10-16). No haplotype 
associations with concentrations of plasma lipids were significant (P> 0.05). 
Owing to the relatively small number of subjects with complete genotype and 
phenotype data (n= 244-256), only the two haplotypes with an expected frequency > 5% 
were modelled to determine haplotype effects. Table 5.8 shows the effect on 




most significant effects of haplotype 2 carriage were seen in increased plasma 
proportions of DGLA and decreased GLA, AA, DPA and DHA. Carriage of haplotype 
2 significantly decreased plasma estimates of D5D and D6D activities compared to 
haplotype 1. In erythrocytes, only the increase in DGLA and the decrease in D5D 





Table ‎5.7 Association of FADS1-FADS2 3-SNP haplotypes with phenotypes at baseline and % 
variance explained. 
 Plasma  Erythrocytes 






association  % variance 
Fatty acids      
18:2n-6 0.050 22.4  0.032 11.5 
18:3n-6 9.80 x 10
-9
 17.6  - - 
20:3n-6 3.13 x 10
-5
 10.9  1.81 x 10
-21
 34.5 
20:4n-6 1.38 x 10
-16
 26.1  0.007 5.2 
22:4n-6 4.02 x 10
-4
 7.4  0.382 1.4 
18:3n-3 0.050 2.9  0.535 2.2 
20:5n-3 2.34 x 10
-4
 8.7  0.023 7.5 
22:5n-3 7.41 x 10
-7
 15.6  0.036 5.7 
22:6n-3 1.91 x 10
-4
 11.9  0.029 6.4 
Desaturase 
activity      
D5D
c
 2.19 x 10
-17





 3.39 x 10
-28
 17.2   - - 
a
P-values adjusted for BMI, age, gender and ethnicity.  
b
Variance explained by most frequent haplotypes 111, 222 and 212 accounting for 98.4% of 
total. 
c
Activity estimated by 20:4n-6:20:3n-6 ratio. 
d





Table ‎5.8 Difference in proportion of plasma and erythrocyte fatty acids and indices of desaturase activity per copy of minor allele haplotype compared to reference at 
baseline. 












rs3834458 alleles 1-1-1 2-2-2 1-1-1 2-2-2 
Haplotype frequency % 68.4 27.2 68.4 27.2 
  Intercept
 




  Intercept   Difference (95% CI) P-value 
18:2n-6 20.700  0.627 (-0.080 - 1.333) 0.08  7.544  0.304 (0.033 - 0.575)  0.03 
18:3n-6 0.108   -0.090 (-0.122 - -0.057) <1.0 x 10
-6
    - - 
20:3n-6 0.489   0.136 (0.076 - 0.196) 8.0 x 10
-6
  0.973  0.317 (0.264 - 0.370) <1.0 x 10
-6
 
20:4n-6 3.250   -1.138 (-1.425 - -0.851) <1.0 x 10
-6
  7.495  -0.651 (-1.059 - -0.244) 0.002 
22:4n-6 0.415  -0.036 (-0.064 - -0.009) 0.01  1.442   -0.173 (-0.618 - 0.272) 0.45 
18:3n-3 0.347   0.045 (0.008 - 0.083)  0.02  0.161  0.011 (-0.026 - 0.048) 0.57 
20:5n-3 0.144   -0.178 (-0.307 - -0.050) 0.007  0.325  -0.100 (-0.197 - -0.003) 0.04 
22:5n-3 0.287   -0.055 (-0.078 - -0.032)  2.0 x 10
-6
  1.493   -0.128 (-0.240 - -0.016)  0.03 
22:6n-3 1.129   -0.259 (-0.395 - -0.123) 1.9 x 10
-4
  2.960   -0.336 (-0.638 - -0.034)  0.03 
20:4n-6:20:3n-6 2.925  -1.003 (-1.242 - -0.765) <1.0 x 10
-6
  4.052  -1.469 (-1.758 - -1.180) <1.0 x 10
-6
 
18:3n-6:18:2n-6  0.000   -0.003 (-0.005 - -0.002) 5 x 10
-6
   NA   NA NA- 
Haplotype effects based on subjects with no missing genotype data: plasma fatty acids n = 250, RBC fatty acids n = 244; D5D and D6D desaturase activity n = 254. 
Mean proportion of fatty acid (%) estimated for reference haplotype 1 (major allele 1 at each locus). Mean difference (95% CI) in proportion of fatty acid (%) 




5.8.6 Changes in proportions of LC-PUFAs and desaturase activities in plasma 
and erythrocytes after EPA+DHA treatment 
In the second part of the study, we investigated the effects on plasma and erythrocyte 
phenotypes of dietary supplementation with EPA+DHA (1.51:1) for 6 months. We first 
assessed changes in proportions of LC-PUFAs, estimated desaturase activities and 
plasma lipids. We then determined whether genetic associations seen at baseline were 
modulated by the treatment. 
As shown in Table 5.9, there were significant changes after treatment in the proportions 
of all plasma LC-PUFAs except adrenic acid, which is rapidly taken up from plasma by 
erythrocytes. The proportions of all other n-6 LC-PUFAs were significantly decreased 
and all n-3 LC-PUFAs were significantly increased. The fall in n-6 LC-PUFA is 
probably due to two factors: decreased conversion from LA caused by inhibition of 
D6D and secondly competition by n-3 LC-PUFA at the level of acyl transferase where 
the fatty acids are incorporated into the lipids. There was a significant increase in D5D 
and a significant decrease in D6D activity after supplementation. There were no 
significant effects of haplotype on changes in the concentrations of plasma lipids (TC, 
HDL-C, TAG) after treatment. 
There were significant changes in proportions of all LC-PUFAs except ALA in 
erythrocyte phosphoglycerides after treatment. The proportions of all other n-3 LC-




in estimated D5D activity in erythrocytes was barely significant at the P< 0.05 level. 





Table ‎5.9 Proportion of fatty acids and desaturase indices in plasma stratified by treatment group after 6 months randomized treatment. 
  Placebo 0.45 g/day 0.9 g/day 1.8 g/day P
 
  n = 71 n = 82 n = 81 n = 82   
18:2n-6 27.57 (26.93,28.20) 27.21 (26.61,27.80) 26.74 (26.14,27.33) 26.28 (25.68,26.88) 0.016 
18:3n-6 0.47 (0.44,0.49) 0.42 (0.39,0.44) 0.39 (0.36,0.42) 0.32 (0.29,0.35) 8.77 x10
-9
 
20:3n-6 1.62 (1.57,1.68) 1.47 (1.42,1.52) 1.41 (1.36,1.46) 1.14 (1.09,1.19) 3.26 x10
-26
 
20:4n-6 6.80 (6.60,6.99) 6.55 (6.37,6.73) 6.45 (6.27,6.63) 6.04 (5.86,6.22) 1.80 x 10
-5
 
22:4n-6 0.60 (0.57,0.62) 0.60 (0.57,0.62) 0.61 (0.59,0.64) 0.63 (0.61,0.65) 0.215 
18:3n-3 0.60 (0.57,0.64) 0.66 (0.62,0.70) 0.63 (0.59,0.67) 0.68 (0.64,0.72) 0.008 
20:5n-3 0.94 (0.74,1.13) 1.86 (1.68,2.04) 2.37 (2.19,2.55) 3.88 (3.70,4.06) 3.86 x 10
-65
 
22:5n-3 0.62 (0.59,0.65) 0.74 (0.71,0.76) 0.79 (0.76,0.81) 0.93 (0.90,0.95) 1.47 x 10
-37
 
22:6n-3 2.27 (2.16,2.39) 2.86 (2.75,2.97) 3.39 (3.28,3.50) 4.04 (3.93,4.15) 4.16 x 10
-52
 
Desaturase activity      
18:3n-6:18:2n-6 4.37 (4.06,4.68) 4.63 (4.31,4.94) 4.93 (4.58,5.28) 5.45 (5.10,5.79) 4.00 x 10
-9
 
18:3n-6:18:2n-6 0.018 (0.016,0.019) 0.016 (0.015,0.017) 0.015 (0.014,0.016) 0.013 (0.012,0.014) 7.56 x 10
-6
 
Data show mean (95% CI) for each LC-PUFA as a % of total fatty acids and mean surrogate estimates of D5D and D6D activities based on ratio of n-
6 product:substrate (95% CI), all adjusted for baseline values. Measurements made after 6 months on placebo or EPA+DHA supplements are shown 
for each randomized treatment group.Significance of difference in change in proportions of fatty acids with respect to baseline between treatment 
groups was tested by multivariate analysis of variance. Significance of differences in desaturase activities adjusted for baseline values was tested by 




Table ‎5.10 Proportion of fatty acids and desaturase indices in erythrocytes stratified by treatment group after 6 months randomized treatment. 
  Placebo 0.45 g/day 0.9 g/day 1.8 g/day P
1
 
  n = 71 n = 82 n = 81 n = 82   
18:2n-6 11.04 (10.79,11.29) 10.79 (10.56,11.03) 10.76 (10.53,11.00) 10.15 (9.91,10.38) 3.32 x 10
-5
 
20:3n-6 1.88 (1.82,1.94) 1.75 (1.70,1.81) 1.66 (1.61,1.72) 1.48 (1.42,1.53) 9.05 x 10
-15
 
20:4n-6 16.58 (16.23,16.92) 15.66 (15.33,15.98) 15.26 (14.94,15.59) 13.94 (13.61,14.26) 1.56 x 10
-12
 
22:4n-6 3.14 (2.93,3.34) 2.43 (2.23,2.62) 2.28 (2.09,2.48) 1.91 (1.72,2.11) 5.75 x 10
-6
 
18:3n-3 0.17 (0.14,0.19) 0.17 (0.15,0.19) 0.16 (0.14,0.18) 0.20 (0.17,0.22) 0.408 
20:5n-3 1.18 (1.02,1.33) 1.97 (1.83,2.12) 2.48 (2.33,2.62) 3.65 (3.51,3.79) 1.87 x 10
-66
 
22:5n-3 3.15 (3.05,3.26) 3.52 (3.43,3.61) 3.81 (3.71,3.91) 4.18 (4.06,4.29) 1.06 x 10
-28
 




    
D5D
2
 9.20 (8.74,9.65) 9.14 (8.71,9.57) 9.67 (9.24,10.10) 9.73 (9.30,10.15) 0.046 
Data show mean (95% CI) for each LC-PUFA as a % of total fatty acids and mean surrogate estimate of D5D activity based on ratio of n-
6product:substrate (95% CI), all adjusted for baseline values. Measurements made after 6 mo on placebo or EPA+DHA supplements are shown for 
each randomized treatment group. 
1
Significance of difference in change in proportions of fatty acids with respect to baseline between treatment groups was tested by multivariate 
analysis of variance. Significance of difference in desaturase activity adjusted for baseline value was tested by univariate analysis of variance. All P-
values adjusted for BMI, age, gender and ethnicity. 
2




5.8.7 SNP associations with plasma and erythrocyte variables after dietary 
intervention 
There were no significant differences in SNP genotype frequencies between the four 
treatment groups: rs174537 χ2 = 6.79, 6 df, P = 0.34; rs174561 χ2 = 9.62, 6 df, P = 0.14; 
rs3834458 χ2 = 9.00, 6 df, P = 0.17. We found no significant differences in LC-PUFA 
proportions between common homozygotes and carriers of the minor allele of any of the 
three SNPs in any treatment group (P> 0.05). There were also no effects on plasma 
lipids dependent on genotype and dose. However, there were significant effects of 
treatment on estimations of desaturase activity when stratified by genotype. Carriers of 
the rs174537 minor T-allele had significantly lower D5D activity than GG subjects in 
the placebo group, but with increasing dosage, activity increased significantly in T-
carriers (P = 3.2 x 10
-10
 in plasma and P = 4.3 x 10
-4
 in erythrocytes), but not in GG 
homozygotes (P = 0.11 in plasma, P = 0.76 in erythrocytes) as shown in Figure 5.2. 
Interaction between rs174537 genotype and intake as a determinant of D5D activity was 
significant at the P< 0.05 level (P = 0.05 for plasma and P = 0.02 for erythrocyte 
estimates) after adjustment for age, BMI, ethnicity, gender and D5D activity at baseline 
but before correction for multiple comparisons. After correction, interaction remained 
significant for the plasma estimate (P = 0.05) but not for the erythrocyte measure (P = 
0.20). Interaction between treatment and rs174561 genotype was not significant (P> 
0.05). Interaction with rs3834458 genotype was significant for the determination in 




0.15). There was no significant interaction between any of the SNP genotypes and 
treatment in determining D6D activity. 
 
 





5.8.8 Spearman’s correlation between erythrocyte phospholipids, total plasma 
fatty acids and dietary fatty acids 
Spearman‟s correlation between the individual fatty acid of the erythrocyte 
phospholipids and plasma total fatty acids after 6 months intervention and those of the 
FFQ are respectively illustrated in Table 5.11. The correlation between available fatty 
acids from the FFQ and those of erythrocyte phospholipids and total plasma revealed a 
significant correlation for PUFA (RBC: ρ=0.128, P=0.02; Plasma: ρ=0.208, P<0.001), 
EPA (RBC: ρ=0.196, P=0.001; Plasma: ρ=0.162, P=0.005), DHA (RBC: ρ=0.127, 
P=0.02; Plasma: ρ=0.199, P<0.001) and the plasma SFA (ρ=0.125, P=0.03), but not 
those of erythrocyte phospholipids. ALA (RBC: ρ=0.075, P=0.186; Plasma: ρ=0.09, 
P=0.116) showed a very weak correlation for the two biomarkers and corresponding 
ones from the FFQ. While MUFA (RBC: ρ=-0.005, P=0.0.934; Plasma: ρ= -0.066, 
P=0.252) and LA (RBC: ρ=-0.025, P=0.62; Plasma: ρ=-0.027, P=0.637) showed a very 






Table ‎5.11 Spearman's correlations between the proportions of different fatty acids in 
erythrocyte lipids and total plasma fatty acids with those in the diet estimated from food 
frequency questionnaire 
 Erythrocytes  Plasma  
  Ρ P-value ρ P-value 
SFA 0.025 0.658 0.125 0.03 
MUFA -0.005 0.934 -0.066 0.252 
PUFA 0.128 0.023 0.208 <0.001 
LA -0.0257 0.652 -0.0272 0.637 
ALA 0.075 0.186 0.09 0.116 
EPA 0.196 0.001 0.162 0.005 












5.8.9 Possible factors influencing Carotid intima-medial thickness (CIMT) 
assessed by high resolution ultrasound at baseline 
Baseline carotid diameter, intima-media thickness (IMT) and presence of atherosclerotic 
plaque in participants as detected by high resolution ultrasound stratified by gender are 
illustrated in Table 5.12. Left and right minimal carotid diameters were higher in males 
than females. The same applies to left and right maximal carotid diameters. Left and 
right anterior IMT and posterior IMT were also higher in males than females.  
Further analysis shows CIMT thickness stratified by erythrocytes phospholipids omega-
3 index (EPA+DHA) tertiles (Table 5.13). There was no significant relationship 
between the omega-3 index and CIMT adjusted for age, gender, carotid diameted, 






Table ‎5.12 Carotid diameter, intima-media thickness (IMT) and presence of atherosclerotic 
plaque in participants as detected by high resolution ultrasound. 
    Left   Right 
 







Minimal carotid diameter 
(mm) 
  
7.03 ± 0.64 6.38 ± 0.59   7.21 ± 0.74 6.57 ± 0.65 
Maximal carotid diameter 
(mm) 
 
7.51 ± 0.61 6.81 ± 0.71 
 
7.69 ± 0.79 7.03 ± 0.63 
  
     Anterior IMT (mm)  0.67 ± 0.14 0.64 ± 0.13 
 
0.66 ± 0.15 0.64 ± 0.15 
Posterior IMT (mm)  0.64 ± 0.17 0.60 ± 0.14 
 
0.61 ± 0.14 0.57 ± 0.11 
  
     Carotid plaque (%)
1











Table ‎5.13 CIMT thickness stratified by tertiles of erythrocyte phospholipids omega-3 index 
(EPA+DHA). 
 Omega-3 index  
CIMT Low Medium High P value  
Left anterior  0.66 (0.64,0.68) 0.65 (0.63,0.67) 0.63 (0.61,0.65) 0.12 
Left posterior 0.62 (0.60,0.65) 0.62 (0.60,0.65) 0.60 (0.57,0.63) 0.231 
Right anterior 0.64 (0.61,0.67) 0.66 (0.64,0.69) 0.64 (0.62,0.67) 0.868 
Right posterior 0.59 (0.57,0.61) 0.59 (0.57,0.61) 0.59 (0.57,0.61) 0.964 
Values are mean (95% CI). 
   Statistical significance is for linear trend.  






In this sample of healthy subjects, the genotypes of three SNPs in the FADS1-FADS2 
gene cluster were strongly associated with proportions of LC-PUFAs and desaturase 
activities estimated in plasma and erythrocytes. Minor allele carriage associated with 
decreased activity of D5D (FADS1) and D6D (FADS2) was reflected in increased 
proportions of substrates and decreased products in n-6 and n-3 LC-PUFA synthetic 
pathways. SNPs and haplotype associations with LC-PUFA proportions and D5D 
activity of similar significance suggested that the analysed SNPs were in LD with a 
potential functional site. However, D6D activity was much more strongly associated 
with haplotype than with single SNP, suggesting an unknown variant on the same 
haplotype might be influential. We have shown that increasing dosage of EPA and 
DHA in a randomized controlled trial reduced n-6 and increased n-3 LC-PUFA 
proportions, and D5D activity. SNP genotypes did not interact with treatment in 
determination of LC-PUFA proportions, but interaction was a significant determinant of 
D5D activity.  
The composition of fatty acids in tissues reflects the dietary fat composition, but 
individual differences reflect genetic control of metabolic efficiency. The D5D and D6D 
genes, FADS1 and FADS2, are important regulators of LC-PUFA synthesis, evidenced 
by the extremely high genetically explained variance of AA (Tanaka et al. 2009). As in 
other investigations (Zietemann et al. 2010; Bokor et al. 2010), separate surrogate 




product:substrate in the n-6 pathway to assess the influence of FADS genetic variants. 
This study confirmed highly significant association of FADS SNP minor alleles with a 
reduction in desaturase activities estimated in plasma and erythrocytes. This may 
indicate a decline in gene transcription and/or enzyme conversion rates in carriers and 
would result in the increased substrate and decreased product proportions generally 
observed. At baseline, we found several highly significant SNP minor allele 
associations with increased proportions of substrates and decreased proportions of 
products in plasma and a strong association with increased DGLA in erythrocytes. 
Previous studies have shown association of several SNPs in this region with LC-PUFAs 
in plasma (Martinelli et al. 2008; Schaeffer et al. 2006) and erythrocyte membranes 
(Tanaka et al. 2009; Xie et al. 2008) although most did not find associations with 
proportions of DHA, for which sources are thought to be mainly nutritional (Schaeffer 
et al. 2006). The higher D5D activity in erythrocytes than in plasma may have reflected 
a preferential incorporation of AA into erythrocyte membrane phosphoglycerides. 
Recent GWA studies have also identified several genetic loci in the FADS gene cluster 
that are associated with blood lipid levels (Aulchenko et al. 2009; Sabatti et al. 2009; 
Chasman et al. 2009; Kathiresan et al. 2009). However, we were unable to replicate 
previously reported associations with plasma lipids, particularly LDL-C (Lu et al. 2010; 
Nakayama et al. 2010; Hellstrand et al. 2012). This most likely relates to the fact that 
lipids are distal phenotypes, which are influenced by many genes and environmental 
factors in addition to desaturase activity. Moreover, this study sample lacked the power 




the liver (Cho et al. 1999a; Cho et al. 1999b), a contribution of FADS1 and FADS2 
genetic variation to plasma cholesterol metabolism seems likely.  
The FADS1 and FADS2 genes have inverse orientation as a cluster on chromosome 11, 
with exon 1 of both genes separated by an 11 kb region (Lattka et al. 2010). The 
proximity of the promoters suggests that their transcription may be co-ordinately 
controlled by common regulatory sequences (Nakamura et al. 2004). Common genetic 
variants at the FADS1-FADS2 locus are in a strong LD block spanning FADS1 and the 
intergenic region (Martinelli et al. 2008; Tanaka et al. 2009; Schaeffer et al. 2006) so 
that any functional polymorphisms within the block could influence expression of both 
desaturases. However, our haplotype analysis suggests that control of D5D and D6D 
activity may have different genetic origins. SNP rs3834458 sited 5‟ to FADS2 is a good 
candidate, but an effect on promoter activity has not been established (Lattka et al. 
2010). Proportions of fatty acids and D5D activity in plasma and erythrocytes 
associated with single SNPs at baseline were also associated with the minor allele 
haplotype with similar levels of significance. The analysed SNPs seem, therefore, to be 
LD markers of a site influencing D5D activity. However, the significance of haplotype 
association with D6D activity was substantially greater than that of single SNPs, 
suggesting that unknown functional SNPs or possibly more than one causal variant on 
the haplotype influences D6D. Further support comes from a recent GWA study of gene 






associated with FADS1 (P=1.6 × 10
−6
) but not FADS2 (P=0.07) expression in 
lymphoblastoid cells (Dixon et al. 2007).  
As enzymes of the synthetic pathways show a higher affinity for n-3 than n-6 PUFA, 
the effect of treatment with EPA+DHA was to increase competition from derivatives of 
the n-3 LC-PUFA supplements and decrease proportions of the n-6 series. The 
significant increase in D5D activity after treatment reflected a greater reduction in the 
product, AA than in the substrate, DGLA. Modulations of the activities of D5D and 
D6D by intakes of EPA+DHA have been detected in previous controlled intervention 
studies (Zhou & Nilsson, 2001; Vessby et al. 2002). Interaction between intake of n-3 
PUFA or fatty fish and FADS genotypes have been established in larger studies by some 
(Hellstrand et al. 2012) but not others (Lemaitre et al. 2011; Lu et al. 2010; Moltó-
Puigmartí et al. 2010). Interaction between genotype and treatment as a determinant of 
LC-PUFA proportions was not significant in plasma or erythrocytes in the present 
study, most likely owing to insufficient power. For example, to demonstrate a 
significant difference in proportion of plasma AA with respect to rs174537 genotype 
across treatments based on a dominant model, a total sample size of 941 would be 
required for alpha = 0.05 and a power of 0.95. To demonstrate a significant difference 
based on an additive model, a total sample size of 1240 would be required. However, 
this study was unable to find that interaction was a significant determinant of D5D 
activity estimated in plasma, which increased significantly with dose in variant allele 




erythrocytes appeared even more pronounced, but was not significant after correction 
for multiple comparisons. D6D activity decreased significantly with treatment, but not 
after stratification by genotype. LC-PUFAs have previously been shown to down-
regulate D6D and increase D5D activity in controlled dietary studies (Vessby et al. 
2001).  
5.10 Limitations and conclusion 
In summary, this study was able to demonstrate that the consumption of as low as 0.45g 
of preformed EPA+DHA, which is equivalent of one portion of oily fish, was powerful 
in increasing proportions of these two fatty acids and their metabolites in erythrocyte 
phospholipids and plasma. Differences in levels of fatty acids between the two 
biomarkers indicate higher affinity of the erythrocyte cell membrane over the plasma. In 
addition, the plasma tends to reflect short-term dietary intake, while the erythrocyte 
represent medium-term intake and tightly regulated.   
The greatest strength of this study was the strict control of the intakes of EPA and DHA, 
shown to be correlated with plasma proportions. Long-term compliance was established 
by measures in erythrocytes. Although adjustments of probabilities for multiple testing 
were done by using multivariate analysis of variance, the best insurance that these 
results are not due to chance lies in replication in an independent sample. However, 




highly significant after correction for multiple comparisons and agree with findings in 
larger studies.  
The main limitation was the relatively small sample of subjects for genetic analysis (n = 
310), which reduced the power to detect some significant genotype associations with 
phenotypes and interactions with diet. Location of the three SNPs within a strong LD 
block on the one hand makes identification of the cause of the observed associations 
difficult, but on the other, high correlation between genotypes enabled haplotype 
reconstruction and analysis. Like other investigators, this study used LC-PUFA ratios as 
surrogate desaturase activities, because direct measures are not possible in population 
studies.  
This study confirmed that FADS polymorphisms are an important regulator of LC-
PUFA synthesis through high genetically explained variance of several fatty acids. 
Haplotypes carrying three SNP minor alleles were associated with lower indices of D5D 
and D6D activities, suggesting that any could be in linkage disequilibrium with a 
functional SNP. However, this study has raised the possibility that another variant on 
the same haplotype might have more influence on indices of D6D activity than the 
studied SNPs. In this relatively small sample, it was demonstrated significant interaction 
between dietary n-3 LC-PUFA intake and rs174537 genotype as a determinant of 
indices of D5D activity, with potential effects on the composition of LC-PUFA depots 






















This thesis set out to evaluate the use of biomarkers of fatty acid intake by testing how 
they performed in large randomized controlled trials of modification of fatty acid intake. 
The conclusion from the CRESSIDA study is that the proportion of SFA in erythrocyte 
lipids did not change when SFA intake was decreased and only minor changes occurred 
in SFA were observed in plasma lipids. The RISCK study (Jebb et al. 2010), which 
carefully controlled SFA intake by lowering the intake of SFA by up to 10% through 
replacing them with either carbohydrates or MUFA, found plasma phospholipids fatty 
acid composition to be a poor indicator of dietary intake of SFA (Table 6.1). Further 
analyses by the author on a subset of plasma samples from RISCK study also failed to 
show any differences in the proportions of SFA between groups fed diets high in 
MUFA or carbohydrate compared to the control diet (Table 6.2). In contrast, the blood 
biomarkers were very sensitive to change in PUFA intake and particularly to increased 
intakes of LC n-3 PUFA. Other trials have shown that fatty acids not synthesised de 
novo in the body such as branched fatty acids (C15:0 and C17:0) and TFA are also 
reflected in these and other lipid biomarkers (Sanders et al. 2003). The data from the 
TwinsUK study showed that PUFA and TFA in adipose tissue and plasma both 
correlated with the proportion in diet and are, therefore, good biomarkers of dietary 
intake. The reason for the lack of sensitivity of the biomarkers to SFA and MUFA is 
likely to be that homeostatic mechanisms keep the proportions of palmitic and oleic 





Table ‎6.1 Intakes of SFA and MUFA and changes in plasma phospholipid SFA and MUFA in the RISCK study. 
Diet SFA n=78 HM/HGI n=106 HM/LGI n=103  LF/HGI n=102 LF/LGI n=109 
SFA % energy 
     Baseline 17.0 ± 3.1 17.0 ± 3.1 17.0 ± 3.1 17.0 ± 3.1 17.0 ± 3.1 
Follow-up 16.9 ± 3.3 10.1 ± 1.3 9.4 ± 2.6 9.4 ± 2.9 8.4 ± 2.6 
MUFA % energy 
     Baseline 12.0 ± 2.2 12.0 ± 2.2 12.0 ± 2.2 12.0 ± 2.2 12.0 ± 2.2 
Follow-up 12.2 ± 2.8 16.9 ± 4.9 16.3 ± 4.3 10.4 ± 3.3 10.0 ± 3.1 
Plasma phospholipids 
    %SFA            
Baseline 44.3 (43.4,45.4) 44.7 (43.5,45.9) 45.0 (43.7,45.7) 44.6 (43.2,45.6) 44.6(43.2,45.6) 
Follow-up 44.3 (43.3,45.5) 44.4 (43.2,45.5) 44.4 (43.3,45.5) 44.7 (43.7,45.6) 44.7(43.5,45.8) 
%MUFA  
     Baseline 11.3 (10.4,12.5) 11.6 (10.4,12.5) 11.4 (10.6,12.0) 11.5 (10.7,12.5) 11.3(10.6,12.6) 
Follow-up 11.2 (10.5,12.5) 12.4 (11.0,13.6) 12.3 (11.5,13.1) 11.8 (10.7,12.6) 12.0(10.9,12.8) 
SFA= control diet, HM/HGI high MUFA low glycemic index diet, HM/LGI low glycemic index diet, LF/HGI low fat high glycemic index diet, LF/LGI low 
fat low glycemic index diet, Mean values ± SD or median values (interquartile range), Data taken from final report submitted to the Food Standards Agency 




Table ‎6.2 Plasma fatty acid composition (wt%) in the RISCK study comparing the SFA rich 
diet with low SFA/high MUFA (HM/HGI) diet and low SFA/high carbohydrate (LF/HGI) at the 
end of the study. Analysis performed by author. 
 
SFA (n= 24) HM/HGI (n= 39) LF/HGI (n= 32) 
SFA 
   14:0 0.94 ± 0.41  1.00 ± 0.29 0.83 ± 0.38 
16:0 17.81 ± 2.8 19.14 ± 1.93 18.40 ± 2.27 
18:0 5.81 ± 0.86 6.28 ± 0.71 5.87 ± 0.89 
20:0 0.19 ± 0.05 0.20 ± 0.11 0.19 ± 0.04 
MUFA 
   16:1n-7 1.94 ± 0.74 2.13 ± 0.73 1.98 ± 0.68 
18:1n-9 17.89 ± 3.35 19.96 ± 2.96 18.53 ± 4.43 
18:1n-7 1.63 ± 0.32 1.76 ± 0.34 1.67 ± 0.41 
TFA: 18:1trans 0.18 ± 0.09 0.22 ± 0.11 0.20 ± 0.1 
n-6 PUFA 
   18:2n-6 25.19 ±5.1 25.56 ± 4.24 24.93 ± 4.86 
18:3n-6 0.46 ± 0.19 0.47 ± 0.14 0.43 ± 0.19 
20:3n-6 1.42 ± 0.39 1.60 ± 0.32 1.44 ± 0.38 
20:4n-6 6.30 ± 1.74 6.50 ±1.65 5.86 ± 1.85 
22:4n-6 0.62 ± 0.15 0.59 ± 0.18 0.58 ± 0.18 
22:5n-6 0.85 ± 0.31 0.79 ± 0.32 0.84 ± 0.27 
n-3 PUFA 
   18:3n-3 0.57 ± 0.22 0.69 ± 0.22 0.62 ± 0.16 
20:5n-3 1.16 ± 0.68 1.04 ± 0.5 1.15 ± 0.7 
22:5n-3 0.56 ± 0.11 0.60 ± 0.12 0.58 ± 0.12 
22:6n-3 2.34 ± 0.63 2.46 ± 0.91 2.39 ± 0.87 
Mean values ± SD. No significant differences by multivariate analysis of variance adjusted for 





It is interesting to speculate why the proportions of palmitic and stearic acids in 
biomarkers are so resistant to change. In the case of erythrocytes and other membrane 
lipids, which are composed primarily of the phosphatidylcholine, 
phosphatidylethanolamine, phosphatidylserine and phosphatidylinositol, there is tighter 
regulation of the type of fatty acids incorporated into the sn-1 and sn-2 positions of the 
phospholipid (Gurr, Harwood & Frayn, 2002). The acyl transferases appear to favour 
PUFA, especially C20-C22 LC-PUFA, in the sn-2 position. Phosphatidylcholine species 
show selectivity for palmitic acid in the sn-1 position rather than stearic acid. However, 
this does not entirely explain why plasma fatty acid composition is also not a good 
biomarker of SFA intake. Plasma NEFA and TAG composition tend to reflect a 
composite mixture of fat from de novo lipogenesis and diet. Animals fed on fat free 
diets synthesise SFA, mainly palmitic acid, but intermediates also accumulate such as 
lauric and myristic acids. Palmitic acid can react with carnitine to form carnitine esters 
and be transported for beta-oxidation in the mitochondria. Alternatively, it can be 
desaturated to 16:1n-7 or chain elongated to stearic acid and then desaturated to oleic 
acid (18:1n-9). The same pathways operate in humans as in mammals. However, there 
is some debate regarding the extent of de novo lipogenesis from carbohydrates in 
humans (McDevitt et al. 2001) with probably only 10g/d at most being synthesised 
from carbohydrate. As dietary fat intakes are typically in the range of 60-100g/d in 
adults, this suggests that most human body fat is derived from dietary fat. However, this 
dietary fat can undergo remodelling in the body as it is stored, released into circulation 




itself may also play a role in modifying the composition of the fat. Indeed, adipose 
tissue does express SCD-1 (Paton & Ntambi, 2009). The observation that palmitoleic 
acid accounted for 5-6% in adipose tissue in the Twins study (much more than in 
plasma lipids), suggests that a substantial portion of palmitic acid is desaturated in 
adipose tissue. The low proportion of stearic acid and the much greater proportions of 
oleic acid in adipose tissue than in diet is also consistent with the idea that adipose 
tissue reprocesses SFA into MUFA. 
Controlled feeding studies in mice by our group (Sim, 2011) at King‟s College London 
have shown that the proportion of palmitic acid in adipose tissue only increased to 24% 
compared to when animals were fed carbohydrate where the value was 22%. This would 
indicate that there are mechanisms that control the proportion of palmitic acid in 
adipose tissue. Both palmitic acid and oleic acid are good substrates for beta-oxidation 
although oleic acid is oxidized at a faster rate (Leyton et al. 1987). The conversion of 
palmitic and stearic acids to oleic acid affects the physical properties of fat by lowering 
the melting point of TAG so that they are in the liquid phase at body temperature. 
Studies on SCD-1 knockout transgenic mice have shown that the failure to produce the 
palmitoleic and oleic acids results in metabolic abnormalities including abnormal 
secretion of sebum causing alopecia and dry eyes (Guilou et al. 2010). In essence, 
palmitic and oleic acids are the major fat fuels used by mammals for energy production 
and there are homeostatic mechanism controlling the levels of these fatty acids, which 




Further support for the view that plasma fatty acids are unreliable indices of SFA intake 
is illustrated by comparing vegans whose intakes of SFA are typically less than 6.5% 
energy with omnivores whose intakes are nearer 12.5% energy (Sanders et al. 2009b). 
Vegans have much higher intakes of LA (about 10% energy) and slightly higher intakes 
of ALA, but no LC n-3 PUFA. Table 6.3 shows the results of serum fatty acid analysis 
comparing vegans with omnivores based on samples collected by Lloyd-Wright in our 
laboratory. Although the proportion of palmitic acid is marginally lower as well as that 
of palmitoleic acid, the main difference is the very high proportion of LA.  The lower 
levels of EPA and DHA reflect the absence of EPA and DHA from the vegan diet and 
the relatively high ratio of LA:ALA in the diet. However, it is to be noted that the 
proportion of AA was slightly higher in the vegans indicating that there were no 
problems regarding the activities of FADS-1 and FADS-2 of converting LA to AA. 
The failure to observe any significant relationship between the intake of SFA with the 
proportion of SFA in adipose tissue of the twins is consistent with the views expressed 
above that the fatty acid composition of plasma or adipose is not a reliable biomarker of 




Table ‎6.3 Plasma fatty acid composition in vegans compared with omnivores. 
  Vegan (n=131) Omnivore (n=141) P value 
SFA    
16:0 19.02 ± 2.00 20.82 ± 1.93 <0.001 
18:0 6.52 ± 1.08 6.27 ± 0.55 0.047 
MUFA 
   
16:1n-7 1.38 ± 0.84 2.25 ± 0.98 <0.001 
18:1n-9 20.65 ± 3.29 21.75 ± 2.83 0.001 
PUFA 
   
n-6 
   
18:2n-6 36.21 ± 4.91 26.21 ± 3.90 <0.001 
20:3n-6 1.48 ± 0.42 1.53 ± 0.30 0.106 
20:4n-6 6.87 ± 1.82 6.24 ± 1.32 0.001 
n-3 
   
18:3n-3 0.84 ± 0.52 0.64 ± 0.22 <0.001 
20:5n-3 0.42 ± 0.26 1.35 ± 0.73 <0.001 
22:5n-3 0.58 ± 0.39 0.69 ± 0.16 0.012 
22:6n-3 0.90 ± 0.35 2.74 ± 0.92 <0.001 
Mean values ± SD in wt %. Data from Sanders (2009b) and (Z. Lloyd-Wright and TAB Sanders 
unpublished). 






The fatty acid composition of total plasma lipids offers some advantages over total 
phospholipids or lecithin in that it is more sensitive to changes in ALA intake. The 
analysis of total plasma lipids is also easier and does not require prior separation of the 
phospholipids before derivatisation and is, therefore, much more suitable for up-scaling 
in large cohort studies. Erythrocyte lipids are sensitive indicators of the intake of LC-
PUFA, but it is necessary to prepare the lipid extracts within a few days of collection in 
order to obtain reproducible results. Frozen red blood cells are susceptible to lipid 
oxidation owing to the presence of iron. The analyses from the MARINA study showed 
clear dose response relationships between the intake of EPA and DHA and levels in 
plasma and erythrocytes. There were strong correlations between values for EPA and 
DHA between biomarkers. Erythrocyte lipids, while more burdensome to prepare lipid 
extracts, do offer some advantage in that they are less readily changed by diet in the 
short term and contain higher amounts of C20-C22 LC-PUFA. 
Theobald et al. (2004) in a cross-over study comparing the effect of 0.85g/d DHA vs an 
olive oil placebo taken for 3 months reported changes in plasma and erythrocyte lipids. 
She found DHA increased from 5.2% to 8.2% in erythrocytes and plasma DHA 
increased by 76%. Sanders et al. (2006b) in a parallel designed study where subjects 
consumed 1.5g/d DHA for six weeks reported an increase in erythrocyte DHA from 
6.1% to 7.6% and an increase in plasma DHA of 128%, indicating that plasma was 
more sensitive biomarker. In an RCT in vegans given 0.2g/d DHA or placebo for 3 




to 1.3% in plasma total lipids (Sanders, 2009b; Lloyd-Wright PhD Thesis, 2005). 
Although the DHA increased, the levels in the vegan still remained much lower than in 
omnivores probably because of competition from the high intake of LA (Sanders, 
2009b). Roshanai & Sanders (1985) in a study in rats demonstrated that high intakes of 
LA reduced levels of DHA and EPA in tissues even when DHA and EPA were provided 
preformed in diet. 
6.1 Relationship of lipid biomarkers with cardiovascular disease 
Khaw et al. (2012) using plasma phospholipids as a biomarker of fatty acid intake in the 
EPIC Norfolk study found higher proportions of SFA and lower proportions of PUFA, 
particularly LA, to be associated with increased risk of CHD. The relationship seemed 
strongest for LA. Clark et al. (2009) found a low P/S ratio in cholesterol ester to be 
associated with increased risk in the Whitehall Study. One interpretation could be that 
the participants at greatest risk had high intakes of SFA but another more plausible 
explanation is that their intake of LA was low with the consequence that palmitic and 
oleic acid proportions were increased. Not reported in this thesis, however, is the use of 
branched chain SFA (mainly C15 and C17) as a biomarker of ruminant fat intake. These 
fatty acids are products of microbial synthesis and are found in the fat from ruminant 
animals as well as in fish, where they accumulate from marine plankton. It is of interest 
that Khaw et al. (2012) found a negative association with branched chain fatty acids and 
risk of CHD because this would suggest that the intake of SFA from butter fat and from 




consumption of butter fat as opposed to margarine was associated with a lower risk of 
CHD. Another fatty acid that has been found to be associated with dairy fat intake is 
conjugated linoleic acid (CLA), which occurs in two isoforms. Lloyd-Wright et al. 
(2003) showed the levels of this fatty acid increased from low levels in vegans, 
intermediate levels vegetarians and higher levels omnivores suggesting it was quite a 
sensitive indicator of intake. There is currently much interest in the potential beneficial 
effects of CLA on human health (McCrorie et al. 2011). 
Harris et al. (2007) has proposed that the sum of EPA+DHA in erythrocyte lipids could 
be used as an index of omega-3 fatty acid status. The work reported in this thesis shows 
that the index in plasma is strongly correlated with that in erythrocytes. Data from the 
MESA study (He et al. 2008) in 5488 adults aged 45-84 years suggested that omega-3 
index was associated with a lower carotid intimal media thickness. The relationship 
between the omega-3 index and CIMT was investigated in both the MARINA and 
CRESSIDA subjects. CIMT was generally greater on the left as opposed to the right 
carotid and was strongly associated with age. When adjustments were made for systolic 
blood pressure, age, TC:HDL-C it was not possible to demonstrate that this index 
influenced CIMT in these subjects who were all non-smokers. It is possible that the 
observation in the MESA study were confounded by smoking, alternatively the number 
of subjects studied in the MARINA and CRESSIDA studies (311 and 160 respectively) 




Anderson et al. (2009) reported an association between plasma EPA and DHA and 
subsequent mortality 20 years later. Mozaffarian et al. (2013) have recently reported on 
a prospective cohort in 2692 US adults aged 74 (±5 years) and found a lower risk of 
death to be associated with high levels of EPA and DHA. The lower risk was largely 
attributable to few cardiovascular than non-cardiovascular deaths. Individuals in the 
highest quintile omega-3 PUFA lived on average 2.22 more years after the age of 65 
years. These findings, however, do not establish a cause effect relationship because they 
are subject to residual confounding of other life-style factors. 
6.2 Genetic influences on fatty acid biomarkers 
A novel finding was the significant influence of additive genetics on the proportion of 
AA in adipose tissue. Further investigations revealed that variation in FADS1 SNP, 
rs174537, explained some but not all of this variation. The association was replicated in 
plasma lipids from the twins and the similar findings in the MARINA study. An 
elevated proportion of AA in adipose tissue was noted in one study to be associated 
with an increased risk of CVD in the review by Harris et al. (2007). However, further 
studies are required to see if this finding with regard to the proportion of AA in adipose 
tissue is associated with increased risk of CVD can be confirmed. AA besides being a 
substrate for prostanoid synthesis is also converted into ligands for the endocannabinoid 
pathway. Anandamide is an amide of AA and arachidonyl glycerol is a powerful agonist 
of cannabinoid receptors, which are expressed mainly in the brain but also in other 




levels in adipose tissue is of physiological importance is uncertain but it could be an 
important reservoir of AA. Similarly, the small amounts of DHA in adipose tissue in the 
context of total body stores. It could be an important reservoir as typically 20-30% of 
body weight is adipose tissue. DHA is believed to play an important role in the brain 
and in the retina and there is some uncertainty about the extent to which it synthesised 
from ALA. The critical period of human development in relation to requirements for 
DHA is in the last trimester of pregnancy and in early lactation. Human milk contain 
about 0.2-0.3% of its fatty acids as DHA. Interestingly, this is similar to the level found 
in adipose tissue. It is possible that variations in FADS1 and FADS2 genes may affect 
levels of LC-PUFA in breast milk and this is an area that could be explored in future 
studies. 
The genetic effect on the delta-5 desaturase metabolites demonstrated by polymorphism 
rs174537 upstream of the FADS1 gene appears consistent with some other recent 
reports (Voruganti et al. 2012). Haplotypes carrying three SNP minor alleles were 
associated with lower D5D and D6D activity, suggesting that any could be in linkage 
disequilibrium with a functional SNP. However, this study has raised the possibility that 
another variant on the same haplotype might have more influence on D6D activity than 
the studied SNPs. In this relatively small sample, a significant interaction between 
dietary n-3 LC-PUFA intake and FADS1 rs174537 genotype, as a determinant of D5D 
activity, was demonstrated with potential effects on the composition of LC-PUFA 




of ALA to LC n-3 PUFA using stable isotope technique in 26 subjects and related the 
isotope enrichment rates to variations in rs174545, rs174583, rs174561, and rs174537. 
They found that carriers of the minor alleles had lower levels of AA and EPA and lower 
levels of enrichment with isotope following administration of ALA. However, they 
were unable to demonstrate any differences in enrichment with isotope of DHA, which 
was very low. A major limitation of this study is very small sample size. 
6.3 Conclusion and implications for further research 
An important finding from this thesis is that the proportion of SFA in commonly used 
biomarkers of fatty acid intakes (erythrocyte, plasma total lipids, plasma phospholipids 
and adipose tissue) are unreliable for assessing relationship between SFA intake and 
chronic diseases. The use of these biomarkers might be misinterpreted to imply a cause-
effect relationship. The Norfolk EPIC cohort is a good example to illustrate this point. 
This study found branched SFA to be associated with a lower risk of CHD but a low P/S 
ratio in the same subjects was associated with a higher risk. As branched chain SFA are 
mainly derived from ruminants, which are rich in SFA, this would suggest that the 
reason for the relation between a low P/S ratio is a low intake of LA. The author 
concluded that even chain SFA in plasma phospholipids were positively associated with 
risk. This information could be claimed to show that SFA increase risk of CHD. 
However, the authors correctly interpreted their finding as being “consistent with 
accumulating evidence suggesting a protective role of omega-6 fats substituting for 




Biomarkers are probably more reliable for assessing the intake of PUFA than 
measurement of dietary intake. They appear very sensitive to small changes in the 
intake of LC n-3 PUFA.  The measurement in plasma total lipids seems just as reliable 
as their measurement in phospholipids or erythrocyte lipids in terms of classifying 
individuals with high, medium or low intakes. A limitation of the genetic studies 
reported in this thesis is the relative small number of subjects studied. However, there 
are some very large cohort studies (over 0.5 million participants such as the Bio-bank 
project and similar projects supported by the Wellcome Trust and the Medical Council) 
that could be used to assess fatty acid intakes using plasma as a biomarker and then 
relate to genotype. One lesson learnt from the TwinsUK study is that the volume of 
blood sample available for analysis is very limited and so it is important to only need 
very small amounts of plasma or serum for analysis. In this thesis, 0.1 ml plasma was 
used, but even smaller samples (certainly 50 µL, but possibly as little as 5µL) could be 
used and robotic techniques (Masood & Salem, 2008) which could speed-up sample 
handling. Run-time can be shortened using fast chromatography, which employs shorter 
(12 m), narrow bore columns (0.1 mm) and higher column pressures. However, the run-
time reported by Masood & Salem (2008) was 15 min, which is similar to a normal 
capillary column analysis as used in this thesis using a 0.2 mm x 25 m capillary column. 
However, the analysis reported in this thesis allowed a longer gap between samples 
because of the late elution of cholesterol methyl ester, which could contaminate the next 
run if it was not “burnt off” from the column. The use of split-less inject would increase 




with optimising the use of small bore columns and faster responding flame ionisation 
detectors could possible reduce run-times to below 10 min or possibly 5 min, especially 
if the late-eluting sterol contaminants could be removed. As an analytical technique, 
plasma fatty acid composition is relatively inexpensive as the reagents are cheap and the 
analytical equipment is robust and inexpensive to operate. However, it would be 
important to have an established quality control procedure to ensure the validity of the 
assays between different laboratories with test plasma that represent high, medium and 
low intakes of PUFA or TFA with acceptable performance criteria and appropriate 
documentation to enable audit. 
There would be great merit in applying plasma fatty acid analysis to estimate intakes of 
fatty acids in populations where food-recording skills are low. It could be applied in 
order to monitor changes in fatty acid intakes in the diet over time, for example in 
national dietary surveys such as NDNS. There is also potential for elucidating 
relationships between PUFA intakes and non-communicable diseases such as 
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Appendix-1 Macadamia study 
A comparison of the differential effects of dietary palmitoleic acid and palmitic acid on markers 
of cardiovascular health in young healthy men aged 18-45. 
Hypothesis 
Consumption of palmitoleic acid alters postprandial lipid and glucose metabolism compared 
with control group  
Objectives 
To conduct a randomized controlled trial to compare the acute effects on lipid and glucose 
metabolism of test meals containing palmitoleic acid (macadamia oil; test group) and palmiticc 
acid (palm oil; control group).  
Study design 
Ethical approval 
Ethical approval was obtained from the Berkshire Research Ethics Committee (Reading, UK) 
(REC reference 11/SC/0131) on 19/05/2011. Written informed consents were acquired from all 
participants before starting the study. All clinical procedures were conducted by qualified staff. 
Study design 
A randomized, single blind, parallel design compared the postprandial response of exchanging 
palmitoleic acid (12g) with palmtic acid (12g) in the diet. Following a run-in diet for 2-weeks 
and participants were randomized to one of the two treatment sequences. Each dietary period 
was to last for one week and was preceded by a test meal. The fat exchanges were achieved by 
providing subjects specially prepared muffins and a supply of nuts to consume. Subjects 
received a standardized meal consisting of a muffin (30g test fat) and milk shake (20g test fat) 
consisting of a total of 50g test fat. Venous blood samples (a total of 80ml) were drawn at 
regular intervals over 6-hours. The amount of fat exchanged in the two meals of this study was 




same amount of palmitoleic acid. A 0.24 mmol/l difference in LDL-C concentration is expected 
between the two groups as calculated by Mensink & Katan equation.  
The primary outcome for the test meal was change in triglycerides concentration. Secondary 
outcome were changes in other blood lipids (HDL-cholesterol, LDL-C and NEFA concentration 
and fatty acid profiles), C-peptide, CRP, IL-6, glucose and insulin sensitivity (assessed by 
HOMA). 
Test materials and methods 
Test meal used  
Subjects were asked to avoid high fat food, alcohol as well as participation in any strenuous 
exercises. Subjects were given a standardized low fat dinner (<10 g fat, Sainsbury‟s „Be good to 
yourself range‟) to consume on the day preceding the study day. Postprandial test meal will 
consist of 1 muffin containing 30g test fat and a milkshake to provide 846 kcal, 20 g fat, 14 g 
protein and 87g carbohydrates. The milkshake contains 220 ml skimmed milk and 15 g nesquik 
milkshake mix and were prepared freshly on the day of intervention providing 131 kcal, 7 g 
protein and 26 carbohydrates. Each muffin contained 15 test fat, 9 g corn flour, 27.5 g wheat 
flour, 27.5 g white caster sugar, 1.9 g baking powder, 36.9 g skimmed milk, 3.9 g egg white and 
3.9 g vanilla essence and to provide 715 kcal, 7 g protein, 62 g carbohydrates and 25 g fat. 
Additional 10% test fat was added to the muffin recipe  to allow for 2.5 g fat loss during baking. 
Table.1 Fatty acid composition of the test meals 
FA Test muffin Control muffin 
14:0 1.27 0.59 
16:0 8.08 9.53 
16:1 16.42 0.28 
18:0 3.22 2.91 
18:1n-9 54.78 74.84 
18:2n-6 6.67 6.90 
18:3n-3 0.17 0.25 
18:3n-6 0.02 0.02 
20:3n-6 0.02 0.03 




Test fats used and their properties 
Test fats consist of commercially available food grade macadamia oil, high in palmitoleic acid, 
and food grade palm olein, high in palmitic acid. 
Control meal (Postprandial study): 
Muffin made with blend of 30g HOS: Palm olein in ratio of 22:8  
Milkshake with 100% HOS 20g 
Macadamia meal (Postprandial study): 
Muffin made with 100% macadamia oil 30g 
Milkshake with blend of 20g macadamia: safflower oil blend in a ratio of 17:3  
Approximate fat composition: 
SFA ~14%, MUFA 79%, PUFA ~7% 
Background muffin 
80% palm olein, 10% safflower oil, 10% HOS 
Composition of the test fats 
Table.2 Fatty acid proportions of the control and test fats 
FA Test oil Control oil 
14:0 0.74 0.23 
16:0 8.06 9.57 
16:1 16.93 0.26 
18:0 3.32 3.00 
18:1n-9 56.45 77.45 
18:2n-6 6.55 6.90 
18:3n-3 0.16 0.01 
18:3n-6 0.01 0.01 
20:3n-6 0.02 0.04 




Statistical analysis of data  
Data were analysed by repeated measures analysis of variance using GraphPad.   
Results 
Characteristics of the study participants 
A total of 6 subjects were recruited and they only completed the first test meal and did not 
complete the 3 week dietary intervention. Table 3 summarizes the characteristics of the study 
participants. 
Table.3 Characteristics of the study male participants stratified by intervention group 
  Intervention Control 
  n=3 n=3 
Age 33.67±8.14 26.67±1.53 
Height 185.00±5.20 180.33±5.86 
Weight 85.37±18.93 80.53±11.12 
Waist 99.50±4.95 94.33±7.51 
BMI 24.90±5.20 24.70±2.21 
Systolic BP (mmHg) 131.67±5.13 124.33±10.52 
Diastolic BP (mmHg) 74.67±2.02 75.17±3.75 
Total cholesterol (mmol/L) 5.20±1.56 5.13±0.35 
Triacylglycerol (mmol/L) 1.10±0.36 1.20±0.78 
LDL-cholesterol (mmol/L) 3.37±1.34 2.90±0.10 
HDL-cholesterol (mmol/L) 1.30±0.35 1.67±0.55 
TC:HDL-C ratio 4.13±1.16 3.30±0.98 
Glucose (mmol/L) 5.50±0.30 5.10±0.20 
Insulin (mIU) 7.34±3.53 5.27±1.26 
Values are mean ± SD 






Postprandial changes in lipids and lipoproteins 
 
Plasma triacylglycerol and fatty acid concentrations 
The increase in plasma TAG was lower on the control diet than on the macadamia test meal, but 
the total fatty acid concentrations did not differ between treatments. The plasma concentration 
of palmitoleic acid was substantially increased following the macadamia oil test meal. The fall 
in plasma NEFA was similar following both test meals and there were no differences in 















                    Figure.2 Plasma concentrations of palmitoleic acid. 
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Figure.3 Changes in plasma NEFA concentrations. 
 
 



































Figure.5 Changes in C-peptide. 
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INFORMATION SHEET FOR PARTICIPANTS                  
REC Protocol Number: 11/SC/0131 
 
YOU WILL BE GIVEN A COPY OF THIS INFORMATION SHEET 
 
The macadamia oil and palm oil trial 
 
We would like to invite you to participate in this original research project.  You should only participate 
if you want to; choosing not to take part will not disadvantage you in any way. Before you decide 
whether you want to take part, it is important for you to understand why the research is being done 
and what your participation will involve. Please take time to read the following information carefully 
and discuss it with others if you wish. Ask us if there is anything that is not clear or if you would like 
more information.  
Do I have to take part? It is up to you to decide whether to take part or not. If you do decide to take 
part you will be given this information sheet to keep and be asked to sign a consent form. You can 
withdraw from the study at any time by informing the researcher and you are not obliged to give a 
reason. A decision to withdraw at any time, or a decision not to take part, will not affect the standard 
of care you receive. 
What is the purpose of this study? 
The main aim of this study is to investigate the differential effects palmitoleic acid, which is a 
monounsaturated fatty acid, found in macadamia nut with that of palmitic acid, which is a saturated 
fatty acid found in many food items. Macadamia oil will be used as a source of palmitoleic acid, which 
is a monounsaturated fatty acid and palm oil will be used as a source of palmitic acid.  
Why have I been chosen? 
You have been contacted as you have expressed an interest in our research. In order to participate in 
this study you need to be able to say ‘Yes’ to the following:  
 I am male 
 I am aged between 18 and 45 years 
 I do not smoke 
 I have never had a heart attack, stroke, high blood pressure (>160/100mm Hg), liver diseases, 
diabetes, chronic gastrointestinal disorder or cancer  
 I do not have a history of excess alcohol intake or substance abuse 
 I do not have allergy to either macadamia, hazelnut or palm kernel   
  
                                                                                                                                                
                                                                                                                                                                  
 I am prepared to consume the muffins everyday for 10 weeks 
 
What will happen to me if I take part? 
Screening: If you would like to participate you would first need to complete a screening questionnaire 
with us over the telephone (approx. 15 mins), after which potentially eligible volunteers will be invited 
to attend a clinic screening appointment (approx. 45 mins) in the Metabolic Unit on 4th Floor, Corridor 
B, Franklin-Wilkins Building, Stamford Street, SE1 9NH. Volunteers will need to attend this visit after 
an overnight fast. 
The study will be explained in detail and you will be able to ask any questions you may have to 
ensure you will be giving fully informed consent. Following the signing of the consent form, your 
height, weight and percentage body fat measurements will be recorded, and a fasting blood sample 
(~3 teaspoons) will be taken to determine whether liver function, haematology, blood glucose and 
blood lipids are within normal ranges. Seated blood pressure will be measured using an automated 
sphygmomanometer (blood pressure monitor) that conforms to the recommendation of British 
Hypertension Society. Refreshments will be provided once all samples and measurements have been 
made. You will also be asked to complete a food frequency questionnaire.  
 
Participation in the Main Study: Eligible subjects will be asked to complete a 10-weeks period 
taking 2 muffins per day whilst following dietary advice to avoid high fat food. The muffins will be ‘run-
in’ or ‘wash-out’ (the same muffins) from weeks 1 to 2 and 6 to 7 of your participation in the study. 
From weeks 3 to 5 and weeks 8 to 10, the muffins will be ‘test’ muffins containing either palmitoleic or 
palmitic acids. We will ask you for a small blood sample at the start of week 3 and week 8. At the end 
of week 5 and week 10 only on your visit to the Metabolic Research Unit, we would ask you to 
consume another muffin and a milkshake. You will be cannulated (a tube inserted into the antecubital 
vein on your arm) for ease of blood withdrawal over a 6 hour post-prandial time. A total of 80mls of 
blood would be taken over this time – so although it is a large time commitment, the amount of blood 
is not so great (about 15 teaspoons). Although you will be cannulated for 6 hours, you can freely 
move. At your four study visits (week 3, 5, 8 and 10) we will also measure your blood pressure, weight 
and percentage body fat. 
 
To standardise all your visits, you will be asked to avoid strenuous physical activity, foods high in fat, 
caffeine or alcohol on the day before the visit. We will give you a list of foods to avoid and a list of 
suggested evening meals to help you with this. Only water will be allowed after 20:00h the evening 
before the study visits.  
 
Will my participation be kept confidential? Any information collected about you during this 
research will be kept strictly confidential. Your GP will not be told that you are taking part in the 
study, unless you request us to do so. Subject confidentiality and anonymity will be observed 
throughout the study by use of subject codes in place of names, and the storage of subject details in 
a secure place. Only the investigators have access to this data. Should you wish to find out the 
results of this study you are welcome to contact us for a copy of the final report once the study is 
finished. 
Possible risks/ benefits from participating the risk associated with the blood collection is small, 
but there may be a small amount of bruising. All blood collection will be conducted by a train 
phlebotomist. Furthermore, a trained first aid specialist in the Diabetes and Nutritional Sciences 
  
                                                                                                                                                
                                                                                                                                                                  
Division is at hand in any event. You will get your blood levels of cholesterol, triglycerides, glucose 
and insulin at the end as benefit from participating in the study 
What will happen to my study results? We hope to publish the results of the whole study in a 
scientific journal. You will not be identified in any publication. We will be happy to discuss the overall 
results with you when the study is completed, and will let you know how you can get a copy of the 
published results if you wish. 
Who is organizing and funding the study? The study is organized and funded by the Diabetes and 
Nutritional Sciences Division, Kings College London.  
 
If this study has harmed you in any way you can contact King's College London using the 
details below for further advice and information:  
Thank you for your interest. 
The contact details for the chief investigator (Maryam Al-Hilal) and her supervisors (Prof Tom Sanders 
and Dr Anne Mullen) are below. Please do not hesitate to contact any of the research group for 
further information or suggestions.  
Maryam Al-Hilal Tel; email: Maryam.Al_Hilal@kcl.ac.uk; tel: 020 7848 4301    
Prof Tom Sanders; email: Tom.Sanders@kcl.ac.uk; tel: 020 7848 4273 
Dr Anne Mullen; email: Anne.Mullen@kcl.ac.uk; tel: 020 7848 4081 
Diabetes and Nutritional Sciences Division, King’s College London, School of Medicine, Franklin 




Appendix-2 Mx script 
Saturated Model 
! MODEL : Phenotypic Univariate Saturated Model, one trait per 
twin 
! INPUT : Raw Continuous Data 
 
#NGroups 3 






X Lower nvar nvar Free                 ! Cholesky decomposition for 
MZs 




M= X*X';                                     ! MZ covariance 
N= Y*Y';                                     ! DZ covariance 
O=\stnd(M);                           ! MZ correlation   
P=\stnd(N);                            ! DZ correlation   
End Algebra; 
Start 1 X 1 1 1 X 1 nvar nvar               ! starting 
values=sqrt(variance) 
Start 1 Y 1 1 1 Y 1 nvar nvar  ! starting values=sqrt(variance) 
Interval O 2 1    ! 95% CI of MZ twin correlations 
Interval P 2 1   ! 95% CI of DZ twin correlations 
End 
 
G2: MZF datagroup 
Data NInput_vars=5 
missing =900 
!REC FILE=C:\Documents and Settings\user\Desktop\Mx\Oleic 
acid\oleictrial.dat  
REC FILE=oleictrial.dat  
Labels  famid  age1 c181n9at1  c181n9at2 zyg 
SELECT if zyg=1 / 
SELECT c181n9at1  c181n9at2  / 
Begin Matrices = Group 1; 
G Full 1 nvar Free                        ! means 
End Matrices; 
 
Start 40 G 1 1 to G 1 nvar                   ! start value for the 
means, change here 
Means G /                                      ! model for means 









!REC FILE=C:\Documents and Settings\user\Desktop\Mx\Oleic 
acid\oleictrial.dat  
REC FILE=oleictrial.dat  
Labels  famid  age1 c181n9at1   c181n9at2 zyg     
SELECT if zyg=2 / 
SELECT  c181n9at1  c181n9at2 / 
Begin Matrices = Group 1; 
G Full 1 nvar Free                        ! means 
End Matrices; 
Start 40 G 1 1 G 1 nvar                       ! start value for the 
means, change here 
Means G /                                      ! model for means 





! Univariate Script for Raw data anlayses 
#define nvar 1 
G1: DEFINE MATRICES 
CALCULCATION NGROUPS=3 
BEGIN MATRICES;   
X LOWER nvar nvar  FREE  !Path coefficients genetic 
Y LOWER nvar nvar  FREE  !Path coefficients shared env 
Z LOWER nvar nvar  FREE  !Path coefficients unique env 
END MATRICES; 
BEGIN ALGEBRA;  
A=X*X';                 
C=Y*Y';                 
E=Z*Z';                 
P=A+C+E;   
S=A%P|C%P|E%P;  ! h2|c2|e2 
END ALGEBRA; 
MA X 1    ! start value= sqrt (variance/3) 
MA Y 1    ! start value= sqrt (variance/3) 
MA Z 1    ! start value= sqrt (variance/3) 
OPTION RS 
!Interval S 1 1 S 1 2 S 1 3   ! 95% CI for h2, c2, e2  
END 
  
G2: MZF Group 
Data NInput_vars=5 
missing =900 
!REC FILE=C:\Documents and Settings\user\Desktop\Mx\Oleic 
acid\oleictrial.dat 
REC FILE=oleictrial.dat 
Labels  famid  age1 c181n9at1  c181n9at2   zyg     
SELECT if zyg=1 / 
SELECT c181n9at1  c181n9at2  / 
MATRICES = GROUP 1 
M full 1 2 FREE 
COVARIANCE 
 ( A + C + E | A + C _ 
  
   A + C     | A + C + E ) / 
 
MEANS M / 
 




G3: DZ Group 
Data NInput_vars=5 
missing =900 
!REC FILE=C:\Documents and Settings\user\Desktop\Mx\Oleic 
acid\oleictrial.dat  
REC FILE=oleictrial.dat 
Labels  famid  age1 c181n9at1  c181n9at2   zyg  
SELECT if zyg=2 / 
SELECT c181n9at1  c181n9at2  / 
 
MATRICES = GROUP 1 
M FULL 1 2 FREE 
H FULL 1 1 
 
COVARIANCE 
 ( A + C + E | H@A + C _ 
   H@A + C   | A + C + E ) / 
 
MEAN M / 
 
MATRIX H .5 
 



















drop X 1 1 1 Y 1 1 1  !this drops the a and c from ACE - 




Appendix-3 CRESSIDA study  
Dietary intervention 
Reduction in SFA: 
A lower SFA intake at 10% was achieved in the high MUFA diet at the same time total fat 
intake sustained at 35%. 
Removal of as much dairy fat as possible. 
Providing the participants with oils and spreads low in SFA. 
Advice to select lean meat (restricting lean meat intake to ≤3 servings/week). 
Increasing proportion of n-6: 
Achieved by exchanging some of the oleic acid with linoleic acid. 
Substitution of fat with varying composition mainly oils, spreads, dairy foods and reformulated 
products. 
Increasing long-chain n-3 PUFA: 
Encouraging participants to increase oily fish intake. 
Reimbursing the subjects for cost of oily fish purchased. 
Supplying the participants with tinned oily fish and other preserved fish products. 
Increasing wholegrain and cereals intake: 
Provide the subject with a choice of breakfast cereals, which are either high or low in 
wholegrain cereals. 
Advice participant to select wholegrain cereals where there has been minimum disruption to the 
grain as opposed to highly processed wholegrain items. 
Advice subjects to consume wholegrain bread. 
Provide participants with packets of microwavable brown rice or long-grain white rice. 
  
Recommend that the potatoes are prepared in a way so that they are not high in fat and the 
potassium content is retained (baked, microwaved, or oven chips). 
Reduction in salt intake: 
Avoidance of food high in salt. 
The use of reduced salt options. 
Reduction in the discretionary salt use. 
Provide the participant with advice to avoid foods high in salt (bacon, olives, some ready 
prepared products such as soups, ready meals that contain >2 g salt/serving). 
Provide the subject with reduced salt alternatives for tomato sauce and baked beans or 
conventional versions of the same product. 
Increasing fruit and vegetables: 
Participants were advised to consume 5 portions of fruits and vegetables/day. 
Consumption of wide variety of fresh fruit and vegetables was encouraged. 
Subjects were provided with sample menus and preparation instructions in order to retain the 
maximum nutritional value   (i.e. cooking in minimum volume of water and avoiding exposure 
of cut vegetable to air, light or heat for long periods of time).  
Participants were discouraged from the consumption of fruit in syrup or vegetable to which salt 
(i.e. pickled foods and olives) or fat (i.e. coleslaw, sun-dried tomatoes in oil) was added. 





A reported history of angina pectoris, myocardial infarction, stroke, peripheral vascular disease 
or congenital heart disease. 
Asymptomatic atrial fibrillation. 
Type 1 or Type 2 diabetes mellitus  (fasting blood glucose > 7.0mmol/L). 
Seated blood pressure > 160/105mmHg. 
Current use of medication for lowering blood cholesterol  (statins) or blood pressure. 
Body Mass Index <18.5 and >35kg/m2. 
An overall risk of cardiovascular disease over the next ten years of >20% assessed according to 
current NICE guidelines plus untreated high blood pressure or raised cholesterol 
Clinical history of cancer (excluding basal cell carcinoma) in the past five years. 
Chronic renal, liver or inflammatory bowel disease. 
Current cigarette smoking (confirmed by urinary cotinine analysis – value > 500ng/L indicates 
current smoking). 
History of substance abuse or alcoholism (previous weekly alcohol intake >60 units/men or 50 
units/women). 
Current self-reported weekly alcohol intake exceeding 21 units for women and 28 units for men. 
Currently pregnant, planning pregnancy or having had a baby in the last 12 months. 
Unwilling to follow the protocol and/or give informed consent. 
Unwilling to refrain from use of dietary supplements. 
Unwilling to restrict or increase consumption of oily fish. 
Weight change of >3kg in preceding 2 months. 
 
Exclusion drugs 
Haemostatic drugs such as Anti-coagulants - e.g. Warfarin  (but do not exclude those taking 
aspirin). 
Medication for lowering blood cholesterol – e.g. statins. 
Medication for lowering blood pressure – e.g. ACE inhibitor, Ca channel blocker, thiazide 
diuretic. 
